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Effective Measures of Weight Gain Five Years Post-Kidney Transplantation 
Abstract 
BACKGROUND: Weight gain is commonly observed post-kidney transplantation and is associated with 
unfavorable health outcomes, such as graft loss, new onset diabetes, and cardiovascular disease. The 
purpose of this study was to determine the most effective measure for assessing body composition after 
kidney transplantation. 
DESIGN: The study was a descriptive correlational follow-up study from a single kidney transplant site. 
SUBJECTS: A total of 45 eligible patients from a 2007-2011 parent study were selected, ages of 37 to 78. 
MEASUREMENTS: Body composition was obtained 5–8 years posttransplant via anthropometric 
measures (waist circumference, body mass index, and dual energy X-ray absorptiometry) and compared 
with baseline (pretransplant) values. Similarly, weight and body mass index (BMI) were obtained. Blood 
sampling was performed to measure levels of serum glucose, hemoglobin A1C, low-density lipoprotein-
cholesterol, high-density lipoprotein, triglycerides, and coronary risk ratio. Kidney function was monitored 
via serum creatinine. Manual blood pressure was taken with two resting blood pressures. 
RESULTS: The sample size was N = 45 and included 29 (64.4%) African Americans and 16 (35.6%) Whites. 
There were 25 (55.6%) males and 20 (44.4%) females. The ages were 37 to 78, with a mean of 56 (SD 
=10.1). Body weight increased from 186.66 ± 42.10 at baseline to 197.89 ± 48.1 at the 5-8 year follow-up, 
and BMI increased from 29.03 ± 4.76 to 32.14 ± 9.61. At the 5-8 year follow-up, anthropometric measure 
of waist circumference was found to be associated with cardiac risk ratio and weight with diastolic BP. In 
contrast, 7 body composition measures were associated with HDL, 4 with cardiac risk ratio, 5 with 
creatinine, and 2 with systolic blood pressure. Significant associations were also found with 
anthropometric measure BMI obtained at the time of transplant surgery and HDL and LDL 5-8 years later. 
There were 13 body composition measures associated with HDL, 6 with cardiac risk ratio, and 2 with 
triglycerides during this same time span. Lastly, one change in anthropometric measure from baseline to 
5-8 year posttransplant was associated with the 5-8 year cardiac risk factors (cardiac risk ratio and BMI). 
There were 18 significant relationships for body compositions measures. These included 7 body 
composition measures associated with creatinine, 5 with LDL, 4 with diastolic blood pressure, and 2 with 
triglycerides. 
DISCUSSION: The significant relationships found among dual-energy x-ray absorptiometry and cardiac-
related outcomes suggest this method may provide a better assessment of body fat, weight gain, and 
potential cardiac risk factors than does the currently used method. The study continued to examine the 
use of dual-energy x-ray absorptiometry to better understand the emerging coronary risk that 
accompanies weight gain and as a basis upon which more precisely targeted interventions could be 
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BACKGROUND: Weight gain is commonly observed post-kidney transplantation and is 
associated with unfavorable health outcomes, such as graft loss, new onset diabetes, and 
cardiovascular disease. The purpose of this study was to determine the most effective 
measure for assessing body composition after kidney transplantation. 
 
DESIGN: The study was a descriptive correlational follow-up study from a single kidney 
transplant site.  
 
SUBJECTS: A total of 45 eligible patients from a 2007-2011 parent study were selected, 
ages of 37 to 78.  
 
MEASUREMENTS:  Body composition was obtained 5–8 years posttransplant via 
anthropometric measures (waist circumference, body mass index, and dual energy X-ray 
absorptiometry) and compared with baseline (pretransplant) values. Similarly, weight and 
body mass index (BMI) were obtained. Blood sampling was performed to measure levels 
of serum glucose, hemoglobin A1C, low-density lipoprotein-cholesterol, high-density 
lipoprotein, triglycerides, and coronary risk ratio. Kidney function was monitored via 
serum creatinine. Manual blood pressure was taken with two resting blood pressures. 
. 
RESULTS:  The sample size was N = 45 and included 29 (64.4%) African Americans 
and 16 (35.6%) Whites. There were 25 (55.6%) males and 20 (44.4%) females. The ages 
were 37 to 78, with a mean of 56 (SD =10.1). Body weight increased from 186.66 ± 
42.10 at baseline to 197.89 ± 48.1 at the 5-8 year follow-up, and BMI increased from 
29.03 ± 4.76 to 32.14 ± 9.61. At the 5-8 year follow-up, anthropometric measure of waist 
circumference was found to be associated with cardiac risk ratio and weight with 
diastolic BP. In contrast, 7 body composition measures were associated with HDL, 4 with 
cardiac risk ratio, 5 with creatinine, and 2 with systolic blood pressure. Significant 
associations were also found with anthropometric measure BMI obtained at the time of 
transplant surgery and HDL and LDL 5-8 years later. There were 13 body composition 
measures associated with HDL, 6 with cardiac risk ratio, and 2 with triglycerides during 
this same time span. Lastly, one change in anthropometric measure from baseline to 5-8 
year posttransplant was associated with the 5-8 year cardiac risk factors (cardiac risk ratio 
and BMI). There were 18 significant relationships for body compositions measures. 
These included 7 body composition measures associated with creatinine, 5 with LDL, 4 
with diastolic blood pressure, and 2 with triglycerides.  
 
DISCUSSION: The significant relationships found among dual-energy x-ray 
absorptiometry and cardiac-related outcomes suggest this method may provide a better 
assessment of body fat, weight gain, and potential cardiac risk factors than does the 
currently used method. The study continued to examine the use of dual-energy x-ray 
absorptiometry to better understand the emerging coronary risk that accompanies weight 
gain and as a basis upon which more precisely targeted interventions could be designed 
that would improve the health and life expectancy of kidney transplant patients.  
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Kidney recipients often experience weight gain the first year posttransplant 
(Baum, 2001a; Cashion et al., 2007; Jezior et al., 2007). These significant may represent 
up to 10% of pretransplant weight (Johnson et al., 1993; Moore & Gaber, 1996). Aksoy 
(2016) found that the average weight gain within the first 6 months posttransplant ranged 
from 6 and 10 kg. Similarly, Cashion et al. (2007) demonstrated mean weight gain 
ranging from 5 -10 kg within the first year of transplant. These findings are critical, as 
increases in body weight have been well associated with adverse health outcomes.   
 
Previous studies have explored the association between kidney transplant and 
weight gain, demonstrating increased morbidity and mortality (Beckmann, Ivanović, 
Drent, Ruppar, & De Geest, 2015; Gore et al., 2006). For example, obesity increases 
kidney sodium reabsorption, which causes hypertension, and excess accumulation of 
adipose tissue may compress the kidney, which increases intrarenal pressure and tubular 
reabsorption (Naumnik & Mysliwiec, 2010). Together, these actions make weight gain 
following kidney transplantation a serious concern.  
 
The precise etiology responsible for the dramatic weight gain within the post-
kidney transplant population is poorly understood but likely composed of several 
contributing factors, including decreased physical activity during the immediate 
posttransplant course, medically indicated dietary changes, and immunosuppressant 
therapy. Additionally, weight gain in this population may be attributed (in part) to a 
global trend toward obesity within developed nations. In the United States since 1960, the 
overall prevalence of disease associated with obesity has increased across all age, gender, 
and ethnic groups (Flegal, Carroll, Kuczmarski, & Johnson, 1998). Today, over 60% of 
the United States adult population is classified as overweight or obese, largely from 
increased adipose stores (Catenacci, Hill, & Wyatt, 2009).   
 
The link between excess body fat weight and health is well established in the 
literature (MacLean, Higgins, Giles, Sherk, & Jackman, 2015). Within the general 
population, obesity-induced, metabolic syndrome is associated with dyslipidemia, 
diabetes mellitus, and hypertension, each representing independent risk factors for 
cardiovascular disease (CVD; Gore et al.,2006). Importantly, kidney transplant recipients 
are more vulnerable to the physiological changes associated with these diseases (Cashion 
et al., 2014; Cupples et al., 2012), yielding more severe health consequences. Obesity-
induced vasculopathy may also contribute to chronic allograft nephropathy, decreased 
graft function, and survival with concomitant decreased life expectancy for kidney 
transplant recipients. This makes monitoring of weight gain and overall body 
composition critical for these populations.  
 
Several methods of measuring body composition are described in the literature, 
including single anthropometric or nontraditional technological methods, such as 
 
2 
bioimpedance analysis (BIA), magnetic resonance imaging (MRI), computerized 
tomography (CT), air displacement plethysmography (ADP), or dual-energy x-ray 
absorptiometry (DXA). To date, few studies have explored quantitative methods useful in 
monitoring body fat composition as a predictor of overall health in post-kidney transplant 
patients. We propose a novel model of utilizing biomarkers and body composition 
methods to better identify patients from this subgroup at high risk for body fat weight 
gain and associated adverse outcomes. Early identification, close continued monitoring, 
and treatment may greatly improve health outcomes in this population.  
 
 
Statement of the Problem 
 
 Numerous studies have shown the burdensome nature of postoperative weight 
gain for kidney transplant patients. This is a common problem and can have negative 
effects on health outcomes, quality of life, and mortality rates. In particular, excess body 
fat is a potential risk factor for CVD and other medical conditions (Cashion et al., 2007; 
Cupples et al., 2012; Gore et al., 2006). The overall problem addressed by our study was 
the lack of research on the association between changes in body composition (measured 
by DXA and anthropometric indices) and biomarkers (serum glucose, lipid levels) as 
predictors of CVD and graft loss after kidney transplant. The specific problem explored 
was the distribution of body fat and its relationship to diseases. For example, the amount 
of visceral adipose tissue (VAT) in the thoracic and abdominal cavities has been 
associated with circulatory disorders and cardiovascular disease. The literature lacks data 
to determine which methods and measures of weight (anthropometric or DXA) are most 
accurate in evaluating risk of CVD for kidney transplant recipients. 
 
Although studies have shown that CT, DXA, and MRI provide a direct measure 
of regional distribution of VAT and have found a strong link between increased 
abdominal fat and increased morbidity and mortality, anthropometric methods remain the 
preferred choice for clinicians to assess body composition. Anthropometric methods are 
commonly preferred due to their relatively low cost and ease of use. The use of 
anthropometric methods is problematic, however, because of their limited sensitivity or 
specificity, high variability, and poor correlation with disease to outcome. Consequently, 
commonly utilized anthropometric approaches provide only a limited assessment of body 
composition in kidney transplant populations. Thus, the study quantitatively explored the 
associations of anthropometric and DXA methods with cardiac-related outcomes in a 
high-risk kidney transplant recipient cohort. 
 
 
Purpose of the Study 
 
 The primary purpose of this prospective longitudinal correlational study was to 
investigate if changes in kidney recipients’ body composition measured by DXA or 
anthropometric indices are related to serum glucose, lipid levels, coronary artery ratio, 
creatinine level, and blood pressure, after 5 years or more. The secondary purpose of this 
study was to explore the relationship between changes in body composition measures 
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assessed by anthropometric measures such as body mass index (BMI), waist 
circumference (WC), and body weight (BW) and DXA measures of the percentage of 
body fat %BF, VAT, total body fat mass (TBFM), android fat mass (AFM), gynoid fat 
mass (GFM), android/gynoid ratio (A/G), and lean mass (LM) in kidney transplant 
patients. 
 
It was anticipated that the main aim of this study would help identify ideal 
anthropometric and/or body composition measures useful in predicting increased 
cardiovascular risk following kidney transplant surgery. Furthermore, correlating these 
findings with elevations within serum glucose, lipid levels, coronary artery ratio, 
creatinine, and blood pressure in kidney transplant recipients could potentially aid in the 
identification of patients most at risk.   
 
 For the purpose of this study, DXA scans were used to exam the distribution of 
body mass and body fat. To the author’s knowledge, no similar studies exist with this 
population.   
 
 
Specific Aims  
 
The overall aim of this study was to compare body composition measures 
assessed by anthropometric measures and DXA with lab values of serum glucose 
(glucose and HgbA1C), lipid levels (triglycerides, high-density lipoprotein [HDL], low-
density lipoprotein [LDL]) and creatinine and blood pressure of kidney transplant 
patients at 1 and 5 or more years post-kidney transplant. Specifically, the study had six 
aims:  
 
1. To determine the association between anthropometric measures and serum levels 
of glucose, lipids, creatinine, and blood pressure of kidney transplant recipients at 
5-8 years posttransplant. 
 
2. To determine the association between body composition measures and serum 
levels of glucose, lipids, creatinine, and blood pressure of kidney transplant 
recipients at 5-8 years posttransplant.  
 
3. To determine if body composition measures by DXA obtained at the time of 
transplant (baseline) are associated with serum levels of glucose, lipids, 
creatinine, and blood pressure of kidney transplant recipients at 5-8 years 
posttransplant. 
 
4. To determine if anthropometric measures obtained at baseline are associated with 
serum levels of glucose, lipids, creatinine, and blood pressure of kidney transplant 




5. To determine the association between changes in anthropometric measures from 
baseline to 5-8 years posttransplant and serum levels of glucose, lipids, creatinine, 
and blood pressure in kidney transplant recipients at 5-8 years posttransplant. 
 
6. To determine the association between changes in body composition measures 
from baseline to 5-8 years posttransplant and serum levels of glucose, lipids, 





 Following are the research questions we sought to answer relative to our aims: 
 
RQ1: What is the association between anthropometric measures and serum glucose, 
lipids, and creatinine levels, and elevated blood pressure in kidney transplant 
recipients obtained 5-8 years posttransplant? 
 
RQ2: What is the association between body composition measures and serum 
glucose, lipids, and creatinine levels, and elevated blood pressure obtained in kidney 
transplant recipients 5-8 years posttransplant? 
  
RQ3: To what degree are body composition measures obtained at the time of 
transplant (baseline) associated with serum levels of glucose, lipids, and creatinine, 
and elevated blood pressure in kidney transplant recipients at 5-8 years 
posttransplant? 
 
RQ4: To what degree are measures of anthropometric obtained at baseline associated 
with serum levels of glucose, lipids, and creatinine, and elevated blood pressure in 
kidney transplant recipients at 5-8 years posttransplant? 
 
RQ5: To what degree are changes in anthropometric measures from baseline to 5-8 
years posttransplant associated with serum glucose, lipids, and creatinine and elevated 
blood pressure at 5-8 years posttransplant? 
 
RQ6: To what degree are changes in body composition measures from baseline to 5-8 
years posttransplant associated with serum glucose, lipids, and creatinine, and 





The Body Composition Assessment Model (BCAM) was developed following a 
comprehensive review of the literature to provide direction for this research. This model 
(Figure 1-1) represents the scientific-technological link between theoretical principles of 
the human body and the empirical constants in fat-estimating equation models and was 










improve the evaluation of weight gain and improve health outcomes in transplant 
recipients.  
 
The different factors involved in influencing weight gain and adverse changes in 
body composition are integrated in the model and represent the effect of overall health 
outcomes. Commonly used anthropometric, as well as more advanced technological body 
composition methods such as DXA and BIA, are included in the model―all of which 
could be used to assess weight and evaluate health outcomes measures in clinical settings. 
Body composition monitoring, in particular, provides an ideal method of assessing 
overall health risks in disease states. This strategy provides a noninvasive method of 
continual evaluation that is well suited for high-risk populations such as kidney transplant 
recipients. The knowledge obtained through these assessments could prove valuable as a 
guiding principle and benchmark towards improving health outcomes overall.  
 
In Chapter 2, the conceptual model will be examined more in depth. The next 
chapter will also discuss an overview of body fat and weight gain in the renal transplant 
and general population, factors that contribute to weight gain, and the literature on the 
conditions that transplant patients (renal and otherwise) develop. Of special interest will 
be the recent history of the use of DXA and the different anthropometric measures used 
to determine body fat and weight gain. The conceptual model for this study is illustrated 
in Figure 1-1. 
 
The BCAM is a systems-based model that helps health care professionals in the 
selection of the most accurate method to evaluate changes in body composition, thereby 
improving monitoring of patient outcomes in clinical settings. Ideally, the use of the 
BCAM model will bridge the gap in understanding the linkage between body 
composition physiology and selection of the most suitable measures for monitoring the 
process of variation in body composition. This will be done specifically by 
acknowledging the interaction among body compositional changes that occur during 
weight gain, aging, the presence or absencs of diseases, and variation in body 
composition that exist among ethnic groups. Selection of the more appropriate measure is 
critical for use of the correct marker for monitoring risk for chronic diseases and to 
evaluate health outcomes.  
  
The BCAM provides an approach to better understand the role of body 
composition in kidney transplant populations and identify the best methods for assessing 
body composition. Clinicians and researchers will gain knowledge of appropriate body 
composition methods and measures for assessing weight gain in the kidney transplant 
population. In addition, future research programs can use and expand upon the BCAM to 
advance methods used to assess body composition in kidney recipients, yielding 






Significance of the Study 
 
The outcome of this study will contribute to our long-term goal of establishing 
clinically useful measures that can reliably identify patients at risk of experiencing 
cardiovascular health complications following kidney transplant surgery. Cardiovascular 
complications are the leading cause of graft failure and death in this population. The 
findings of this study could potentially improve the health and life expectancy of kidney 
transplant patients by providing data that could be used to help design and monitor the 
efficacy of new treatment modalities, particularly for those patients who experience 
substantial posttransplant weight gain. The significance of this study could help increase 
long-term survival rates for kidney transplant patients, improve their quality of life, and 





This study assumed that the outcome measures would be reflective of the 
individuals’ cardiac risk status.   
 
 
Limitations of the Study 
 
Several limitations were present that should be considered when examining the 
study results:  
 
1. Use of a single site may not be generalizable to other populations; however, the 
study site serves as a diverse representation of the general transplant population.  
 
2. Study measures were taken at different times and by different individuals.  
However, all measures were validated and standardized, with the same protocol 
and equipment used at all measurement points.  
 
3. Use of a single posttransplant time point approximately 5 years or longer 
posttransplant may limit utility of study findings. For example, when weight gain 
occurs at 3-4 years or 6-8 years, other medical conditions could worsen along 
with CVD risk. However, previous studies suggest these comorbidities generally 
occur during the early years following transplant surgery.   
 
4. Only measures of body fat and specific aspects of blood chemistry were 
considered even though there are many other factors associated with CVD risk for 
kidney recipients and in the general population. However, those used in this study 




Definition of Key Terms 
 
Substantial literature provides consistent definitions for variables and major 
concepts, especially scientific concepts. Key terms and definitions we used during our 
research follow:    
 
Abdominal obesity. The excessive subcutaneous and visceral fat locate in the 
abdominal region also known as upper-body obesity (Heyward & Wagner, 2004).   
 
Adipose tissue. Body fat that is approximately 83%, 2% protein, and 15% water 
(Heymsfield, Lohman, Wang, & Going, 2005).  
  
Air displacement plethysmography (ADP): Air displacement method measures 
body volume and body density to assess body composition (Heyward & Wagner, 
2004).  
 
Anthropometry. The science of measuring body size and proportion (Heyward & 
Wagner, 2004). 
 
Android fat mass (AFM). The amount of adipose tissue in the abdominal 
area and below the individual neck. It is derived from the fat tissue in the 
android region in grams (Tanamas et al., 2012). 
 
Android obesity.  Identified by localized excess body fat found in the upper-body; it 
is also known as an apple-shaped body (Heyward & Wagner, 2004).   
 
Android/Gynoid Ratio. Android fat is the amount of fat between the 
bottom of an individual’s head and the top of the iliac crest in the lowest 
20% region. Gynoid fat is the amount of fat located downward from the 
android region and from the top of the greater trochanter. It is derived 
from percentage of fat in the android region divided by percentage of fat in 
the gynoid region (Fu et al., 2014).  
 
Bioelectrical impedance analysis (BIA). A body composition method used to 
measure total body water and fat-free mass (Dehghan & Merchant, 2008).   
 
Body composition. Body composition refers to the partitioning of body makeup, 
including protein, fat, water, and minerals fat-mass (weight or percentage) and fat-
free mass weight (Heymsfield et al., 2005). 
  
Body density (Db). The measure of the total body mass to total body volume 
(Heyward & Wagner, 2004).    
 




Bone mineral content (BMC).  The measure of mineral in bones by the DXA 
method that is independent of the body composition calibration method selected 
(Heyward & Wagner, 2004). 
 
Cardiovascular disease (CVD). Cardiovascular diseases are disorders involving the 
heart and blood vessels, such as hypertension, coronary artery disease, cardiac 
dysrhythmias, cerebrovascular disease, heart failure, peripheral vascular disease, and 
congenital cardiac abnormalities (World Health Organization [WHO], 2018). 
 
Dual energy x-ray absorptiometry (DXA). Refers to a method used in clinical and 
research settings to estimate bone mineral density, bone mineral content, fat, and lean 
soft tissue mass (Heymsfield, Wang, Baumgartner, & Ross, 1997).   
 
Essential lipids.  These compound lipids are important for cell membrane formation 
and make up a small portion of the body the total lipid (Heyward & Wagner, 2004).  
 
Fat-free mass (FFM) density or fat-free body (FFB) density.  The measure of 
lipid-free chemicals and tissues found in internal organs, connective tissue, muscle, 
bone, and water (Heyward & Wagner, 2004). 
 
Fat mass (FM) density.  The measure of lipids found in adipose tissue and other 
tissues (Heyward & Wagner, 2004).     
 
Four-component models (4-C).  4-C models refers to the development of 
technological advances in measuring based on water, minerals, protein, and fat 
components in the body at the molecular level (Heyward & Wagner, 2004). 
 
Gynoid fat mass (GFM). The amount of fat in the lower portion of an 
individual’s body around the hip area. It is derived from the fat tissue in the 
gynoid region in grams (Heyward & Wagner, 2004). 
 
Gynoid obesity.  Identified by localized excess body fat found in lower body fat; 
pear-shaped. It is known also called pear-shaped body (Heyward & Wagner, 2004). 
  
Healthy body weight.  A body weight that does not increase the possibility of 
developing a disease risk (Heyward & Wagner, 2004). 
 
Hydrometry.  A human body measurement of water (Heyward & Wagner, 2004).   
 
Hydrodensitometry, also called hydrostatic weighing (HW) or underwater 
weighing (UUW). A method used to estimate total body volume submerging a 
person’s body into water (Heyward & Wagner, 2004). This is a good measure of body 




Magnetic resonance imaging (MRI). “Technique used to create computerized cross-
sectional images of the human body radio frequency signals emitted by hydrogen 
nuclei” (Heyward & Wagner, 2004, p. 230). 
 
Multifrequency BIA (MFBIA). “A BIA approach in which a wide range of 
frequencies (1 kHz to 1 MHz) are used to estimate extracellular, intracellular, and 
total body water:  
Also known as bioelectrical” (Heyward & Wagner, 2004, p. 230). 
 
Multicomponent models. A model composed of  three or more components that is 
used to develop advanced technology methods and measurements based on variation 
in water, mineral, and protein in the fat-free mass of the human body (Heyward & 
Wagner, 2004).  
 
Nonessential lipids. Triglycerides found in the adipose tissue in the human body 
(Heyward & Wagner, 2004).  
  
Percentage of body fat or relative body fat (%BF).  %BF is an individual total 
amount of fat divided by total body weight Percent Fat (android + gynoid regions). % 
BF = 100 × (Fat Mass)/Mass. %BF will be lower for the “classic” calibration 
(Heymsfield et al., 2005). 
 
Reference method. Refers to direct measures of human body components that are 
used and considered “gold standard” in the development of models, methods, and 
prediction equations for assessing body compositions (Heyward & Wagner, 2004).  
 
Six-component models (6-C). 6-C models refer to the development of technological 
advances based on direct measure of chemical composition in vivo of six components 
in the body: water, calcium, potassium, sodium, nitrogen, and chloride (Heyward & 
Wagner, 2004). 
 
Three-component models (3-C). 3-C models refer to the development of 
technological advances based on water, minerals, and tissues components in the body. 
These components are divided into three levels called 3-C water molecular level, 3-C 
mineral molecular level, 3-C cellular level, or 3-C tissue level (Heyward & Wagner, 
2004). 
 
Total body water (TBW). The total amount of extracellular and intracellular fluid 
found in the different areas of the body (Heyward & Wagner, 2004)    
 
Total body bone mineral (TBBM). A measure of all the bone mineral content in the 
body (Heyward & Wagner, 2004).  
 
Total body mineral (TBM). The amount of mineral found in the human body bone 




Total bone mineral density (TBMD). The measure of mineral in bone and cells 
measured by DXA and for this study, is independent of the body composition 
calibration method selected of the 4500 HolgicA equipment  (Heyward & Wagner, 
2004). 
 
Total fat mass (TFM). An indirect measurement of body fat that is estimated from 
total body water or the mean density of the whole body. The fat mass is measured by 
DXA in grams Android + Gynoid regions.  Fat mass measures depend on the Body 
Composition Calibration Method (Heyward & Wagner, 2004).      
 
Total lean tissue mass (TLM). The total body mass less the bones and fat in an 
individual’s body total lean mass in the Android +Gynoid regions. It derived from the 
lean standard deviation value. This is known as the soft tissue component of “Fat-
Free” Mass.  Lean Tissue Mass = Mass – Fat mass – BMC (Heyward & Wagner, 
2004).      
 
Two-component models (2-C). 2-C models are divided into FM and LBM 
and assume these components are consistent for all individuals (Heyward & 
Wagner, 2004).   
 
Visceral Adipose Tissue (VAT).  This is the amount of fat tissue 
surrounding an individual’s organs that impacts a wide variety of clinical 
risk factors including fasting glucose levels, serum triglycerides, and 
cholesterol (Bergman et al., 2006). 
 
Waist circumference (WC). “Measure of central adiposity and upper-body obesity; 
waist girth” (Heyward & Wagner, 2004, p. 232). 
 
Waist-to-hip ratio (WHR). Waist circumference divided by the hip circumference; 
used “as a measure of upper-body obesity and visceral fat” (Heyward & Wagner, 
2004, p. 232). 
 
Whole-body fat. Total body fat measurements provide useful physiological and other 
medical conditions information. They are measured in grams by DXA and include all 
fat tissues in all regions including extractable lipids from adipose tissue and other 
tissues. Also called total body fat mass (TBFM; (Heyward & Wagner, 2004).   
 
For other important abbreviations used in this document, see the List of 





This prospective correlational study attempted to examine the association of 
various methods and measures of body composition and serum glucose, lipid levels, 
coronary artery ratio, creatinine, and blood pressure associated with weight gain in 
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kidney transplant patients. The population included individuals who had undergone 
kidney transplant procedures 5-8 years prior to this study and had participated in the 
parent study. Current blood work was obtained from these individuals to determine serum 
glucose, lipid, and creatinine levels.  
 
This chapter outlined the goals and purpose of the study used to address the 
research problem and gain knowledge regarding the best measures to assess changes in 
body composition that occur during weight gain in kidney transplant recipients. The 
translation of this knowledge will bridge the gap in research and clinical settings by 
identifying accurate measures to evaluate the risk of CVD. The significance of the 
research lies with the potential of how the study’s results may impact further research and 
practice in the monitoring and treatment of kidney transplant recipients, as well as others 
who are in high cardiac risk groups.  
 
Chapter 2 will provide an overview of the relevant literature, including support 
for the conceptual framework, an overview of the CVD and weight gain problems 
experienced by kidney and other transplant patients, and a review of studies on body 





CHAPTER 2.    LITERATURE REVIEW 
 
 
Kidney transplantation has been the preferred choice of treatment for patients 
with end-stage renal disease (ESRD) and is the most commonly performed organ 
transplantation. However, after transplant, a number of recipients experience short-term 
and long-term complications (Urstad, Wahl, Andersen, Oyen, & Fagermoen, 2012). 
Short- term complications typically occur in the immediate postoperative course and 
include edema, kidney dysfunction, pain, and respiratory insufficiency (Elster et al., 
2008).  Powerful immunosuppressive therapies have enabled prolonged survival 
enlarging subpopulations that develop long-term complications. Thus, long-term 
complications pose the greatest source for morbidity and mortality in posttransplant 
recipients. This makes identification and management of long-term complications 
critical. One important long-term complication is weight gain. Increased fat mass 
accumulation contributing to obesity is a serious concern in kidney transplant recipients. 
This chapter will briefly review effects of adipose accumulation on health, morbidity, and 
mortality in renal transplant recipients.  This is followed by an overview of existing 
methods available to quantitate body composition, focusing on those most likely to 
accurately predict well-being within this study population.  
 
Body composition assessments vary in precision and in the target tissue (s) of 
interest. Both the target body composition tissue (s) such as visceral adipose or android 
tissue and the patient health conditions are key players for assessing body composition. 
Both are important phenomenon to address to guide clinicians to use anthropometric 
methods with cautions. These commonly used methods, such as BMI, WC, and WHR do 
not provide suitable body composition measures, specifically body fat, which is critical to 
health outcome. The continuous and frequent use of these methods is due to its quick, 
simple, and inexpensive use. Clinicians should caution the use of these anthropometric 
methods with the general population, as well as in the kidney transplant population due to 
possible health threats for people in this country. The continuous use of body 
composition methods that yield unsuitable body composition measures may potentially 
increase morbidity and mortality rate in kidney recipients (Lee & Gallagher, 2008).  
 
The link between obesity and chronic disease is well established in the literature, 
negatively impacting individuals across all ages, races, gender, and ethnic groups. The 
literature also begs this question: Why is BMI considered an appropriate method for 
assessing body composition and evaluating obesity-related risk in the healthy and 
unhealthy population, in the face of a continuous rise in the obesity epidemic?  
 
The literature in this chapter will also explore reasons why simply tracking body 
weight is neither adequate for assessing body composition, nor suitable for identifying 
risk factors associate with weight gain. In addition, it is important for clinicians to 
understand how biological and pathological factors such as age, ethnicity, gender, and 
presence or absence of diseases influence changes in body composition versus height and 
weight.  For this reason, the literature will discuss advantages and disadvantages of 
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appropriate advanced technology methods and anthropometric methods in the clinical 
setting.   
 
The literature strongly guides and illustrates the need to conduct the study 
effective measures of weight gain 5 years post-kidney transplantation.  In addition, the 
literature outlines numerous influential factors that alter body compositional changes in 
the human body, however, the literature lacks a consensus on the most suitable body 
composition methods and measures.  The literature also provides the foundation for 
development of the BCAM platform, which aids selection of the most effective method 
and measure for measuring weight, particularly for individuals with chronic conditions 
such as kidney recipients.  
 
This chapter presents a review of literature related to the presence and risks 
associated with weight gain and obesity, and methods employed to measure body fat and 
weight gain. The first section describes the search strategy used to identify literature for 
this review followed by sections that discuss the conceptual model, body fat in the 
general population and kidney transplant population, weight gain and obesity in the post-
kidney transplant population in the factors contributing to weight gain and obesity in the 
kidney transplant population, measurement of body fat and weight gain; and the 





 The search strategy for this review used primary sources (e.g., World Health 
Organization) and secondary sources (e.g., research method books) from 1991-2018. The 
search yield was sorted by scientific rigor and relevance to the topic area. Relevant 
articles were identified, and MeSh terms were used to identify other credible and relevant 
articles. Endnote and Refworks were used for reference mangers. Relevant reviews and 
studies were obtained from the UTHSC library database using PubMed Central, PubMed 
Health, and Web of Science. Searches also included database such as CINHAL 
Complete, JAMA, JSTOR, Medline Plus, and Goggle Scholar. Searches were limited to 
studies on humans, adult kidney transplant recipients, single organ transplant, and studies 
published in English. Unpublished studies were not reviewed.  
 
The search also included systematic reviews and meta-analyses, literature 
reviews, and other types of research using Boolean search terms that included body 
composition measures and methods, body composition and weight gain, weight gain and 
kidney transplant population, obesity and kidney transplant population, weight gain and 
obesity and kidney transplant population, risk factors and kidney transplant population, 
body fat and kidney transplant population, over weight and obesity and kidney transplant 
population, complications and kidney transplant population, immunosuppression 
medications and kidney transplant population, cardiovascular disease and kidney 
transplant population, dietary intake and physical activity and kidney transplant 
population, measurement and body fat and weight gain, anthropometric measures and 
instrumental scans, DXA and BIA methods and measures, MRI, CT, ADP and body 
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composition assessment, body composition and cardiovascular disease, kidney transplant 
population, and the measurement of weight and obesity.  
 
Studies were considered for inclusion whether they were observational, cross-
sectional, cohort, longitudinal, prospective and retrospectives, or comparative. The 
participants of the studies included adult kidney/kidney transplant recipients and adults 
who used methodological measurement to assess health outcomes, and predictions were 
included. Recipients of any transplant other than a kidney transplant were excluded, 
including kidney-pancreas transplant recipients.  
 
 The literature search was repeated multiple times using these same search terms 
prior to publication of the parent study’s findings, and likewise throughout the 
preparation for, conduct of, and reporting of results from this follow-up study.  New 





The Body Composition Assessment Model (BCAM) is a novel approach that 
incorporates dynamic factors in guiding clinicians to appropriate body composition 
analysis, tailored to the unique individual. BCAM provides a conceptual framework for 
assessing body composition and may prove beneficial in better identifying specific 
etiology for weight gain.  This model comprises both system and scientific concepts 
(Figure 1-1). System functions involve biological, biometric, health-related (disease), 
and lifestyle factors. These four concepts influence body compositional changes, either 
directly or indirectly during active weight gain or in the presence of chronic diseases, as 
detailed below.  
 
Additionally, there are three science-based concepts involving body composition 
measure, body composition variation, and body composition methods which can be used 
as a platform to accurately select a body composition method.  For example, kidney 
transplant recipients who develop complications of kidney dysfunction are prone to fluid 
imbalance and may develop fluid shifts from third spacing and fluid overload.  Weight 
gain from fluid imbalance is difficult to differentiate from weight gain due to other 
sources, such as fat accumulation.  BCAM could be utilized in this setting to guide 





Science-based approach concepts are organized into three interconnected areas 
within the center of the BCAM framework called body composition measure, body 
composition method, and body composition variation. Within the clinical setting these 
factors are routinely assessed during routine visits. In the following paragraphs, the 




First, body composition variation is the largest science-based concept because it is 
a key player in the determination of method selection in this framework. Typically, this is 
the first concept assessed during routine clinic visits. Body fat within adult populations is 
distributed within whole body and regional locations and comprised of visceral adipose 
and subcutaneous fat deposits. Variations in subcutaneous fat can be readily apparent 
during physical exam.  Patients may exhibit characteristic android or gynoid fat 
distribution patterns (defined in body composition assessment section). Visceral adipose 
tissue (VAT) describes fat deposits surrounding visceral organ tissue and is more difficult 
to assess and quantitate. For example, visceral fat kills healthy patients. Patients that have 
undergone kidney transplant are more susceptible to alterations within visceral fat stores. 
One underlying assumption in the BCAM is the ongoing direct and/or indirect 
relationship between each concept in the system-science based approach with body 
composition variation for determining appropriate measures.   
 
Secondly, body composition measures quantify the relationship between the 
effective measures and suitable methods. This is an important step to determining the 
most effective measure to assess body composition.  Components of body composition 
are quantified from fat mass (FM), fat-free mass (FFM), protein, mineral, or bone density 
(Db) measurements. These measurements are mathematically calculated to estimate body 
composition measures such WBF, VF, AFM, GFM, A/G Ratio, and LM (Heymsfield et 
al., 1997). The most effective measure to assess body composition is determined by body 
composition models and predictive equations. Each model estimates measures such as 
%BF, WBF, FM, FFM, AFM, GFM, and A/G ratio from a mathematical equation based 
on known or unknown component-, property-based, or combined-based models (Table  
2-1) to develop suitable predictive equations to design effective body composition 
methods.  For example, according to Heyward and Wagner (2004) a known component-
based method (i.e., hydration, Db) measures %BF from FM divided by BW x100 (see 
Table 2-1, Heymsfield, et al., 2005). Clinicians’ careful application of the model’s 
principles and assumptions are essential to effective measures of weight gain in kidney 
recipients.   
 
Lastly, the appropriate method selection is determined by the available measures 
of three types of body composition methods referred to as component-, property-, and 
combined-based methods. The three methods are the platform for determining the most 
appropriate measure and the best method to evaluate body composition in a kidney 
transplant population or a general population. 
   
The author argues for population specificity body composition methods based on 
disease, gender, age, ethnicity, or physical status are critical to effectively assess weight 
gain.  Predictive equations are useful in diverse populations as well as a specific 
population where alteration in fat distribution and fluid disturbances are common.  A 4-C 
molecular model should not be considered in kidney transplant recipients or any 
population with a chronic disease who may experience fluid disturbance with electrolyte 








Note. % BF = relative body fat; Db = total body density (g/cc); FM = fat mass (kg); W = 
(kg)/BW (kg), where TBW = total body water and BW = body weight; M = TBM = total 
body mineral (osseous + cell mineral) and BW = body weight; B = TBBM (kg)/BW (kg), 
where TBBM = total body bone mineral (osseous mineral only) and BW = body weight; 
 
Level Model Body Equation  Reference 
Two-Component 
Molecular Level 
BW = fat + fat free 
body 
%BF = [(4.57 / Db) – 
4.142] x 100 
Brozek, 1963 
 %BF = [(4.95 / Db) – 






BW = fat + water + 
(mineral and protein 
combined) 
%BF = [(2.118 / Db) 




BW = fat + mineral 
+ (water and protein 
combined) 
 
%BF = [(6.386 /Db) – 







BW = bone + bone-
free lean tissue fat  
%BF = FM / BW x 
100 
Ellis, 2000 
    
Four-Component 
Molecular Level 
BW = fat + water + 
bone mineral + 
protein  
%BF = [(2.559 / Db) 
– 0.734W + 0.983B – 
1.841] x 100 
Friedl, 1992 
 %BF = [(2.747 / Db) 
– 0.714W + 1.146B – 
2.053] x 100 
Selinger, 1977 
 %BF = [(2.513 / Db) 
– 0.739W + 0.947B – 
1.790] x 100 
Heymsfield, 1996 
 %BF = [2.747 / Db) – 
0.718W + 1.148B – 






BW = TBW + TBN 
+ TBCa + TBK + 
TBNa + TBCI 
FM (kg) = BW – 
(TBW + 6.525 TBN 
+ 2.709 TBCa + 2.76 
TBK + TBNa + 1.43 
TBCI) 
Wang et al., 1998 
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Table 2-1.  Continued. 
 
Constant: TBBM = bone ash x 1.0436; TBM = bone ash x 1279; TBN = total body 
nitrogen; TBCa = total body calcium; TBK = total body potassium; TBNa = total body 
sodium; TBCL = total body chloride.  
 
Note. Reprinted with permission from author Dale R. Wagner 9-16-18. Originally 
published in “Applied body composition assessment”, by Heyward, V. H., & Wagner, D. 





body water (Heyward & Wagner, 2004). The multi-compartment (4-C) model is a highly 
significant predictor of the relationship between age and ethnicities. For example, Asian 
populations have a high level of adipose tissue, especially in the abdominal area and 4-C 
model would be a better estimate of body fat than an anthropometric method such as BMI 
or WC. The use of anthropometric method such as BMI in an Asian population may 
prolong diagnosing individuals who are at risk for cardiovascular disease. Multicom-
ponent models are generally thought to provide more accurate estimates of body fat than 
two-component models, especially when one of the assumptions of the two-component 
model might be violated, such as constant hydration, which is not likely in the kidney 





The BCAM is a system approach for assessment of body composition in the 
clinical setting. The system concept describes the function of biological, health-related, 
biometric, and lifestyle factors in guiding optimal body composition assessment in 
healthy or unhealthy populations. In the BCAM (Figure 1-1), biological factors influence 
body composition variation. First, it is important to understand the body composition 
changes at the cellular, the molecular level, and tissue-organ level when determining the 
most effective measure for assessing body composition   (Baumgartner, Heymsfield, 
Lichtman, Wang, & Pierson, 1991; Gao et al., 2008) and the underlying assumptions used 
to estimate %BF. For example, health-related factors such as metabolic syndrome, 
hyperlipidemia, hypertension, diabetes, cardiovascular disease, graft loss, and mortality 
(Anjana et al., 2004) alter body composition changes at the cellular, molecular, or tissue-
organ level and during active weight gain. 
 
The health-related concept is essential for determining the most suitable measure 
for assessing body composition, and the presence of a specific disease during active 
weight gain. For example, kidney recipients often experience fluid disturbance and 
accumulation of body fat with increased body weight. As a result, weight gain could alter 
fat distribution in different anatomical areas and cause disturbance intra- and extracellular 
fluid (Heyward & Wagner, 2004). Both variations in body composition conditions may 
cause health-related conditions such as cardiovascular disease or new onset diabetes.  A 
clinician could apply the presence of a health-related condition to determine the best 
measure for assessing body composition in a patient with alteration in fluid disturbance 
or distribution of fat.  Next, the biometric factors in the BCAM represent the relationship 
between anthropometric methods and whole body composition (WBC). The 
anthropometric variables are measurable biometric factors used to calculate BMI, WC, 
WHR, and skinfold (SKF) methods. These methods include measures of body weight, 
body volume, body surface, waist, hip, thigh, arm, bi-iliac, knee, ankle, elbow, height, 
and recumbent length. The BCAM describes a direct or indirect relationship between 
biometric factors and each factor within the system-based approach and one concept 
science-based approach called body composition variation.  For example, the BCAM 
lifestyle factors such as decreased physical activities and increased caloric intake may 
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indirectly influence body composition variation by altering fat distribution throughout the 
body.  
 
Collectively, the BCAM concepts and factors demonstrate a direct and/or indirect 
interaction between a systematic-science-based approach that helps to identify accurate 
measures of body composition to determine the most effective method for assessing body 
composition. The understanding of the relationship between components of body 
composition and biological and pathological impact on body composition changes is key 
to accurate measures and methods and improving health outcomes. 
 
 
Body Fat in the General Population and Kidney Transplant Population 
 
Body fat is the fat found in adipose tissue, which is stored below the skin and 
surrounding the internal organs (Heymsfield, Lohman, Wang, Going, 2005). Percent 
BF is an estimate of total body fatness used to evaluate the relationship between excess 
body weight, accumulation of adipose tissue, and health (Teixeira, Sardinha, Going, & 
Lohman, 2001)). Historically, studies have shown a relationship between BMI, %BF, and 
metabolic complications of adiposity, elevated lipoproteins, and cardiovascular 
disease (Despres et al., 1990; Kissebah et al., 1982; Teixeira et al., 2001). More critical 
findings by Kwakernaak, Toering, and Navis (2013) suggested numerous factors that 
contribute to health complications were also associated with excess weight measured by 
BMI. Health complications such as chronic kidney disease were strongly linked to central 
body fat distribution.  
 
Numerous studies have identified limits in BMI guidelines and variation in 
measures in population specificity. For example, some studies found a correlation 
between accumulation of visceral fat in the abdominal cavity elevates triglycerides, 
reduces high-density lipoprotein cholesterol, elevates blood pressure, and elevates fasting 
plasma glucose and measures of body fat by BMI or adiposity (Cofan, Vela, & Cleries, 
2005; Ojo et al., 2000).  Cofan et al. (2005) found weight gain after transplantation 
contributed to the prevalence of obesity, with women significantly higher than men (21% 
vs. 13%; P <0.0001). Numerous studies found a link between increased adiposity, %BF, 
BMI, and CVD risk factors.  However, BMI category and the excessive abdominal fat in 
Asians and Europeans were largely different and the Europeans were more susceptible to 
CVD and obesity-related health diseases (Gill, 2001).  
 
Another study reported a significant increase in body fat and BMI among women 
African American women, 12 months following kidney transplantation (Pantik, Cho, 
Hathaway, Tolley, & Cashion, 2017). Another author found Asians with a low BMI had a 
higher percentage of fat compared to Caucasians and African Americans, showing BMI 
is an unreliable predictor of mortality risk Gallagher et al. (2000a).  
 
There is substantial literature to support BMI limitations, specifically the inability 
to accurately assess body fat and predict health outcomes in a diverse population. This 
prompts an urgency for future research to address continuous pitfalls of BMI use and 
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challenges for the reduction in prevalence of morbidity and mortality found among 
weight gainers. In addition, an appropriate future consideration is the identification of 
population-specific body composition measures based on age, gender, ethnicity, race, 
physical activity, and presence and absence of a disease.  
 
 
Weight Gain and Obesity in the General Population 
 
According to WHO (2018), the prevalence of overweight and obese adults has 
tripled and continues to rise in the general population. In 2016, over 1.9 billion adults 
were categorized as overweight and 650 million were considered obese. This was 
approximately 13% of the world’s adult population and 15% women and 11% men. 
Within this population, it was reported that 39% of the adults were overweight and 13% 
obese with an estimated 35.5% women and 32.5% men (WHO, 2018).   
 
More alarming, by 2030, if the current trend continues to rise at a steady rate, the 
future prevalence of BMI measures in the unhealthy category is projected at 86.6 % in the 
adult population. More specifically, Black women (96.9%) and Mexican American 
women (91.1%) will be most affected in the adult population. The study also suggested 
by 2048, all adults’ BMI measures could be classified as unhealthy, and by 2034, Black 
women will be among the first group to reach unhealthy BMI measures (Wang, Beydoun, 
Liang, Caballero, & Kumanyika, 2008). Another study projected 65 million more obese 
adults in this country by 2030 (Wang, McPherson, Marsh, Gortmaker, & Brown, 2011). 
According to the Centers for Disease Control and Prevention (CDC, 2014), the obesity 
trend differs among racial and ethnic groups, and for adults ages 20 or older is as follows:  
 
1. Hispanic population 8.5% for Central and South Americans, 9.3% for Cubans, 
13.9% for Mexican Americans, and 14.8% for Puerto Ricans;  
 
2. Asian American population including Chinese (4.4%), Filipinos (11.3%), Asian 
Indians (13.0%);  
 
3. American Indian (8.8%) and Alaska Natives (6.0%), and 24.1% of the American 
Indians in southern Arizona. 
 
The CDC (2014) also reported the prevalence of diabetes was expected to rise 
based on prediabetes cases in 2009-2012. In the U.S., the prediabetes cases are different 
between ethnic and racial groups. The percentages of nonHispanic Whites, nonHispanic 
blacks, and Hispanics diagnosed with prediabetes were 35%, 39%, and 38%, 
respectively. In 2012, 37% of the prediabetes cases in the U.S. were adults ages 20 or 
older, and 51% ages 65 or older. The total number of prediabetes cases for the American 
population was 86,000,000 for ages 20 and over. Monitoring of body composition and 
weight gain should be examined to include measures more suitable for estimating body 




BMI is commonly used to classify individuals based on abnormal or excess 
accumulation of fat  (Beckmann, Ivanović, Drent, Ruppar, & De Geest, 2015). WHO 
defines healthy BMI measures as 18.5 to 24.9, while unhealthy BMI measures range from 
≥25 to ≥30. The unhealthy ranges are categorized as overweight and obese, as shown in 
Table 2-2. 
 
Regardless of the exact percentage of increase, the rising rate of obesity in the 
United States and worldwide has serious ramifications for the health of the population 
and concomitant demands on the health care system, due to the associated chronic 
conditions accompanying excessive weight gain. For example, short-term complications 
from significant weight gain and obesity are delays in wound healing and wound 
infection (Zrim, Furlong, Grace, & Meade, 2012), while long-term complications include 
development of chronic diseases such as Type 2 diabetes, CVD, hypertension (HTN), and 
other comorbidities (Lafranca, IJermans, Betjes, & Dor, 2015a; Silkensen, 2000).  
Adversely, the rise in the prevalence of weight gain and unhealthy BMI measures in 
adults yields an increased burden in several diseases such a cardiovascular diseases and 




Weight Gain and Obesity in the Post-Kidney Transplant Population 
 
Obesity is a common problem in the post-kidney transplant population. However, 
more critical is the accumulation of excess weight gain in areas that specifically 
contribute to the prevalence of life-threatening clinical and subclinical diseases. The 
severity and complications of these diseases are associated with the quantity and 
distribution of body fat in the kidney recipients. In addition, the increase in body fat may 
influence fluid disturbance and increase distribution of visceral adipose tissue in the 
body. As a result, kidney recipients may develop NODAT or CVD (Cashion et al., 2007). 
DM and CVD whether preexisting or new-onset following transplantation are common 
diseases diagnosed  in transplant recipients and cause life-threatening health 
complications (Calò et al., 2017; Neale & Smith, 2015; Ogden, Carroll, Kit, & Flegal, 
2013; Paripovic, Kostic, Spasojevic, Kruscic, & Peco-Antic, 2010b). 
 
The precise extent to which obesity affects the health of the general population is 
uncertain; however, it is known that weight gain influences changes in body 
compositions that are magnified in kidney transplant recipients. While weight gain and 
obesity are risk factors for hyperlipidemia, hypertension, atherosclerosis, and decreased 
life expectancy in the general population, these threats are exacerbated for kidney 
transplant recipients and accompanied by additional risks for allograft nephropathy and 
graft loss. It is also noteworthy that the enhanced CVD risk following transplant is 
manifested by nearly all recipients with experiences of elevated blood pressure, high low-
density lipoprotein and low high-density lipoprotein-cholesterol levels (elevated total 
cholesterol), elevated insulin levels and blood glucose, and abnormal blood lipids. Given 




Table 2-2. World Health Organization Classification of Weight Status by BMI 
 
Weight Status Body Mass Index, kg/m2 
Underweight <18.5 
Normal Weight 18.5-24.9 
Overweight 25-29.9 
Obese  
Class I obesity 30-34.9 
Class II obesity  35-39.9 
Class III obesity  >49 
 
Note: Adapted with permission from World Health Organization (2018). Global Database 






abdominal (visceral) adiposity is undoubtedly responsible for cardiovascular-related 
events being the leading cause of graft loss. In addition to increasing the risk for CVD, 
visceral adiposity has also been identified as a risk factor for DM and specifically 
associated with insulin resistance, dyslipidemia, and hyperinsulinemia (Banerji, Faridi, 
Atluri, Chaiken, & Lebovitz, 1999). 
 
Excessive body weight and obesity pose significant serious threats to health 
outcomes of transplant recipients compared to individuals in the general population 
(Beckmann et al., 2015). Typically, a weight gain of 10 kg occurs during the first year 
following transplant surgery and may double to 32 kg after the first year (Beckmann et 
al., 2015; Cashion et al., 2007; Cupples et al., 2012; Lentine et al., 2008; Stanfill et al., 
2015). Consequently, the incidence of short-and long-term health complications 
associated with weight gain is higher in the transplant population compared to the general 
population (Beckmann, Ivanović, Drent, Ruppar, & De Geest, 2015).  In addition, several 
studies have reported that the average weight gain that occurs following transplant 
surgery is an independent risk factor for graft loss (Cashion et al., 2007; Jezior et al., 
2007; Stanfill, Bloodworth, & Cashion, 2012) and  serves as a negative predictor of 
patient survival (Gore et al., 2006).  
 
The following sections will discuss weight gain and obesity risk on cardiovascular 
disease post-kidney transplant recipients; the influences of posttransplant fluid and fat 
distribution on their weight; and the relationships among donor source, gender, race, and 
posttransplant weight gain. 
 
 
Weight Gain, Obesity Risk, and Cardiovascular Disease Post-Kidney Transplant 
 
The evidence of health complications associated with excess body weight and the 
prevalence of increased body weight and fat following kidney transplantation remains a 
constant, as well as a serious impact on health conditions. In the United States, since 
1960, the overall prevalence of a metabolic diseases has been associated with increased 
weight gain across all age, gender, and ethnic groups (Flegal et al., 1998). 
 
More critically, weight gain leads to progressive changes in the quantity and 
distribution of certain compartments of body composition such as visceral adipose tissue 
(VAT) and often results in two major diseases including CVD and Type 2 diabetes 
(Cashion et al., 2007; Fernandes et al., 2013; Lafranca, Ijermans, Betjes, & Dor, 2015b). 
Additionally, there is convincing evidence that VAT volume, rather than subcutaneous 
fat, is correlated with the presence of other CVD risk factors such as dyslipidemia and 
hyperinsulinemia (Banerji et al., 1999).  
 
The risk of CVD associated with weight gain highlights the importance of 
monitoring and periodically measuring changes in body composition in the kidney 
transplant population. A study by Rao and Coates (2018) found an association between 
CVD risk factors such as hypertension and dyslipidemia and diabetes following kidney 
transplantation. Alshehri (2010) found that measures such as abdominal adiposity, 
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elevated blood pressure, high low-density lipoprotein and low high-density lipoprotein-
cholesterol levels (elevated total cholesterol), elevated insulin and blood glucose, and 
abnormal blood lipids were significant markers for cardiovascular risk and other health 
complications. 
 
For the above reasons, this study explores the association between markers of 
CVD identified in the literature and body composition measured by anthropometrics and 
DXA (Baum, 2001b; Fernandes et al., 2013; Lafranca et al., 2015b; Rao & Coates, 2018).  
As studies have shown, individuals with extreme levels of body fat are at greater risk for 
developing CVD (Shah & Braverman, 2012). Therefore, a goal of this study was to better 
understand the effective monitoring of body weight and measures, and to evaluate the 
level of body fat that falls at or near extreme levels that could result in serious health 





CVD is one of the leading causes of mortality and long-term morbidity in kidney 
transplant recipients (Fernandes et al., 2013; Lentine et al., 2010; Neale & Smith, 2015). 
The number of deaths due to CVD was estimated at 36% for the kidney transplant 
population (Elli, Traversi, & Ponticelli, 2000). On the other hand, in general, a 
prospective study in 2007 estimated the deaths associated with CVD at 66% in 
individuals with central obesity compared to 44% with non-central obesity (Orazio et al., 
2007), while the estimated deaths in the after kidney transplant population ranged from 
30% to 50% (Dimeny, 2002). Following transplantation,  CVD risk is manifested by 
more than half of the recipients experiencing elevated BP, high low-density lipoprotein 
(LDL), low high-density lipoprotein (HDL), elevated total cholesterol, elevated insulin 
levels and blood glucose, and abnormal blood lipids (Dimeny, 2002; Elli et al., 2000; 
Neale & Smith, 2015). These  health conditions, typically associated with excess 
abdominal (visceral) adiposity, are susceptible  markers for CVD, which is one of the 
leading causes of allograft loss (Neale & Smith, 2015). 
 
Patients with CKD and on dialysis have a higher risk of developing CVD 
(Marcén, 2006; Neale & Smith, 2015) compared to the general population (Jun, Lv, 
Perkovic, & Jardine, 2011). Although kidney transplantation reduces the recipients’ risk 
of cardiovascular (CV) events (Neale & Smith, 2015), the presence of excess fat 
increases the patients’ risk of developing CVD (Armstrong, Campbell, Hawley, Johnson, 
& Isbel, 2005; Baum, 2001b; Cashion et al., 2007; Chan, Garneau, & Hajjar, 2015; 
Cordeiro et al., 2013; Dimeny, 2002; Fernandes et al., 2013; Lafranca et al., 2015a) or 
worsening CV events (Armstrong et al., 2005). CVD can lead to morbidity and mortality 
for posttransplant patients (Marcén, 2006), dialysis patients, and CKD patients as an 





New Onset Diabetes Mellitus 
 
According to Ogden, Carroll, Kit, and Flegal (2014), more than one third of U.S. 
adults (34.9%) are obese. On the other hand, Eckel et al. (2011) stated that 34% of the 
U.S. adult population is obese, with more than 11% of individuals over the age of 20 
diagnosed with diabetes and the number is expected to increase 21% by 2050. Many 
individuals who are obese will develop Type II diabetes (Eckel et al., 2011). Eckel et al. 
(2011) stated that a connection between obesity and Type II diabetes exists, but the 
connection remains unclear.   
 
Diabetes is diagnosed with excess blood glucose within the body (Shivaswamy, 
Boerner, & Larsen, 2016) and may lead to kidney failure (Ogden et al., 2013). DM  is 
diagnosed in 3% to 20% of the kidney transplant population (Baum, 2001a).  Historically, 
in 2011–2012, 36.5% of the U.S. chronic kidney disease adults aged 20 years or older 
were diagnosed with diabetes based on fasting elevated blood sugar levels or HgbA1C 
(CDC, 2017). Similarly, in 2015, the CDC estimated, 30.2 million people are affected 
with diabetes, which represents 7.2 million of the U.S. population who are undiagnosed 
with diabetes. Prediabetes is found in 48.3 % of adults aged 65 years or older. Also in 
2015, approximately, 84.1 million American adults were diagnosed with prediabetes 
based on HgbA1C (CDC, 2017). 
 
Consequently, if the prevalence of excess weight gain in the kidney transplant 
population continues to rise (Kwan, Hajjiri, Metwally, Finn, & Perkins, 2016), it is 
possible the prevalence of new onset diabetes mellitus after transplantation (NODAT) 
will continue to rise (Olyaei, deMattos, & Bennett, 1999; Shivaswamy et al., 2016; Yu et 
al., 2016b). Approximately 4% to 25% kidney transplant recipients will develop NODAT 
(Peev, Reiser, & Alachkar, 2014). NODAT can result in graft loss and poor survival rates 
for kidney recipients (Kwan et al., 2016; Yu et al., 2016a). Obesity pre and posttrans-
plantation may worsen NODAT (Peev et al., 2014; Yu et al., 2016a), especially since 
several immunosuppression medications to reduce transplant rejection increase 
diabetogenic potential (Peev et al., 2014).  
 
New onset diabetes mellitus following transplantation (NODAT) occurs in the 
presence of excessive weight gain and increased triglyceride levels following transplant 
surgery (Olyaei et al., 1999; Pham, Pham, Pham, Pham, & Pham, 2011; Shivaswamy et 
al., 2016; Yu et al., 2016a); (Kim et al., 2013). In addition, up to 50% of kidney 
transplant recipients are reported to develop NODAT (Pham et al 2011), which often 





According to Paripovic, Kostic, Spasojevic, Kruscic, and Peco-Antic (2010a), 
suggested hypertension is a serious and common problem after kidney transplantation; 
therefore, early intervention should begin immediately after surgery. The acute and 
chronic complications experienced after kidney transplant are critical to survivability of 
 
27 
the allograft; therefore, new onset HTN should be avoided after kidney transplant. With 
respect to HTN guidelines, formerly, HTN was classified as BP above 140 mmHg 
systolic blood pressure (SBP) and above 90 mmHg diastolic blood pressure (DBP) 
(Mafutha & Wright, 2013). However, the Whelton et al. (2018) guidelines identify two 
stages to classify HTN: Stage I defines HTN as SBP >130-139 mmHg and DBP >80-89 
mmHg. However, stage two defines HTN as SBP >140 mmHg and DBP > 90 
mmHg. Azancot et al. (2015) found an association between hypertension and subclinical 
inflammation and atherosclerosis 24 hours after kidney transplant with elevated SBP 
(p<.0001). Another study found 50% to 90% of the kidney transplant population were 
diagnosed with HTN (Fernandes et al., 2013).  
 
There are several factors that contribute to HTN in the kidney transplant 
population, which are more critical when patients gain weight while taking 
immunosuppressive medications. First, a high percentage of transplant recipients 
experience a sedentary lifestyle, which contributes to the obesity, thus influences the 
onset of HTN (Neale & Smith, 2015; Paripovic et al., 2010b). Secondly, the life-long use 
of immunosuppression after kidney transplantation, such as corticosteroids and 
calcineurin inhibitors (CNIs), may trigger elevated blood pressure and HTN (Calò et al., 
2017; Neale & Smith, 2015; Paripovic et al., 2010b). Next, the use of corticosteroids by 
kidney recipients may cause hypernatremia that could lead fluid disturbance, such as 
fluid retention. Unfortunately, fluid retention is a common problem in the kidney 
transplant population, which may trigger elevated BP, leading to HTN (Tantisattamo, 
2017). Lastly, the use of CNIs prevents acute organ rejection and prolongs graft survival 
(Hoorn et al., 2012; Kalluri & Hardinger, 2012; McPartland & Pomposelli, 2007), 
yielding favorable post-kidney transplant outcomes. Lastly, the use of CNIs causes 
vasoconstriction in the kidney and often induces HTN (Hoorn et al., 2012).  
 
 
Influence of Posttransplant Fluid and Fat Distribution on Weight Gain 
 
Heyward and Wagner (2004) stated that fluid disturbance influences body 
compositional changes and is altered by weight gain; specifically, declines in lean body 
mass and total body water (TBW) lead to increased total body fat. The decline in TBW 
and a rigorous medication regimen following kidney transplantation can induce a severe 
fluid imbalance and additional complications, such as congestive heart failure, poor 
kidney function, insulin resistance, ascites, and edema. For example, kidney transplant 
recipients routinely take medications from several drug classes, which influences 
symptomatic changes, such as fluid retention or loss and hyper- and hyponatremia. 
Unlike in the general population, kidney recipients are more susceptible to developing 
hyponatremia from volume overload, a serious condition that can cause death in the 
kidney recipients (Gore et al., 2006). 
 
Fat distribution can influence body composition changes that affect cardiac 
structure and function, impacting outcomes and contributing to major complications in 
kidney transplant patients (Weiner et al., 2012).  For example, increased fat distribution 
leads to decreased cardiac function, which can cause myocardial infarction. The cardiac 
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structure is altered by large deposits of adipose tissue in the atrioventricular groove and 
right ventricular epicardium. These compositional changes influence aortic stiffness and 
can cause cardiac complications, including systolic blood pressure fluctuations and 
atherosclerosis. The latter is strongly influenced by cholesterol levels, which is important, 
because changes in total cholesterol and triglyceride levels in kidney transplant recipients 
could affect metabolism and increase the risk for CVD (Weiner et al., 2012). 
 
 
Donor Source, Gender, Race, and Posttransplant Weight Gain 
 
 
Donor Source  
 
The prospective study by Moore and Gaber (1996) aimed to determine the 
relationship between weight gain and donor gender in 50 kidney allograft transplant 
recipients. The study participants included living related donor recipients (N = 11) and 
cadaver donor recipients (N = 39). The study examined the relationship between kidney 
function in diabetic and non-diabetic recipients who gained weight compared to non-
weight gainers. The collection of data occurred at the time of transplant and 6 months 
posttransplant. As a result, 76% of the participants gained a mean average of 4 kg, while 
the other 30% either lost weight or did not gain weight.  The women’s average weight 
gain was 8 kg, while the men’s average weight gain was 7 kg (Moore & Gaber, 1996). 
Moore and Gaber (1996) reported that Live renal donor allograft recipients had a weight 
gain of 6 kg ± 2 kg, which was higher than the cadaveric recipients (p < .0001) and 
participants with diabetes gained 5 kg while nondiabetics gained 4 kg (p < .0001). No 




Gender and Race  
Some studies explored the difference between weight gain in African Americans 
and Whites. Between 1983 and 1999, a retrospective review examined the records of 506 
kidney transplant recipients following kidney transplantation (Baum et al., 2002). The 
study found that African Americans gained significantly more weight than Whites (13.6 
kg versus 9.1 kg; p < 0.05) during the first year following transplantation (Baum et al., 
2002). Similarily, 2 and 3 years following transplant surgery African-Americans 
continued to gain more weight than Whites (16.2 kg and 16.4 kg, versus 11.5 kg and 11.1 
kg, respectively; p < 0.05; Baum et al., 2002). In addition, Clunk, Lin, and Curtis (2001) 
found a significantly higher weight gain in African Americans compared to Whites, as 
did Gallagher et al. (2000a) in a retrospective review of 974 kidney recipients. In another 
study Gallagher et al. (2000b) confirmed weight gain after kidney transplantation is 
common, with an average weight gain of 10.3 kg. The study also found that over 87% of 
the weight gainers averaged a minimum of 2 kg over 12 months.  
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Cashion et al. (2007) conducted a more comprehensive retrospective analysis of 
weight changes in 171 individuals one year following kidney transplant surgery from 
January 1998 to January 2002. The recipients were women and men, and African 
American and White (Cashion et al., 2007). Study outcomes included fasting glucose, 
triglycerides, creatinine levels, and BMI (Cashion et al., 2007). Descriptive analysis 
found that all 171 kidney transplant recipients had a significant increase in mean weight 
(6.2 kg ± 10.7 kg; p < 0.05) and BMI (2.1 kg ± 3.8 kg; p < 0.05) one year following 
kidney transplantation (Cashion et al., 2007). In addition, most of the African Americans 
(30.5 kg) were more obese than Whites (29.5 kg), and more women (31.4 kg) were obese 
than men (29.2 kg), regardless of ethnicity and gender (Cashion et al., 2007). The study 
also found higher levels of triglyceride in the obese compared to nonobese transplant 
recipients (Cashion et al., 2007).  
Collectively, these studies confirm weight gain occurs following kidney 
transplantation with significant gain presented one year following kidney transplantation, 
with a particular difference among population specificity. For example, women had a 
greater weight gain than men, and African Americans had a greater weight gain than 
Whites. The seemingly predictable weight gain and obese status following kidney 
transplantation could possibly threaten the viability of the new kidney, as well as, the 
recipient’s life, and even more so for African American recipients, who also have a 
higher incidence of hypertension.  
 
 
Other Factors Contributing to Excess Weight Gain in the Kidney Transplant 
Population 
 
There is substantial literature that suggests weight gain following kidney 
transplantation is a well-known occurrence. Attempts to explain this phenomenon have 
been attributed to several factors including immunosuppression medications (de Oliveira 
et al., 2014; McPartland & Pomposelli, 2007; Ryan et al., 2014) increased caloric intake 
due to history of reduced dietary restrictions (Bloodworth, Ward, Relyea, & Cashion, 
2014; Cupples et al., 2012; de Oliveira et al., 2014; Ryan et al., 2014), decreased level of 
physical activities following transplant surgery (Cupples et al., 2012; de Oliveira et al., 
2014; Ryan et al., 2014; Sanchez et al., 2007), and consequences of concomitant chronic 





Weight gain often associated with immunosuppression medications (McPartland 
& Pomposelli, 2007) can increase rejection and decrease the viability of kidney function 
(Allison, 2016; Bamoulid et al., 2016; Saemann & Sunder-Plassmann, 2008; Snowsill et 
al., 2017). Other complications associated with immunosuppression medications and 
weight gain include new onset of HTN, hyperglycemia, Type II diabetes, CVD, and 
hyperlipidemia (McPartland & Pomposelli, 2007). According to Aksoy (2016), there is 
an association between weight gain and posttransplant steroid therapy use. This study 
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found, after 36 months, 9% of kidney recipients experienced weight gain due to increased 
appetite. The use of immunosuppressive medications, such as steroid therapy, may cause 
hypernatremia and fluid disturbance, which lead to other health-related complications 
(Calò et al., 2017).  
 
A retrospective study investigated the association between weight gain and impact 
of immunosuppressive therapy, without steroids, in 203 kidney transplant recipients from 
January 2005 to December 2009 (de Oliveira et al., 2014). The average weight gain 
found was approximately 15 pounds, after first months, and 9% of the participants gained 
weight after 36 months, post-kidney transplantation (de Oliveira et al., 2014). de Oliveira 
et al. (2014) suggested a negative impact of steroid therapy on weight gain following 
kidney transplantation; instead the study reported significant weight gain was associated 





Following kidney transplant, recipients often experience weight gain that is 
attributed to increased appetite and an increased food consumption. Some studies have 
shown immunosuppression medications and steriod therapy increased the recipients’ 
appetites, thus increased body weight and BMI (Elster et al., 2008).  Bloodworth et al. 
(2014) found significant weight gain after kidney transplantation, with an average weight 
gain of 4.2 kg in a year. The study reported an increase in BMI (p < .05) for participants 
(n = 229) that lived within 1 mile of a grocery store near the kidney recipients were 
asssociated with an increase in BMI (p < 0.05); however, fast food restaurants and 
convenience stores did not significantly lead to BMI changes. 
 
 
Physical Activity  
 
 Physical activity plays a role in reducing weight gain and obesity, and in 
improving overall health after transplant, although few transplant recipients engage in 
physical activity (Dontje et al., 2014; Sanchez et al., 2007). O'Brien and Hathaway 
(2016) reported physical activity is essential following transplantation; however, they 
found no specific standards or recommendations for increasing posttransplant physical 
activity in the literature. Nevertheless, guidelines in performing physical activity should 
be compatible with the kidney recipient’s cardiac tolerance and physical ability (Bellizzi, 
Cupisti, Capitanini, Calella, & D'Alessandro, 2014). As health care providers begin to 
encourage and prescribe activity regimens for transplant recipients, it will be critical to 
select methods, like DXA scans, which have the ability to assess body components such 






Measurement of Body Fat and Weight Gain  
 
In general, there are several measures available to monitor body weight and body 
composition components.  The anthropometric measurements assess the ratio of size and 
proportion of the body’s composition such as BMI and WC. These measurements are 
advantageous because they are widely available, rapid, safe, and inexpensive, making 
them ideal for clinical and hospital settings. Anthropometric measures do not directly 
measure body fat and therefore lack the ability to assess body fat and predict new onset 
and progression of diseases as well as other health complications found in kidney 
recipients.   
 
In kidney recipients, DXA provides indirect measures of regional and whole-body 
composition. DXA measures masses of soft tissue and fat and lean tissues. Unlike 
anthropometric measures, DXA assesses visceral fat, whole body fat, subcutaneous fat, 
and lean mass and is useful to predict health risk in kidney recipients. In addition, DXA 
provides a precise whole-body measurement and can explain variations in predicting 
outcomes post-kidney transplants (Heyward & Wagner, 2004). 
 
The monitoring of weight gain and subsequent obesity following transplant 
surgery is essential in order to assess and evaluate new onset and progression of 
concurrent chronic conditions. The more precise measurement of weight gain and obesity 
requires assessment of body composition (Duren et al., 2008; Heyward & Wagner, 2004). 
One option for measurement is called the direct method. A direct method refers to body 
composition methods that provide validated estimates of %BF, FFM, muscle, bone 
density (Db), hydration, or other body components, while indirect methods refer to the 
methods of measuring body composition that estimate %BF, FFM, muscle, Db, 
hydration, or other body components (Heyward & Wagner, 2004). Regardless of the 
underlying cause, the need exists for accurate measures that reflect not just weight or 
BMI, but more specifically the distribution of body fat in areas most associated with 
weight-related morbidities. Such measures could be used not only to identify individuals 
who are at high risk but also more accurately monitor efforts to reduce fat mass. 
 
 
Body Composition Methods 
 
 Early body composition research developed some important concepts; however, 
the methods were not practical nor precise for clinical settings due to the environmental 
conditions required for assessment. Later, an anthropometric model evolved, to estimate 
total body muscle mass which was an important contribution to body composition 
research. Today, many clinicians use simple and practical methods to measure FM and 
FFM with different measurement methods such as the two-compartment models and 
hydrodensitometry, air displacement plethysmography (ADP), anthropometric, or BIA 
three-and four compartment models, and multicompartment models.  This section will 
discuss anthropometric methods and regional and whole-body composition measures, and 
the underlying assumptions of each method, accuracy, precision, reliability and validity, 





According to Duren et al. (2008), anthropometric body composition 
measurements involves several parameters relevant to measures such as area; body 
volume; body weight; lengths at the knee height, arm span, and stature; skinfold 
thickness; breadths of the elbow, bi-iliac, ankle, wrist, and biacromial; and bodily 
circumference at the head, trunk, waist, hip, calf, wrist, arm, and chest. These 
anthropometric variables are useful in the predictive equations in the determination of 
quantitative techniques used to measure an individual's body fat composition. For 
example, estimation of body composition measurements from skinfold thickness 
measurement is primarily based on the large proportion of total body fat that is located 
underneath the skin (Heyward & Wagner, 2004). Therefore, by obtaining measures from 
skinfold thickness and using a method such as underwater weighing, the percentage of 
body fat could be estimated in a healthy population. Unfortunately, anthropometric 
measures are limited when used as a single measure (Heymsfield et al., 2005).  
 
Common anthropometric measures assess total and regional body composition. 
BMI, WHR, and WC are relatively simple and inexpensive methods to assess body 
composition (Vazquez, Duval, Jacobs Jr, & Silventoinen, 2007). These anthropometric 
measures are useful and widely used to assess body weight and several health-related risk 
factors associated with excess adiposity (Heymsfield, Peterson, Thomas, Heo, & Schuna, 
2016). However, anthropometric methods are not useful when tissue-based measurements 
such as VAT compartment performed by DXA and CT scans are needed to capture the 
association between adiposity and health-related conditions (Cordeiro et al., 2013; 
Vatanparast et al., 2009).   
 
 
Body Mass Index 
 
BMI, a ratio of weight (kg) and height², is an attribute of obesity. BMI guidelines 
assume there is an association between body fat and body mass, but there is not. 
Furthermore, BMI lacks the ability to calculate an individual’s body composition and 
assess body fat. Since body fat is known as a primary physiological risk factor for 
morbidity and mortality (Gallagher et al., 2000b; Josse, Azizian, French, Kramer, & 
Phillips, 2011), BMI is not a good measure to predict cardiac mortality (Josse et al., 
2011) and its utility as a measure is limited in the general as well as the kidney transplant 
population.  
 
According to Heymsfield et al. (2016), BMI is an acceptable measure for 
estimating total body fat and assessing adiposity. BMI measures are a problem for two 
reasons. First, they lack the ability to estimate body fat among different ages, genders, 
ethnicity groups, and athletic build (Schoeller et al., 2005), which are factors that affect 
the relationship between BMI and %BF. Secondly, BMI measures often inaccurately 
misclassify individuals as underweight, overweight, or obese because of their age, 
gender, or ethnicity (Carpenter et al., 2013; Daniels, 2009; Heyward & Wagner, 2004). 
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For example, Heymsfield et al. (2016) found that the relationship between BMI and 
adiposity differed across race and ethnic groups, specifically among Whites, African-
Americans, and Mexican-Americans. This finding raises questions about the suitability of 





Waist-to-hip ratio (WHR) is an indirect measure used for assessing body 
composition and determining risk factors associated with cardiovascular and metabolic 
diseases. Table 2-3 provides the waist-to-hip circumference ratio norms for men and 
women. The WHR measure is a simple calcualtion of WC in centimeters divided by hip 
circumference in centimeters (Heyward & Wagner, 2004; Simmons, 2001). According to 
(WHO), the cutoff point for at-risk metabolic complications for men is WHR ≥ 0.90 cm 
and WHR ≥ 0.85 cm for women. (Alberti, Zimmet, & Shaw, 2006). However, the 
International Diabetes Federation recommended a different set of cutoff points for 
different ethnic groups: for Europids men the WHR ≥ 94 cm and WHR >80 cm for 
women. Meanwhile, the recommendations for South Asians, Chinese, and Japanese men 
suggest WHR > 90 cm and WHR > 80 cm for women (Alberti et al., 2006). 
 
The distribution of upper body fat called the android and lower body fat called 
gynoid typically is different in men and women. The upper body fat or central obesity is 
more common in men, while lower body fat appears more in women deposited on the 
hips and thighs. However, if a person is obese, they are often categorized into either 
group. The location of body fat is important when using WHR for examining excess 
weight and disease risk, especially in different genders and ethnic groups. Although 
WHR is a useful anthropometric measure for central adiposity and visceral fat, there are 
limitations between gender and ethnicity. One study found an association between 
increase in WHR and postmenopausal women (Donato, Fuchs, Oppermann, Bastos, & 
Spritzer, 2006), because women experience a menopause fat distribution pattern that is 
similar to men during menopause. Murray (2006) found an association between increased 
WHR and myocardial infarction, for women at 0.83 and for men at 0.9. Asians, typically, 
have a strong association between increased WHR and cardiac mortality (Josse et al. 
(2011). This is due to the waist circumference association with visceral fat. However, the 
WHR measure is limited in the kidney transplant population because the hip 
circumference is subcutaneous fat deposition and the waist circumference is 
subcutaneous and visceral fat. 
 
 
Air Displacement Plethysmography 
 
ADP is used to estimate body volume and does not provide measurements of the 
regions. It is a less expensive validated and accurate method to measure %BF in obese 
and extremely obese kidney transplant patients compared to DXA (Heymsfield, 2005). 




Table 2-3. Waist-to-Hip Circumference Ratio Norms for Men and Women 
 
  Risk 
Gender Age  Low  Moderate         High Very High 
Men 20-29 <0.83 0.82-0.88 0.89-0.94 <0.94 
 30-39 <0.84 0.84-0.91 0.92-0.96 <0.96 
 40-49 <0.88 0.88-0.95 0.96-1.00 <1.00 
 50-59 <0.90 0.90-0.96 0.97-1.02 <1.02 
 60-69 <0.91 0.91-0.98 0.99-1.03 <1.03 
Women 20-29 < 0.71 0.71-0.77 0.78-0.82 < 0.82 
 30-39 <0.72 0.72-0.78 0.79-0.84 <0.84 
 40-49 <0.73 0.73-0.79 0.80-0.87 <0.87 
 50-59 <0.74 0.74-0.81 0.82-0.88 <0.88 
 60-69 <0.76 0.76-0.83 0.840.90 <0.90 
 
Note. Reprinted with permission from author Dale R. Wagner 9-16-18. Originally 
published in “Applied body composition assessment”, by Heyward, V. H., & Wagner, D. 






are derived from 3-C compartment consisting of fat mass, lean body mass, and bone 
mass. These measures should be used with caution in the elderly and children because of 
the alteration in the density of FFM (Baumgartner et al., 1991). 
  
 
Dual-Energy X-Ray Absorptiometry 
 
DXA is one of the most popular methods for measuring whole body and regional 
body. DXA is able to discriminate between soft tissue mass, total body adipose, bone 
mineral, and bone mineral density. DXA remains a widely used indirect method for 
estimation of total body mineral density (TBMD), total body mineral (Mo), bone mineral-
free lean tissue mass (LTM), fat mass (FM), fat-free mass (FFM=LTM=BMC), and soft 
tissue mass (STM=LTM+FM) compositional changes in human body composition 
research (Dordevic et al., 2018; Heyward & Wagner, 2004; Ng et al., 2018). DXA 
provides a more precise and accurate measurement of estimating %BF compared to 
anthropometric measures, because it can assess regional body composition at the tissue 
level (Heyward & Wagner, 2004; Teixeira et al., 2001; Vatanparast et al., 2009), 
especially in men (Ball, Altena, & Swan, 2004). 
 
While DXA was not originally developed to measure body fat, it can be useful in 
this regard because the scans can be focused on a single area. This can be employed to 
measure visceral fat, which is a critical factor for renal transplant patients. The scans used 
can also be whole-body to measure overall body fat percentage. 
 
Additional advantages include low exposure to radiation and no requirements for 
restriction prior to testing regarding eating, drinking, or exercise for renal recipients. 
DXA can distinguish VAT, a marker for increased risk for Type 2 diabetes and 
cardiovascular diseases (Latt, Maestu, & Jurimae, 2018; Ng et al., 2018) from other 
tissues.. DXA also provides precise and accurate estimates of body composition such as 
percentage of body fat (%BF) from three-body compartments (3-C) that consist of fat 
mass (FM), lean body mass, and bone mass (Table 2-4).  
 
These whole-body and regional body measurements provided by DXA are based 
on a 3-C model that is part of two equations (soft tissue + bone and lean tissue + fat 
tissue). Assessment of regional body areas such as legs, arms, and trunk are advantageous 
in kidney transplant recipients to estimate fat, lean mass, and total regional bone mineral 
density (BMD; Heymsfield, 2005). Other estimates of soft-tissue composition such as 
FM and lean tissue mass are used to determine percentage of body fat (%BF) and fat-free 
mass (FFM). It is the estimate of soft tissue composition that contributes to the major 
assumptions of DXA methods and limitations of DXA (Heyward & Wagner, 2004).  
 
The DXA method has several limitations. One limitation is that it does not offer 
high resolution of soft tissue imaging; therefore, it cannot accurately assess soft tissue 




Table 2-4. Bioelectrical Impedance Analysis Approaches and Uses 
 





Series To estimate TBW and FFM in healthy clients with 
normal hydration status and normal fluid 
distribution 
 Parallel To estimate ICW and BCM 
 
Segmental BIA Series To measure fluid distribution or regional fluid 
accumulation in clinical populations 
 
 Parallel To measure regional or segmental ICW 
 
Multifrequency BIA Cole To estimate ECW, ICW, and TBW; to monitor 




hand) BIA and lower-
body (leg-to-leg) BIA 
NA To estimate %BF in healthy clients with normal 
hydration status and normal fluid distribution 
 
Note: BCM = body cell mas; FFM = fat-free mass; ECW = extracellular water; ICW = 
intracellular water; TBW = total body water; NA = not applicable (these analyzers are 
based on series model but do not provide impedance or resistance data). 
 
Note. Reprinted with permission from author Dale R. Wagner 9-16-18. Originally 
published in Applied body composition assessment”, by Heyward, V. H., & Wagner, D. 






compartments (i.e., FM and FFM); therefore, soft tissue measurements such as fat and 
lean tissue mass can only be measured in anatomical locations without bone. DXA 
measures cannot distinguish between the components of abdominal adipose tissue, like 
VAT and subcutaneous adipose tissue (SAT).  The accuracy of estimates of body 
composition components measures by DXA are determined by the manufacturers’ 
software which accounts for the inconsistencies in measurements (Heymsfield et al., 
1997; Heyward & Wagner, 2004).  
 
Other limitations of DXA include in adults and an older kidney transplant 
population, especially when the underlying assumed value is not met, the validity of the 
results are compromised and the %BF is either over- or underestimated (Heyward & 
Wagner, 2004, p. 124). Variables that influence measurement errors include age, 
exercise, and diet. For example, age affects the assumed value of fat-free mass body 
density (FFBd), which changes the FFM value. FFBd value in men and women > 65 
years old ranges from 1.093 and 1.099 g/cc, compared to < 65 years old, which assumes 
the value of 1.1000 g/cc (Heyward & Wagner, 2004, p. 124).  This is also true for relative 
hydration of FFM in older women (73.6-75.6% FFM) and older men (72.4-74.4% FFM), 
which affects body composition in the kidney transplant population. This variable 
contributes to the limitation of DXA and typically underestimates %BF in an older 
population (Heyward & Wagner, 2004, p. 133). Need to look quotes up out of book  
 
The validity of DXA is challenged for several reasons. The validity of DXA is 
difficult to evaluate because the assumptions used to derive body composition estimates 
of soft tissue body composition are considered proprietary by DXA manufacturers (i.e., 
Lunar, Hologic, and Norland). The DXA method has body size restrictions based on the 
width and length of the equipment table.  The ability to perform DXA scan in a morbidly 
obese patient poses a challenge because of a maximum weight restriction.     
 
 
Bioelectrical Impedance Analysis  
  
Bioelectrical impedance analysis (BIA) is a rapid, noninvasive method used for 
measuring body composition. Bioelectrical impedance indirectly estimates the volume of 
the body’s TBW or FFM when a low-level electrical current is carried by water and 
fluids through the body. Therefore, there are certain assumptions and principles 
surrounding this method. However, this section will describe the two principles of BIA 
(Dehghan & Merchant, 2008; Ng et al., 2018). First, the principle of BIA is based on the 
biological characteristic of tissues acting as conductors or insulators, and the direction of 
the electrical current transmitting through the path of least resistance. For example, FFM 
contains ~73% of water and electrolytes, which makes it a better conductor than fat, 
which is considered anhydrous with a poor electrical conduction (Heyward & Wagner, 
2004). This method uses the two factors that human body is composed of highly 
conductive tissue referred to as lean body mass and less conductive tissue with an 
insulator such as body fat and measured impedance reflects the ratio between conductive 
tissue and nonconductive tissue, which is why it is called bioelectrical impedance 
analysis. Secondly, impedance is a function of resistance and reactance.  Resistance is a 
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measure of pure opposition to current flow through the body, and the reactance is the 
opposition to current flow caused by voltage storage produced by the cell membrane 
(Gonzalez, Orlandi, Santos, & Barros, 2018). Clients must meet certain conditions prior 
to BIA:  
  
• No eating or drinking within 4 hours of the test. 
• No exercise within 12 hours of the test. 
• Client should urinate within 30 minutes of the test. 
• No alcohol consumption within 48 hours of the test. 
• No diuretic medications within 7 days of the test. 
• No testing of female clients who perceive they are retaining water during that stage 
of their menstrual cycle.* 
 
The advantage of using BIA is that it is a quick, noninvasive, and inexpensive 
method that can be used in the clinical or field setting to estimate body composition with 
obese patients, and it does not require a highly skilled technician (Heyward & Wagner, 
2004). The BIA method is recommended for assessing percent of body fat in a pre- and 
posttransplantation heart, liver, and lung population (Heyward & Wagner, 2004). A 
disadvantage in using BIA is that it may lead to measurement error. To avoid 
measurement errors, the test individual must adhere to the BIA pretesting client 
guidelines just shown.  
 
 
Computed Tomography  
 
Computed tomography (CT) uses radiation to create an image to assess BC at the 
tissue and organ level (Heyward & Wagner, 2004; Heymsfield et al., 2005). CT 
accurately measures body composition, such as bone, adipose, and lean tissues (Heyward 
& Wagner, 2004). There are two advantages of CT. First, it is more reliable than MRI 
(Heyward & Wagner, 2004). Second, CT can measure large body sizes (Duren et al., 
2008). However, there are several disadvantages, including the cost and exposure to 
radiation, requirement of a skilled technician (Heyward & Wagner, 2004), the need for 
special software, and only regional not whole body imaging of body composition (Duren 
et al., 2008). 
 
 
Magnetic Resonance Imaging 
 
Magnetic resonance imaging (MRI) measures body composition at the tissue level 
(Heyward & Wagner, 2004; West et al., 2018). MRI produces a computer-generated  
 
 
* Reprinted with permission from author Dale R. Wagner 9-16-18. Originally published 
in “Applied body composition assessment”, by Heyward, V. H., & Wagner, D. (2004), p. 




image using a radio frequency signal from hydrogen nuclei. The hydrogen nuclei act like 
a little magnet (Heyward & Wagner, 2004). The advantage of MRI is that it can be used 
for full body scan in patients with normal weight or moderately overweight (Duren et al., 
2008). The disadvantages of MRI are the same as for CT. 
 
 
The Challenge of Measuring Body Fat and Weight Gain 
 
Body composition measures are important components to monitor short-term and 
long-term impact in the general population and health outcomes. Weight gain and 
increased body fat cause enlarged adipocytes and increased VAT in the abdominal area, 
which could subsequently lead to diabetes or CVD (Pi-Sunyer, 2018). Obesity is a global 
epidemic (Despres, 2012; Ghoorah et al., 2016; Kovesdy et al., 2017) and risk factors for 
chronic diseases and poor health outcomes in transplant recipients. Several direct (e.g., 
human cadaver) and indirect BC methods (e.g., anthropometric method, BIA and DXA) 
can be used to measure body fat and weight gain and have been previously discussed. 
While these methods are used to measure body fat and weight gain in the general 
population, challenges exist with using indirect methods to measure body fat and weight 
gain in the general population and those with clinical conditions. Age, ethnicity/race, and 
clinical conditions impact the measurement of body fat and weight gain in the general 





Physiological changes occur with aging and significantly affect changes in body 
composition. During the aging process, water, mineral, and protein components of FFM 
are altered, which affects the FFMd (Heymsfield, Peterson, Thomas, Heo, & Schuna, 
2016; Heyward & Wagner, 2004; Jura & Kozack, 2016; Shaw et al., 2007). For example, 
as the body ages, excessive body weight in the older population versus the younger 
population is characterized by increased FM and may contribute to an increase in 
distribution of internal deposits of visceral fat, leading to medical conditions associated 
with abdominal fat such as diabetes. The presence of increased visceral fat is associated 
with a concurrent decrease of muscle mass (Kathryn, Shelley, Julia, & Connie, 2016; 
Sharp, Andrew, Burchfiel, Violanti, & Wactawski-Wendek, 2012).  
 
Obesity in an older population is characterized by an increase in body weight, 
which results in an increase in deposits of visceral fat and abdominal fat in the body 
(Elia, 2001; Heyward & Wagner, 2004; Jura & Kozack, 2016). Increased deposits of 
visceral fat and abdominal fat in the body are subsequently accompanied by an increased 
risk of morbidity and mortality (Elia, 2001) from chronic diseases (Heyward & Wagner, 
2004; Jura & Kozack, 2016). In addition, the physiological changes in the older 
population affect measurements of BC. For this reason, problems exist with using 
anthropometric measurements such as SKF to measure BC in the older population, 
particularly because of decreased elasticity and skin hydration, as well as, the shrinkage 
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in fat cells may cause an increase in the measurement for SAT and connective tissues 
(Guerra, Amaral, Marques, Mota, & Restivo, 2010).  
 
Snead, Birge, and Khort (1993) studied age-related differences in BC by 
hydrodensitometry (HD) and DXA to determine if %BF was overestimated with HD in 
older male and female population because aging leads to a decrease in bone mineral 
content. The studied consisted of 113 women and 72 men between the ages of 21 to 81 
(Snead, Birge, & Khort, 1993). Snead et al. (1993) found that HD and DXA 
underestimated %BF in the older population, with DXA significantly underestimating it 
by 4% to 5% (Snead et al., 1993).  
 
Shaw et al. (2007) used DXA BC and anthropometric measurements to study 
aging in a population-based older cohort. Seven hundred and thirty adults between the 
ages of 50 to 79 who were men and women were measured with standardized 
measurements of BMI, WC, WHR, and DXA scan from March 2002 to January 2004 
(Shaw et al., 2007). The DXA scan focused on four measurements: total body fat mass, 
% total body fat, % trunk fat, and lean body mass (Shaw et al., 2007). Three separate 
statistical analyses were performed on men and women. Linear regression was used to 
test the trends in BC with the separate age categories of men and women (Shaw et al., 
2007). Partial correlations and Bland-Altman analysis were used to measure if a 
consensus occurred between DXA and anthropometric measurements (Shaw et al., 2007).  
Results showed lean body mass with DXA decreased significantly with the advancing 
age of the men and women (p < 0.05). In males, BMI and body weight decreased with 
advancing age (p < 0.01).  In aging females, DXA showed an increase in fat, %BF (p < 
0.02), % trunk fat (p < 0.05), and WHR (p < 0.05; Shaw et al., 2007). No differences 
existed between DXA total body fat, WC, or hip circumference (Shaw et al., 2007). 
These results showed a high consensus existed between DXA measurements, BMI, and 
WC in the measurement of BC in the older cohort population. However, WHR was not 
consistent with DXA measurements of BC in the older cohort population. This study 
concluded there was an overall consensus between the BC measurement of DXA and 
anthropometric methods except WHR, which suggests that WHR is not a suitable BC 





Obesity differentially impacts certain ethnic and racial groups (Heyward & 
Wagner, 2004; Richmond et al., 2015; Wang et al., 2017). A report from a national 
survey (2011-2012) in the United States showed Asians have the lowest percentage of 
obesity and Blacks have the highest (Wang et al., 2017). The survey specifically reported 
obesity rates for Asians were 10.8%, Whites 32.6%, Hispanics 42.5%, and African 
Americans 47.8% (Wang et al., 2017). Wen and Kowaleski-Jones (2012) corroborated 
results of the national survey reporting the highest rate of obesity was found in Hispanics 




While the rate of obesity differs among the four ethnic groups, specific BC 
measurements (e.g., BMI and WHR) may not accurately estimate %BF, resulting in 
misclassification of some individuals to high- or low-risk groups (Heyward & Wagner, 
2004). For example, in a study by Heyward and Wagner (2004), DXA classified 25% of 
American-Indians as obese, but HD and a three- body composition classified 78% of 
American-Indians as obese. The different estimation of obesity with the DXA, HD, and 
3-body composition showed problems exist with using these three BC methods to classify 
obesity in American Indians. According to Heyward and Wagner (2004), ethnic 
differences exist across the groups with subcutaneous fat distribution from the trunk to 
the extremity and limb lengths to total height. These differences may make it difficult to 
estimate %BF among the different ethnic groups accurately; therefore, a multicomponent 
model should be used as a reference method since 2-C models and DXA are the only 
models used to accurately estimate %BF in the different ethnic groups (Heyward & 
Wagner, 2004).  Thus, standardized BC methods and equations must be developed to 





 Clinical conditions may make certain BC methods unsuitable for accurate 
assessment of  %BF. It is important to acknowledge DXA measures and reference 
databases should not be used to diagnose disease or conditions, nor provide 
recommendations for treatment regimens. Instead, the presence or absence of certain 
diseases is a critical step for selecting accurate methods and measures in body 
composition. The clinical conditions discussed as exemplars are pregnancy and kidney 
failure and dialysis, although other examples exist such as trained athletes and muscular 




 One anthropometric method used to safely assess body composition in pregnant 
women is SKF (Heymsfield et al., 2005). However, a study found that SKF 
overestimated %BF in pregnant women. Robic et al. (2018) examined the best 
anthropometric methods to use in pregnant women to measure body fat and concluded 
that body height, body weight, SKF, and limb circumferences were the best measures.  
The three methods provided a wide range of prediction equations for estimating body fat 
in pregnant women. 
 
 Kidney Failure and Dialysis 
 
 Kidney failure results in metabolic waste accumulation in the body from a decline 
in kidney function. The treatment for kidney failure is dialysis. Dialysis removes 
metabolic waste and excess fluid from the body (Heyward & Wagner, 2004), thereby 
influencing body composition, yet there is no standardized method to assess BC in 
dialysis patients. The methods used to assess BC have led to varying results, either 
overestimating or underestimating %BF in kidney failure and dialysis patients (Heyward 
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& Wagner, 2004). This suggests total body water is strongly associated with 
hypertension.   
 
 Cooper et al. (2000) studied 54 patients with end-stage kidney disease. Deuterium 
dilution technique was used to estimate TBW and compared to estimates from 
anthropometric methods, 58% body weight, Watson equations, and BIA. FFM produced 
from anthropometric methods was also used to estimate TBW and compared with BIA 
estimates of TBW. Last, measurements of total body nitrogen (TBN; p = 0.04) were 
linked with TBW estimates and BIA-derived resistance. The results showed the Watson 
equation significantly underestimated TBW (p = 0.01), and overestimated body weight. 
The BIA equation did not significantly differ from the gold standard methods used to 
estimate TBW (p = 0.12. Nevertheless, the agreement varied on the equation methods 
used to estimate TBW, but BIA obtained resistance accurately estimated TBW and other 
body composition components (Cooper et al., 2000).  
 
 Kang, Cho, Park, Yoon, and Do (2014) studied 41 Asian patients on maintenance 
peritoneal dialysis to determine the effect of peritoneal dialysate on BIA measurement of 
BC. Prior to multifrequency BIA measurement, dialysate was drained from the abdomen 
with the patients standing (D-) (Kang, Cho, Park, Yoon, & Do, 2014)(Kang, Cho, Park, 
Yoon, & Do, 2014). Dialysate was administered in the patients and measurement was 
taken and repeated (D+). Bland–Altman was used to analyze agreement and bias. Bias 
was D+ measurement and D- measurement (Kang et al., 2014). The presence of 
peritoneal dialysate increased ICW (D-: 20.33 ± 3.72 L; D+: 20.96 ± 3.78 L), ECQ (D-
:13.53 ± 2.54 L; D+: 14.10 ± 2.59 L), and TBW (Kang et al., 204). The increase of ICW 
and ECW in the presence of peritoneal dialysate was significant (p < 0.001).  In the 
presence of peritoneal dialysate, total and trunk edema indices were higher, but both 
extremities were not significantly different (Kang et al., 2014). Moreover, mineral 
content and FFM for total body and trunk were overestimated and body fat was 
underestimated (Kang et al., 2014). In the presence of peritoneal dialysate, trunk had a 
lower BIA measurement, but in both extremities, no changes were found in BIA 
measurements (Kang et al., 2014). Biases were found in soft lean mass (1.53 kg), FFM 
(1.68 kg), fat mass (-1.71 kg), and edema index (0.003 kg). The overall findings from the 
Kang et al. (2014) study showed in the presence of peritoneal dialysate agreements and 





There are five distinct body composition levels: atomic, molecular, cellular, 
tissue-organ, and whole-body. Each level is divided into discrete components, except the 
whole-body level, which is divided into regions. First, the atomic level contains four 
major elements that make up 96% percent of body mass: oxygen, carbon, hydrogen, and 
nitrogen. These major elements are used by various models to estimate total body fat, 
body cell mass, and protein. In addition, seven other elements compile the atomic level, 
including calcium, phosphorous, potassium, sodium, sulfur, chlorine, and magnesium.  
On the other hand, there are six major components at molecular level: protein, bone 
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mineral, lipid, water, carbohydrate, and soft tissue mineral. These components are used to 
develop complex models that consist of three to six components referred to as 
multicomponent models. The cellular level is compiled of three components: 
extracellular solids, extracellular fluids, and cells. At this level, the cells are further 
metabolized into fat and body cell mass (BCM) components. The fourth level of body 
composition is the tissue-organ level. The major components at the tissue-organ level 
include adipose tissue, skeletal muscle, visceral organs, bone, and other single organs 
such as brain, heart, liver, and spleen. The final body composition level is the whole-body 
level. This level is divided into three regions: appendage, trunk, and head.  The regions at 
this level provide anthropometric measures such as skinfolds, length, and circumference, 
which are used in estimation of prediction equations.   
 
According to Wang, Pierson Jr, and Heymsfield (1992), the two-compartment (2-
C) model was developed to standardize a basic method for assessing body fat, 
particularly in the absence of weights of measure components (Table 2-1). Two-
component models divide the body into fat and fat-free body components.  The limitation 
of the two-component and the DXA method (Withers et al., 1998) involves the 
assumption of constant hydration of water of 73% in FFM, sex, and body size, which is 
inaccurate. The three-component model (3-C) model divides the body into fat, water or 
mineral and residual components. The 3-C model precision is better for estimating body 
composition variation of body fat, and is preferred when compared to the 2-C reference 
methods, including hydrodesitometry (HD) and TBW. The HD method evolved into a 3-, 
4-, and 6- model. This model is useful in DXA, BIA, and ADP devices.   
 
The Siri’s three-component (3-C) hydrodensitometry method was derived from 
the Behnke’s two-component (2-C) method, which was composed of known and constant 
proportions of fat-free mass (FFM). The 3-C method is composed of fat, water, and 
residual components. The expansion of the 3-C method led to the estimation of three 
quantifiable measures that included body mass, body volume, and total body water 
(TBW). The inclusion of TBW reduced the errors associated with Behnke’s 2-C method. 
Later, the 3-C method expanded to the four-component (4-C) method by adding a bone 
mineral content, which reduced possible measurement errors associated with bone 
mineral. These 4-C multicomponent methods quantify the following measures: body 
volume, TBW, body mass, and bone mineral.  On the other hand, the six-component (6-
C) methods such as neutron activation method include fat, total body water, protein, bone 
mineral, soft tissue mineral, and glycogen, whereas the 6-C total body carbon method 
includes components at the molecular level such as fat, protein, and glycogen; it requires 
direct analysis of the chemical composition of the body in vivo. 
 
The 3-C model is not recommended in the KTR population or any population 
with impaired kidney function and physiological compensation related to age or disease. 
Additionally, it is recommended that the 3-C (water) or the 4-C (water) should be used to 
obtain reference measures of body composition of older adults. The FFM is the model 
divided by its own water content and the additional solids, primarily protein and 
minerals. Three-component calculations combine fat, density of water, fat, and body 
solids to estimate body fat mass. An inaccurate estimate may occur if an individual has a 
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significant decline in body protein mass, BMM, or when there is estimated density for 
solid compartments (Heyward & Wagner, 2004). 
 
Heyward and Wagner (2004) found that age, sex, and ethnic group body 
composition differed during body compositional changes at the molecular level: lipid 
metabolism, protein, nutrition area, water balance, bone and mineral, and homeostasis. 
Measurable properties at this level are DXA method, which are used to assess whole-
body composition.  Because adipose and fat are measured at different component levels, 
MRI and CT would not be a suitable reference for estimates of fat by another method 
such as DXA underwater weighing (UWW). Fat is at the molecular level and DXA lacks 
direct measures in the regional areas and can only provide estimates of percentage of 
body fat from soft tissue mass, fat mass, and lean body mass.  
 
The multicompartment (4-C) model is a highly significant predictor of the 
relationship between age and ethnicity. For example, Asian populations have a high level 
of adipose, and an anthropometric method such as BMI could prolong the risk for 
cardiovascular disease. MRI would not be a suitable reference comparison for estimates 
of fat by another method that considers the variability of water or mineral content of the 
fat-free body, or both. They are generally thought to provide more accurate estimates of 
body fat than 2-component models, especially when one of the assumptions of the 2-
component model might be violated, such as constant hydration, which is not likely in the 
kidney transplant population (Heyward & Wagner, 2004).  
 
In addition, in vivo neutron activation analysis (NAA), the 4-C model, measures 
bone density and unknown quantity of mass for each body compartment. The unknown 
values are obtained from DXA measures, which have the ability to quantify bone mineral 
content or NAA that quantify the protein content. The indirect pathway to estimate FM 
from two additional methods, DXA and NAA, makes the 4-C UWW method 
cumbersome and time consuming for technicians and participants. However, the 4-C 
UWW and DXA are more commonly used than 4-C UWW and NAA (Heyward & 
Wagner, 2004). UWW, which is also referred to as hydrostatic weighing, is considered 
the gold standard for measuring body composition from body density. There are several 
methodological issues that occur when comparing a person’s underwater weight to their 
dry-land weight, which is the inversely proportional to body fat, including the following: 
subject position, residual volume, number of trials and selection criteria, alternative lung 
volumes, and head placement. The subjects’ positions include sitting, kneeling, or prone, 
which generally depends on the size of the tank. However, measurement errors may 
occur if the subject is tall or has a large abdomen. In addition, UWW requires the subject 
to exhale completely under the water; therefore, potential measurement errors may occur 
if the subject lacks the ability to completely exhale underwater, thus reducing the 
accuracy and reliability of the measurements of the subjects. The technician’s ability to 
accurately determine the repeated measurements of a subject is another possible 
measurement error (Heymsfield et al., 2005). UWW method is limited in specific 
populations including young children, disabled, elderly, sick, and other special groups.  
The complete submersion in water could cause complications and may not be possible in 




The 4-C DXA component model is preferred for an aging population for 
estimating %BF. This model calculation assumes the bone mineral calcium and bone 
mineral in carbon and the measures are adjusted for variation in an older population due 
to the decline in bone and muscle components. If the 4-C is not available, the 2-C is an 
alternative method to improve measures for estimating %BF, by averaging the value of 
fat-free body density (FFBd). This adjustment for FFBd is critical in different ethnic and 
racial groups because of the variation in bone density mass (Heyward & Wagner, 2004).  
  
A 4-C molecular model should not be considered in kidney transplant recipients 
or any population with chronic disease who may experience fluid disturbance such those 
individuals with electrolyte imbalance. Transplant recipients often experience fluid 
disturbance and electrolyte imbalance, in which the 4-C components of fat, protein, bone 
mineral, and total body water (Heyward & Wagner, 2004) can be used to derive a 
suitable predictive equation.  
 
Studies have shown (Heyward & Wagner, 2004) BIA equation accurately 
estimates changes in FFM and TBW in obese women on a low caloric diet. Several 
studies have shown that the BIA method is sensitive to detect body composition change 
relative to weight loss. On the other hand, BIA method FFM is not accurately reported if 
weight loss occurs. The BIA method is not useful if hydration is altered or there is a fluid 
disturbance. However, the NIR method was recommended in subjects with fluid 
disturbance such as a dialysis patient.  
 
Studies have shown BIA measures derived from SKF are suitable for predicting 
percentage of body fat (Heyward & Wagner, 2004).  BIA estimate is suitable body 
composition in obese population for several reasons.  
 
 
Disease-Specific Population  
 
The BIA method is best for disease-specific populations. Predictive equations are 
useful in a population with metabolic syndrome, particularly in a disease-specific 
population with alteration in fat distribution and fluid disturbance. Two diseases, known 
as Type 2 diabetes or thyroid diseases, do not have a predictive equation. The BIA 
method or Segal fat-specific measure are the best measures and methods to use in obese 
and Type II diabetes populations.  The Leiter Disease-Specific Predictive BIA equation is 
more preferred in a disease-specific population compared to the BIA method. 
Understanding the interaction between methods and measures could be a challenge in 








Heyward and Wagner (2004) used a disease-gender prediction equation to 
estimate percentage of fat in a cardiopulmonary population.  The BIA method and 
Geneva predictive equation DXA measures are suitable for chronic obstructive 
pulmonary disease. This predictive equation is used in equipment called Xitron-4000 
BIA. In some cases, the measure and method must factor in disease and gender. For 
example, the BIA –BIO-Z method is suitable for men and women with cystic fibrosis. On 
the other hand, the measure is not gender specific. Men with cystic fibrosis could use 
DXA measures and the Geneva predictive equation for more accurate assessment of %BF 
compared to women using measures by Kotler.    
 
Studies have shown (Heyward & Wagner, 2004) BIA equation accurately 
estimates changes in FFM and TBW in obese women on a low caloric diet. Several 
studies have shown that the BIA method is sensitive to detect body composition change 
relative to weight loss, except when weight loss occurs rapidly. BIA method is not useful 
if hydration is altered or fluid disturbed. However, the NIR method was recommended in 
subjects with fluid disturbance such as a dialysis patient.  Studies have shown BIA 
measures derived from SKF are suitable to predict percentage of body fat in an obese 
population but not in an extremely obese population (Heyward & Wagner, 2004). Other 
recommendation UWW method included limited in specific populations including young 
children, disabled, elderly, sick, and other special groups. The complete submersion in 





In summary, kidney transplantation is the preferred choice of treatment for 
patients with ESRD. After transplantation, kidney recipients experience short-term and 
long-term complications, such as weight gain. In the kidney transplant population, weight 
gain is a serious issue. Factors affecting weight gain in the kidney transplant population 
posttransplant are immunosuppression medications, increased caloric intake from 
reduced dietary restrictions, decreased level of physical activities, and consequences of 
concommittent chronic diseases. The monitoring of weight gain and subsequent obesity 
following transplant surgery is essential to assess and evaluate new onset and progression 
of concurrent chronic conditions. Although indirect methods, such as anthropometric 
method, BIA, and DXA, are commonly used methods to measure body fat and weight 
gain in the general and kidney transplant population, challenges exist with using indirect 








CHAPTER 3.    METHODS 
 
 
There is little consensus on which method of measuring body composition is 
superior for identifying patients at increased risk for CVD. Therefore, the overall aim of 
this study was to compare associations of anthropometric measures versus those obtained 
by DXA scan with cardiac-related risk factors at 5-8 years following kidney 
transplantation. The specific aims addressed by this study were:  
 
1. To determine the association between anthropometric measures and serum levels 
of glucose, lipids, creatinine, and blood pressure of kidney transplant recipients at 
5-8 years posttransplant. 
 
2. To determine the association between body composition measures and serum 
levels of glucose, lipids, and creatinine and blood pressure of kidney transplant 
recipients at 5-8 years posttransplant.  
 
3. To determine if body composition measures by DXA obtained at the time of 
transplant (baseline) are associated with serum levels of glucose, lipids, and 
creatinine and blood pressure of kidney transplant recipients at 5-8 years 
posttransplant. 
 
4.  To determine if anthropometric measures obtained at baseline are associated with 
serum levels of glucose, lipids, and creatinine and blood pressure of kidney 
transplant recipients at 5-8 years posttransplant.  
 
5. To determine the association between changes in anthropometric measures from 
baseline to 5-8 years posttransplant and serum levels of glucose, lipids, and 
creatinine and blood pressure in kidney transplant recipients at 5-8 years 
posttransplant. 
 
6. To determine the association between changes in body composition measures 
from baseline to 5-8 years posttransplant and serum levels of glucose, lipids, 
creatinine, and blood pressure at 5-8 years posttransplant. 
 
The remainder of this chapter describes the methodology used to address the 
above research aims, including the research design, setting and sample, instrumentation, 





A quantitative, descriptive follow-up study was conducted that included data 
acquired during a parent study conducted between 2008 and 2011 (Cashion et al., 2014), 
which examined genetic, environmental, and lifestyle factors contributing to post-kidney 
transplant obesity. The parent study data were collected at the time of transplantation and 
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served as baseline measures.  Additional data were collected for this follow-up study, 
which took place 5 years following completion of the parent study. 
 
 





The parent study was conducted in a large sized midsouth university with an 
affiliated transplant institute that has been performing kidney transplants for over 40 
years. Demographic characteristics of the 120 to 130 individuals receiving kidney 
transplants each year in this institute was reflective of the regional population. The 
immediate urban area surrounding the transplant institute was predominately of African 
Americans descent, many of whom resided in lower socioeconomic communities.  The 
transplant institute also provided services to individuals located in rural communities and 
other urban cities in the region and across the country. Data from 2016 to the present 
indicated demographic characteristics of kidney transplant recipients at this center had 
remained relatively stable with 27.7 to 28.4% being Whites, and 69.1 to 69.6% African 
Americans; 1.6 to 1.9 % Hispanics, 1.6 to 1.0% Asians; 2.8 to 65.6% were males and 
47.1 to 34.3% were females; 12.1 to 10.7% were 8-34 years, 34.9 to 28.4% were 5-49 
years, 44.4 to 46% were 0-64 years, and 11.3 to 14.7% were 65+. This study, although 
reflective of the population served, had a higher proportion of African American patients 





The parent study (Cashion et al., 2014) included 96 post-kidney transplant 
recipients who were 18 years or older; 42.71% were females and 57.9% males. By 
ethnicity, 53.12% were Non-Hispanic and 2.08% Hispanic. By race, 65% were African 
Americans, 31% were Whites, and 4% were other. Of the 96 participants in the parent 
study, 45 patients received DXA scans at the transplant baseline time-point and 54 
received a scan at 1 year. Because additional study participants received DXA scans at 
the 1 year following posttransplant, all 96 participants of the parent study were screened 





 Participants in the parent study who had a DXA during the peritransplant and/or 1 








• Current hospitalization. 
• Loss of the transplanted graft.  
• Receipt of steroid therapy prior to the time of transplantation to control for the 





In the current study, empirical data were obtained using a) anthropometric 
assessment, (b) body composition assessment, and (c) physiological assessment.  
 
 
Anthropometric Assessment  
 
Anthropometric assessments included measurement of Body Mass Index (BMI), 
Body Weight (BW), and Waist Circumference (WC). These measures are defined as 
follows: 
 
• Body Mass Index (BMI) measures weight and height by calculating 
weight in kilogram (kg) divided in height in meter squared (m2) 
(Caballero, 2014). 
 
• Body Weight (BW) measures human body total mass in kilograms or 
pounds. 
 
• Waist Circumference (WC) measures the central abdominal area. 
 
 Height, weight, and waist measurements were obtained from each participant by 
the principal investigator. Each participant was required to remove shoes and bulky outer 
garments before height and weight were measured. Height was obtained using a wall-
mounted scale and measured to the nearest centimeter. A calibrated balance scale was 
used to assess each participant’s weight in kilograms. BMI was calculated using each 
participant’s weight in kilograms divided by the height in meters squared (Antillon & 
Towfighi, 2011; Beckmann et al., 2015; Caballero, 2014; Ghoorah et al., 2016; WHO, 
2018). A tape measure was used to measure each participant’s WC by holding the end of 
the tape measure at the participant’s navel and then bringing it around the participant’s 
waist and back to the front.  
 
 
Body Composition Assessment 
 
The DXA scan was performed by a DXA-certified research nurse to measure the 
distribution of fat and lean mass in various compartments of the body. Specifically, the 
android and gynoid ratio quantifies the adipose tissues that accumulate in the abdominal 
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region and around the hips, total body mass percentage (total body mass minus bone and 
fat), and the amount of fat tissue located deep in the abdomen and around the internal 
organs (Heyward & Wagner, 2004), as follows: 
  
• Android/Gynoid Ratio: Android fat is the amount of fat between the 
bottom of an individual’s head and the top of the iliac crest in the lowest 
20% region. Gynoid fat is the amount of fat located downward from the 
android region and from the top of the greater trochanter. It is derived 
from % fat in the android region divided by % fat in the gynoid region. 
 
• Android Fat Mass (AFM) is the amount of adipose tissue in the 
abdominal area and below the individual’s head. It is derived from the 
fat tissue in the android region (grams). 
 
• Gynoid Fat Mass (GFM) is the amount of fat in the lower portion of an 
individual’s body around the hip area. It is derived from the fat tissue in 
the gynoid region (grams). 
 
• Total Fat Mass (TFM) is the fat mass in grams (android + gynoid 
regions). It is derived from the standard deviation value. 
 
• Lean Mass (LM) is the total body mass less the bones and fat in an 
individual’s body total lean mass (android + gynoid area). It is derived 
from the lean standard deviation value. 
 
• Percentage of Body Fat (%BF) is an individual’s total amount of fat 
divided by total body weight percent fat (android + gynoid regions). 
 
• Visceral Adipose Tissue (VAT) is the amount of fat tissue surrounding 
an individual’s organs that impacts a wide variety of clinical risks 
(Bergman et al., 2006). VAT is a valid predictor of cardiometabolic risk 
factors and the study found that DXA clinical thresholds were validated 
in White men (154cm2) and women (143cm2) compared to African 
American men (101cm2) and women (114 cm2). VAT is derived from 




Physiological Assessment  
 
The blood collection for glucose, total cholesterol, LDL-cholesterol, HDL-
cholesterol, and triglycerides was performed in the clinical research center by a registered 
nurse at no cost to participants. Forty cubic centimeters (about 3 tablespoon) was 
collected from each participant in a BD vacutainer SST tube for serum determination in 
ethylenediaminetetraacetic acid (EDTA) tubes for anticoagulation. Each tube was 
inverted after the blood samples were collected to prevent clotting. The blood samples 
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were stored on ice for no more than two hours before blood sample centrifugation. The 
plasma and serum were separated into cryotubes and stored at -80 °C until processed. 




Method and Subjects  
 
Prior to research, approval from the university Institutional Review Board (IRB) 
was obtained (IRB Approval Supplement) as well as approval of the parent study by the 
principal investigator. Potential study participants were identified from the parent study 
database; those who met inclusion criteria (n = 96) were contacted by phone, the follow-
up study described, and the opportunity for them to participate in the study offered. 
Twenty-one out of the 96 transplant patients were excluded from the study due to loss of 
graft functions or death (n = 45), two participants declined, and those expressing interest 
in the study were scheduled to meet with the Principal Investigator at the General Clinical 
Research Center (GCRC). Appointments were coordinated with an upcoming routine 
clinic appointment, or another time at the potential study participant’s convenience. The 
GCRC was located in the same building, just a few floors above the transplant clinic; 
research staff met potential participants in the transplant clinic and escorted them to the 
GCRC, if needed.   
 
After greeting the potential study participant, the research staff described the 
study again in detail and reviewed the consent page by page. Questions were solicited, 
and the potential participants understood their participation in the study was voluntary 
and that no additional appointments were required. Each potential participant was assured 
they had the right to opt out of the study at any time and that such a decision would not 
affect their current or future medical treatment. Additionally, each person was informed 
that there would be no cost to them for the study procedures, including the DXA scan and 
blood studies, and that the results of these tests would be shared with them per request.   
 
After the 45 participants signed the participant-informed consent (Participant 
Informed Consent Supplement), health records were reviewed as electronic medical 
records. The data retrieved from the parent study participants were laboratory values, BP, 
height, weight, and previous DXA scans. If a participant was a female of childbearing 
age, a urinary pregnancy test was performed prior to the scan.  
  
During the single clinical visit, 40 cubic centimeters (about 3 tablespoons) of 
blood was drawn from each participant followed by a Whole-Body DXA scan using a 
DXA scanner die body composition estimate (Hologic QDR 4500A, software version 
4.5.2.1, Bedford, MA). DXA equipment has set values for the fat standard deviation 
value, which is 68, and the standard deviation value for lean tissue, which is always -10.  
The calibration for this software estimate was the %fat 3-4% higher than the Classic 
software and underestimates that FM compared to the criterion methods in adults 




Table 3-1 Normal Value of the Blood Sample  
 
Blood Sample  Normal Value in mg/dl 
Glucose 65-100 mg/dl 
Hemoglobin A1C 
Total Cholesterol  
4.6-5.6 % 
< 200 mg/dl 
LDL-Cholesterol < 100 mg/dl 
HDL-Cholesterol males > 40 mg/dl and females > 50 
mg/dl 








According to Wang et al. (1992),  FFM (in kg) was calculated as the difference between 
body weight (W, in kg) and body fat mass measured by the four-component model as the 




Each DXA scan was performed by a DXA-certified research nurse.  
 
Upon completion of study procedures, participants were given a $30 Visa or 
Walmart gift card in honor of their time and effort, and to help defray and costs (e.g., 





An initial descriptive analysis was conducted to review measures of central 
tendency and assure assumptions regarding adequate variability and normality were met.  
Because all research questions sought to determine whether relationships existed among 
various measures of body mass and cardiac risk factors, Pearson Product Moment or 
Spearman Rho correlation coefficients were determined and used to address all the 





There are three statistical assumptions for the Pearson Moment Correlation 
Coefficient: 
 
1. Independent observations between the participants. The scores for each 
participant should be independent of all other participants’ scores. 
 
2. The X scores should be continuous. 
 
3. Bivariate normality for scores on X and Y. Each participant’s scores on Y should 
be normally distributed in the population X and Y should be normally distributed 
in the population among the X scores.  
 













This chapter described the methods to address the aims of the study and research 
questions, including the research design, setting and sample, inclusion and exclusion 
criteria, and the data collection procedures.  The analyses used to address the research 
questions were described along with statistical assumptions.  Results of these analyses are 





CHAPTER 4.    RESULTS 
 
 
Description of the Sample 
 
The study sample consisted of 45 participants (see Table 4-1); 29 (64.4%) were 
African American and 16 (35.6%) were White. There were 25 (55.6%) males and 20 
(44.4%) females. The age of the sample, at 5 years or longer years posttransplant follow-
up, ranged in age from 37 to 78 with a mean of 56 (SD =10.1) in Table 4-2. 
Anthropometric and cardiac-related outcome measures of study participants obtained at 
the time of transplant and 5 years or more follow-up are presented in Table 4-3 below 
followed by measures of body composition components at the same measurement points 





Tables 4-3 to 4-5 show the descriptive statistics for lab values (creatinine, 
glucose, Hgb A1C, triglyceride, HDL, LDL, and coronary risk ratio), elevated blood 
pressure (systolic and diastolic), BC (VFAT, AFM, GFM, A/G ratio, LM, FM, and %BF) 






Research Question 1 
 
Research Question 1 asked, What is the association between anthropometric 
measures and serum glucose, lipid, and creatinine levels and elevated blood pressure in 
kidney transplant patients obtained five to eight years posttransplant? Findings that 
address this question are shown in Table 4-6, which reports the correlational analyses of 
cardiac-related outcomes and anthropometric measures of BMI, weight, and WC at 5-8 
years post-kidney transplant. A significant relationship exists with coronary risk ratio and 
waist circumference (r = 0.33; p = 0.05) and with diastolic BP and weight (r = 0.28; p = 
0.06). Relationships reaching levels of significance (p ≤ 0.20) that warrant continued 
consideration in fully powered studies include weight and HDL (r = -0.26; p = 0.09), 
LDL (r = -0.22; p = 0.16), and coronary Risk Ratio (r = -0.28; p = 0.09) as well as waist 
circumference and diastolic BP (r = 0.30; p = 0.07), and BMI and LDL (r = -0.21; p = 
0.18). These correlations are considered to be weak in strength and positive in direction 
(Sheskin, 2011). This means that as coronary risk ratio increases so does BMI, weight, 





Table 4-1. Demographic Characteristics  
 
Variables  Total Sample n (%) 
Race  
White 16 (35.6%) 
African-American 29 (64.4%) 
Gender  
Male 25 (55.6%) 





Table 4-2. Age of the Participants 
 
N M ± SD  Min  Max 





Table 4-3. Anthropometric and Cardiac-Related Outcome Measures at 5-8 
Years Post-Kidney Transplantation 
 









Weight 197.89 ± 48.15 89.80 305.80 
Waist reading 41.39 ± 7.12 23.75 54.00 
 











Glucose 142.41 ± 91.38 54.00 574.00 
Hgb AIC 6.93 ± 2.22 5.00 16.40 
Triglyceride  178.40 ± 119.38 38.00 665.00 
HDL   52.71 ± 16.85 25.00 96.00 
LDL  92.30 ± 36.57 3.85 184.00 
Coronary risk ratio 3.78 ± 1.31 2.10 8.68 
Systolic BP 134.42 ± 17.85 99.00 181.00 
Diastolic BP 78.80 ±  8.47 59.00 98.00 
 
Note. BMI = body mass index; Hgb = Hemoglobin; HDL = high density lipoprotein; 




Table 4-4. Anthropometric, Body Composition, and Cardiac-Related Outcome Measures at Time of Transplant and at 5-8 
Years Post-Kidney Transplantation 
 
 At Time of Transplant  5-8 Years Posttransplant 















Weight 186.66 ± 42.10 112.4 277.7  197.89 ± 48.1 89.8 305.80 
Body Composition  
Total Fat 
 











Total Lean 12238 ± 2998 6872 19647  12199 ± 3413 6353 19120 
Total Mass 19572 ± 4558 10731 27897  20733 ± 6166 9051 34147 
Total PFat  37.12 ± 7.76 18.17 51.42  40.19 ± 8.10 20.31 52.80 
Android Fat 2726 ± 1101 826.79 5215  3399 ± 1676 462.30 6823 
Android Lean  4440 ± 1266 2376 8356  4301 ± 1289 2213 7348 
Android Mass 7166 ± 2052 3879 11958  7700 ± 2693 3002 13130 
Android PFat 37.21 ± 8.88 17.47 54.49  42.14 ± 10.53 15.40 56.06 
Android/ Gynoid Ratio 1.01 ± 0.16 0.71 1.38  1.08 ± 0.21 0.6047 1.55 
Android Percent Fat 36.73 ± 9.22 17.47 54.49  42.14 ± 10.52 15.39 56.06 
Gynoid Fat 4607 ± 1440 1524 7623  5136 ± 1878 1540 9860 
Gynoid Lean  7797 ± 1828 4208 11291  7898 ± 2207 4140 12035 
Gynoid Mass 12405 ± 2674 6852 16796  13034 ± 3626 6044 21895 
Gynoid PFat 36.90 ± 7.94 18.54 53.88  38.81 ± 7.72 22.6 52.91 
VFat Body Fat 1428 ± 608.45 340.28 2831  1833 ± 876.70 206.24 3411 
VFat Body Lean 2555 ± 579.06 1400 4308  2563 ± 595.90 1260 3909 
VFat Body Mass 3983 ± 998.67 2243 5813  4396 ± 1305 1638 6690 
VFat Body PFat 34.71 ± 9.32 13.02 51.73  39.61 ± 11.16 10.29 53.81 
Total Fat Mass 29590 ± 9877 10301 48639  35287 ± 1587 8121 58531 
Fat Mass Ratio 1.03 ± 0.15 0.70 1.40  1.09 ± 0.201 0.73 1.534 
Total Whole Body Fat 28508 ± 9545 7480 48639  35151 ± 13362 8121 58531 
Total Whole Body Lean 55024 ± 13063 32189 78965  54514 ± 13901 28387 81653 
Total Whole Body Mass 83531 ± 18689 47975 120691  89665 ± 23949 40816 135562 
Total Whole Body PFat 33.90 ± 8.12 12.07 48.58  38.40 ± 8.41 19.02 51.19 
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Table 4-4. Continued 
 
Note. M = mean; SD = standard deviation; Min = minimum; Max = maximum; BMI = body mass index; PFat = percent fat; VFat = 




Table 4-5. Changes in Anthropometric and Body Composition Measures from 
Baseline to 5-8 Years Post-Kidney Transplantation 
 









BMI Change     3.05 ± 7.99 -10.08 21.35 
DXA Composition  
Total Fat 
 





Total Lean    -39.26 ± 1795 -4567 4081 
Total Mass 1162 ± 3735 -10224 9669 
Total PFat   3.07 ± 8.13 -29.29 15.25 
Android Fat     672.63 ± 1317 -2743 3516 
Android Lean    -138.60 ± 782.80 -2162 2222 
Android Mass     534.0 ± 1705 -4886 4794 
Android PFat   4.93 ± 10.47 -31.51 21.73 
Android Gynoid Ratio   0.080 ± 0.15 -0.411 0.312 
Android Percent Fat   5.411 ± 9.981 -31.51 21.73 
Gynoid Fat     528.9 ± 1440 -5165 3139 
Gynoid Lean     100.20 ± 1107 -2434 2803 
Gynoid Mass     629.10 ± 213 -6395 5412 
Gynoid PFat   1.90 ± 7.19 -28.42 13.80 
VFat Body Fat     405.28 ± 704.25 -1696 1537 
VFat Body Lean   7.86 ± 323.7 -595.42 809.75 
VFat Body Mass     413.15 ± 799.02 -1914 2072 
VFat Body PFat   4.900± 11.36 -34.25 23.10 
Total Fat Mass 56961 ± 9325 -2537 22788 
Fat Mass Ratio   0.065 ± 0.116 -0.247 0.267 
Total WB Fat Change 6644 ± 16424 -29458 36866 
Total WB Lean Change    -509.79 ± 19193 -40183 38939 
Total WB Mass Change   4.50 ± 10.31 -21.75 22.33 
Total WB PFat Change 6134  ±  32149  -66194 71662 
 
Note. M = mean; SD = standard deviation; Min = minimum; Max = maximum; PFat = 
percent fat; VFat = visceral fat; BMI = body mass index; WB= whole body.
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Table 4-6. Relationship Among Cardiac-Related Outcomes and Anthropometric 
Measures at 5-8 Years Post-Kidney Transplantation. 
 
Variable  BMI 
r (p value)* 
Weight 
r (p value)* 
Waist Circumference 
r (p value)* 
Creatinine 0.11 (0.44) -0.02 (0.88) -012(0.49) 
Glucose 0.04 (0.98) 0.46(0.80) 0.12(0.47) 
Hgb-AIC 0.04 (0.81) 0.10 (0.50) 0.13(0.45) 
Triglyceride 0.05 (0.73) 0.009 (1.00) 0.15(0.36) 
HDL -0.25 (0.10) -0.26 (0.09) -0.19(0.26) 
LDL -0.21 (0.18) -0.22 (0.16) -0.15(0.39) 
Coronary Risk Ratio  0.27 (0.07) 0.28 (0.09) 0.33(0.05) 
Systolic BP 0.05(0.74) 0.15 (0.49) -0.087(0.60) 
Diastolic BP 0.22 (0.15) 0.28 (0.06) 0.30 (0.07) 
 
Note. *Pearson Correlation Coefficients: Prob > [r] under Ho: Rho=0  
BMI = body mass index; Hgb = hemoglobin; HDL = high density lipoprotein; LDL = 
low density lipoprotein; BP = blood pressure; r = correlation coefficient; p value ≤ 0.05 






Research Question 2 
 
Research Question 2 asked, What is the association between body composition 
measures and serum glucose, lipid, and creatinine levels and elevated blood pressure 
obtained in kidney transplant recipients 5-8 years posttransplant? Findings that address 
this question are shown in Tables 4-7 to 4-12, which report the correlational analyses of 
cardiac-related outcomes and BC measures by DXA at 5-8 years post-kidney transplant.  
 
The relationship with creatinine and total fat (r = -0.30; p = 0.02), creatinine and 
total percent fat (r = -0.42; p = 0.004), HDL and total lean (r = -0.40; p = 0.01), and HDL 
and total mass (r = -0.16; p = 0.01) are inversely related (Table 4-7). Relationships 
reaching levels of significance (p ≤ 0.20) that warrant continued consideration in fully 
powered studies include HDL and total fat (r = -0.30; p = 0.09), LDL and total lean (r = -
21; p = 0.18), coronary risk ratio and total lean (r = 0.27; p = 0.075), coronary risk ratio 
and total mass  (r = 0.26; p = 0.09), systolic and total percent fat (r = -022; p = 0.15), 
diastolic and total mass (r = 0.24; p = 0.12), and diastolic and total percent fat (r = 0.25; p 
= 0.10). These correlations are considered to be weak to moderate in strength. Some are 
negative, and some are positive in direction (Sheskin, 2011). As total fat and total 
percentage of fat go up, creatinine goes down and when total lean and total mass go up, 
HDL goes down. For relationships reaching levels of significance (p ≤ 0.20) that warrant 
continued consideration in fully powered studies, these correlations are also weak in 
strength.  As total fat increases, HDL goes down. As total lean increases, LDL decreases 
while coronary risk ratio increases. As total mass increases so do coronary risk ratio and 
diastolic blood pressure. As total percentage of fat increases so does diastolic pressure 
while systolic blood pressure decreases.   
 
Table 4-8 demonstrates a significant inverse relationship between creatinine and 
android percentage fat with (r = -0.45; p = 0.001), HDL and android fat (r = -0.32; p = 
0.03). A significant relationship exists with coronary risk ratio and android lean (r = 0.38; 
p = 0.01) and coronary risk ratio and android mass (r = 0.35; p = 0.02), and systolic blood 
pressure and android percent fat (r = -0.30; p = 0.05).  Relationships reaching levels of 
significance (p ≤ 0.20) that warrant continued consideration in fully powered studies 
include creatinine and android fat (r = -0.27; p = 0.07), Hgb A1C and android fat (r = 
0.21; p = 0.18), coronary risk ratio and android fat (r = 0.27; p = 0.07), diastolic and 
android fat (r = 0.23; p = 0.13), diastolic and android mass (r = 0.22; p = 0.14), and 
diastolic and android percent fat (r = 0.24; p = 0.10). HDL and android lean (r = -0.40; p 
= 0.006), and HDL and android mass (r = -0.39; p = 0.008) are inversely related.  These 
correlations are considered to be weak in strength. Some are negative, and some are 
positive in direction (Sheskin, 2011). As android fat goes up, creatinine goes down and 
when android fat percentage goes up HDL goes down. As coronary risk ratio goes up so 
do android mass and android lean. For, relationships reaching levels of significance (p ≤ 
0.20) that warrant continued consideration in fully powered studies, these correlations are 
also weak in strength.  As android fat increases, creatinine goes down; while Hgb A1C 
goes up. Coronary risk ratio increases as android fat increases. Diastolic blood pressure 




Table 4-7. Relationship Among Cardiac-Related Outcomes and Body 
Composition Measures of Total Fat, Total Lean, Total Mass, and Total Percent Fat 
at 5-8 Years Post-Kidney Transplantation 
 
Variables  Total Fat 
r (p value)* 
Total Lean- 
r (p value)* 
Total Mass- 
r (p value)* 
Total PFat- 
r (p value)* 
Creatinine -0.30(0.05) 0.06(0.69) -0.13(0.42) -0.42(0.004) 
Glucose 0.13(0.40) 0.08(0.59) 0.12(0.44) 0.13(0.40) 
Hgb AIC 0.19(0.22) 0.12(0.44) 0.17(0.27) 0.12(0.43) 
Triglyceride 0.03(0.87) 0.02(0.88) 0.03(0.86) 0.04(0.78) 
HDL -0.30(0.09) -0.40(0.01) -0.36(0.01) -0.01(0.93) 
LDL -0.08(0.61) -0.21(0.18) -0.16(0.31) 0.16 (0.32) 
Coronary risk 
ratio 
0.19(0.22) 0.27(0.08) 0.26(0.09) 0.07(0.67) 
Systolic BP -0.13(0.40) 0.08(0.59) -0.02(0.87) -0.22(0.15) 
Diastolic BP  0.27(0.78) 0.167(0.27) 0.24(0.12) 0.25(0.10) 
 
Note. *Pearson Correlation Coefficients: Prob > [r] under Ho: Rho=0; Hgb = 
hemoglobin; HDL = high density lipoprotein; LDL = low density lipoprotein; BP = blood 





Table 4-8. Relationship Among Cardiac-Related Outcomes and Body 
Composition Measures of Android Fat, Android Lean, Android Mass, and Android 




r (p value)* 
Android 
Lean 
r (p value)* 
Android 
Mass 
r (p value)* 
Android 
PFat 
r (p value)* 
Creatinine -0.27(0.07) 0.12 (0.43) -0.11 (0.48) -0.45(0.001) 
Glucose 0.16 (0.31) 0.10 (0.64) 0.15(0.34) 0.15(0.33) 
Hgb A1C 0.21(0.18) 0.10 (0.51) 0.18 (0.25) 0.16(0.30) 
Triglyceride 0.11(048) 0.15(0.32) 0.14 (0.36) 0.09(0.55) 
HDL -0.32(0.03) -0.40(0.006) -0.39(0.008) -0.14(0.37) 
LDL -0.14(0.37) -0.18(0.25) -0.17(0.27) 0.09(0.60) 
Coronary risk ratio 0.27 (0.07) 0.38(0.01) 0.35(0.02) 0.15(0.29) 
Systolic BP -0.16 (0.28) 0.14(0.34) -0.03(0.87) -0.30 (0.05) 
Diastolic BP 0.23 (0.13) 0.16 (0.29) 0.22(0.14) 0.24(0.10) 
 
Note. *Pearson Correlation Coefficients: Prob > [r] under Ho: Rho=0; Hgb = 
hemoglobin; HDL = high density lipoprotein; LDL = low density lipoprotein; BP = blood 





Table 4-9. Relationship Among Android Gynoid Ratio and Cardiac-Related 
Outcomes at 5-8 Years Post-Kidney Ttransplantation   
 
Variables Android Gynoid Ratio 
r (p value)** 
Creatinine -0.28(0.06) 
Glucose 0.13(0.39) 




Coronary risk ratio 0.21(0.71) 
Systolic BP -0.29(0.05) 
Diastolic BP 0.12 (0.5) 
 
Note. **Pearson Correlation Coefficients: Prob > [r] under Ho: Rho=0; Hgb A1C = 
hemoglobin A1C; HDL = high density lipoprotein; LDL = low density lipoprotein; BP = 





Table 4-10. Relationship Among Cardiac-Related Outcome and Body 
Composition Measures of Gynoid Fat, Gynoid Lean, Gynoid Mass, and Gynoid 
Percent Fat at 5-8 Years Post-Kidney Transplantation 
 
Variables Gynoid Fat 
r (p value)* 
Gynoid Lean 
r (p value)* 
Gynoid Mass 
r (p value)* 
Gynoid PFat 
p value)* 
Creatinine     -0.28(0.06) 0.02(0.88) -0.13(0.39) -0.34(0.02) 
Glucose 0.09(0.55) 0.07(0.65) 0.09(0.56) 0.09(0.54) 
Hgb A1C 0.15(0.32) 0.13(0.41) 0.16(0.31) 0.08(0.62) 
Triglyceride -0.05(0.74) -0.06(0.72) -0.06(0.69) -0.02(0.92) 
HDL -0.18(0.24) -0.38(0.10) -0.32(0.03) 0.09(0.54) 
LDL -0.02(0.91) -0.22(0.16) -0.14(0.36) 0.20(0.20) 
Coronary 
risk ratio 
0.10(0.52) 0.20(0.20) 0.17(0.26) - 0.003(0.98) 
Systolic BP -0.09(0.58) 0.04(0.77) -0.02(0.91) -0.12(0.42) 
Diastolic BP 0.27(0.07) 0.16(0.28) 0.24 (0.11) 0.23(0.14) 
 
Note. *Pearson Correlation Coefficients: Prob > [r] under Ho: Rho=0;Hgb = hemoglobin; 
HDL = high density lipoprotein; LDL = low density lipoprotein; PFat = percent fat; BP = 






Table 4-11. Relationship Among Cardiac-Related Outcome and Body 
Composition Measures of VFat, VBody Lean, VBody Mass, and VPercent Fat at 5-8 
Years Post-Kidney Transplantation 
 
Variables VFat 
r (p value)* 
VFat Body 
Lean 
r (p value)* 
VFat Body 
Mass 
r (p value)* 
VFat Body 
PFat 
r (p value)* 
Creatinine- -0.30(0.05) 0.20(0.20) -0.17(0.49) -0.47(0.001) 
Glucose 0.16(0.30) 0.15(0.33) 0.18(0.25) 0.15(0.34) 
Hgb A1C 0.18(0.23) 0.10 (0.50) 0.17(0.27) 0.15(0.33) 
Triglyceride 0.07(0.64) 0.15 (0.33) 0.12(0.44) 0.06(0.72) 
HDL -0.28(0.07) -0.37(0.02) -0.34(0.02) -0.15(0.33) 
LDL -0.09(0.58) -0.19(0.38) -0.12(0.45) 0.09 (0.55) 
Coronary risk ratio 0.23(0.13) 0.37 (0.01) 0.32(0.03) 0.15 (0.34) 
Systolic BP -0.19(0.21) 0.17(0.26) -0.05(0.74) -0.29 (0.05) 
Diastolic BP 0.26(0.09) 0.19 (0.21) 0.26(0.09) 0.26(0.09) 
 
Note. *Pearson Correlation Coefficients: Prob > [r] under Ho: Rho=0;Hgb = hemoglobin; 
HDL = high density lipoprotein; LDL = low density lipoprotein; VFat = visceral fat; BP 








Table 4-12. Relationship Among Cardiac-Related Outcomes and Body 
Composition Measures of Whole Body Total Fat, Whole Body Total Lean, Whole 




Variables  WBTotal Fat 
r (p value)* 
WBTotal 
Lean- 
r (p value)* 
WBTotal 
Mass- 
r (p value)* 
WBTotal 
PFat- 
r (p value)* 
Creatinine -0.24(0.11)            -0.05 (0.76 )          -0.16 (0.28)           -0.26(0.08) 
Glucose -0.28(0.07) -0.11(0.49) -0.22(0.15) -0.26(0.09) 
Hgb AIC -0.27(0.08 ) -0.11(0.46) -0.22(0.16) -0.23(0.14) 
Triglyceride 0.11 (0.48) 0.15(0.33 ) 0.15(0.33) 0.01(0.92) 
HDL 0.16(0.31) 0.12(0.44) 0.15(0.44) 0.04(0.80) 
LDL -0.13(0.44 ) -0.06(0.69) -0.11(0.49) -0.14(0.39) 
Coronary risk ratio -0.04(  0.81) 0.02(0.88)   -0.01(0.97) -0.06( 0.68) 
Systolic BP -0.27(0.07) -0.43(<0.001)    -0.40(  0.01) -0.08(0.61) 
Diastolic BP -0.23(0.16) -0.20(0.20) -0.24( 0.11) -0.15(0.32) 
 
Note. WB= Whole-body; Hgb = hemoglobin; HDL = high density lipoprotein; LDL =l 
density lipoprotein; PFat = percent fat; BP = blood pressure; r = correlation coefficient; p 






An inverse relationship with significance exists with systolic BP and android 
gynoid ratio (r = -0.29; p = 0.05). The relationships between glucose and Hgb A1C (r = 
0.91; p = 0.001) and triglyceride and Hgb A1C (r = 0.225; p = 0.137) are both significant 
(Table 4-9). Relationships reaching levels of significance (p ≤ 0.20) that warrant 
continued consideration in fully powered studies include creatinine and android gynoid 
ratio (r = -0.28; p = 0.06) and HDL and android gynoid ratio (r = -0.27; p = 0.07). These 
correlations are considered weak to strong in strength and some are negative, and some 
are positive in direction (Sheskin, 2011).  As the android gynoid ratio increases, systolic 
blood pressure decreases. For relationships reaching levels of significance (p ≤ 0.20), as 
android gynoid ratio increases, creatinine and HDL decrease. 
 
Table 4-10 demonstrates a significant relationship with an inverse relationship 
existing with creatinine and gynoid percent fat (r = -0.34; p = 0.02) and HDL and gynoid 
mass (r = -0.32; p = 0.03), which are presented in Table 4-10.  Relationships reaching 
levels of significance (p ≤ 0.09) that warrant continued consideration in fully powered 
studies include creatinine and gynoid fat (r = -0.28; p = 0.06), and diastolic and gynoid 
fat (r = 0.27; p = 0.07).  
 
Table 4-11 demonstrates a significant relationship with coronary risk ratio and 
visceral fat body lean (r = 0.37; p = 0.01), and coronary risk ratio and visceral fat body 
mass (r = 0.32; p = 0.03). An inverse relationship exists with creatinine and visceral fat (r 
= -0.30; p = 0.05), HDL and visceral fat body lean (r = -0.34; p = 0.02), HDL and 
visceral fat body mass (r = -0.34; p = 0.02), and systolic pressure and visceral fat body 
percent fat (r = -0.29; p = 0.05). Relationships reaching levels of significance (p ≤ 0.20) 
that warrant continued consideration in fully powered studies include creatinine and 
visceral fat body lean (r = 0.20; p = 0.20), HDL and visceral fat (r = -0.28; p = 0.07), 
coronary risk ratio (r = 0.23; p = 0.13), diastolic and visceral fat (r = 0.26; p = 0.09), 
diastolic BP and visceral fat body mass (r = 0.26; p = 0.09), and diastolic BP and visceral 
fat body percent fat (r = 0.26; p = 0.09). These correlations were weak in strength.  For 
relationships reaching levels of significance (p ≤ 0.20), as visceral fat body lean 
increases, so does creatinine. As visceral fat increases HDL decreases and coronary risk 
ratio and diastolic BP increase. Diastolic pressure also increases as visceral fat body mass 
and visceral fat body percent increase. These correlations are considered to be weak in 
strength and are positive (Sheskin, 2011).   
 
The relationships with WB total lean and systolic BP (r = -0.43; p = <0.001) and 
WB total mass and systolic BP (r =-0.40; p = 0.01) are inversely related (Table 4-12). In 
addition, an inverse relationship reaching significance of (p ≤ 0.20) was found with 
systolic and WB total fat (r = -0.27; p = (0.07). An inverse relationship with creatinine 
and WB total fat (r = -0.24; p = 0.11), creatinine and WB total PFat (r = -0.26; p = 0.08); 
and glucose and WB total fat (r = -0.28; p = 0.07), glucose and WB total mass (r = -.022; 
p = 0.15), and glucose and WB total PFat (r = -0.26; p = 0.09. These correlations are 
considered to be weak in strength and negative in direction. As systolic BP increases, WB 
total lean, WB total mass, and WB total fat decrease. For relationships reaching levels of 
significance (p ≤ 0.20) that warrant continued consideration in fully powered studies, 
these correlations are considered weak in strength and negative in direction. An inverse 
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relationship with HgbA1C and WB total fat (r =-0.27; p = 0.08); HgbA1C and WB total 
mass (r =-0.22; p = 0.16); and HgbA1c and WB total PFat (r = -0.23; p = 0.14); diastolic 
BP and WB total fat (r = -0.23; p = 0.16), diastolic BP and WB total lean (r=-0.20; p = 
0.20); diastolic BP and WB total mass (r=-0.24; p = 0.11). As WB total fat and WB total 
PFat go up, the creatinine and glucose levels go down. The glucose level also goes down 
when WB total mass goes up. As diastolic BP and HgbA1C go up, WB total fat and WB 
total pfat go down.  Diastolic BP also goes down when WB total lean values increase. As 
HgbA1c decreases, so does WB total mass.     
 
 
Research Question 3 
 
Research Question 3 asked, To what degree are body composition measures 
obtained at the time of transplant associated with serum levels of glucose, lipids, and 
creatinine and elevated blood pressure in kidney transplant recipients at 5 to 8 years 
posttransplant? Tables 4-13 to 4-18 report the correlational analyses of cardiac-related 
outcomes and BC measures at time of transplant is associated with recipients at 5-8 years 
post-kidney transplant.  
 
An inverse relationship with significance was found with HDL and total fat (r = -
0.34; p = 0.02), HDL and total lean (r = -0.50; p = <0.001), and HDL and total mass (r = 
-0.51; p = 0.0004). A significant relationship exists with coronary risk ratio and total lean 
(r = 0.42; p = 0.004) and coronary risk ratio and total percent fat (r = 0.38; p = 0.01) 
(Table 4-13). Relationships reaching levels of significance (p ≤ 0.20) that warrant 
continued consideration in fully powered studies include glucose and total fat (r = 0.20; p 
= 0.18), LDL and total fat (r = -0.20; p = 0.20), and coronary risk ratio (r = 0.25; p = 
0.24). Relationships reaching levels of significance (p ≤ 0.20) that warrant continued 
consideration in fully powered studies include as glucose levels increase so does total fat, 
and as LDL increases, so does total fat. 
 
A significant relationship was found with triglyceride and android lean (r = 0.30; 
p = 0.050), coronary risk ratio and android fat (r = 0.32; p = 0.03), and coronary risk ratio 
and android mass (r = 0.47; p = 0.001). An inverse relationship exists with HDL and 
android fat (r = -0.46; p = 0.001), HDL and android lean (r = -0.45; p = 0.002) and HDL 
and android mass (r = -0.53; p = <0.001); Table 4-14). Relationships reaching levels of 
significance (p ≤ 0.20) that warrant continued consideration in fully powered studies 
include glucose and android fat (r = 0.24; p = 0.12), Hgb A1C and android fat (r = 0.21; p 
= 0.16), and triglyceride and android mass (r = 0.28; p = 0.07). The correlations range 
from weak to moderate in strength.  As android lean increases so do triglyceride levels; 
coronary risk ratio increases with android fat, android, and android mass increases. HDL 
decreases as android lean, fat, and mass increase.  For relationships reaching levels of 
significance (p ≤ 0.20), glucose and HgbA1C go up with android fat, and triglycerides go 





Table 4-13. Relationship Among Cardiac-Related Outcomes at 5-8 Years Post-
Kidney Transplantation and Body Composition Measures of Total Fat, Total Lean, 
Total Mass, and Total Percent Fat Obtained at Time of Transplant   
 
Variables Total Fat- 
r (p value) 
Total Lean 
r (p value) 
Total Mass 
r (p value) 
Total PFat 
r (p value) 
Creatinine -0.03(0.86) 0.11 (0.46) 0.061(0.69) -0.13(0.39) 
Glucose 0.20(0.18) 0.11(0.48) 0.18(0.25) 0.12(0.44) 
Hgb A1C 0.19(0.21) 0.07(0.63) 0.01(0.33) 0.11(0.46) 
Triglyceride 0.08(0.61) 0.18(0.24) 0.16 (0.29) -0.03(0.86) 
HDL -0.34(0.02) -0.50( <0.001) -0.51(0.0004) -0.01(0.96) 
LDL -0.20(0.20) 0.01(0.95) -0.12(0.46) -0.16(0.30) 
Coronary risk ratio 0.25 (0.24) 0.42(0.004) 0.38(0.01) -0.09 (0.54) 
Systolic BP 0.05(0.76) 0.08(0.61) 0.075(0.625) -0.04(0.79) 
Diastolic BP 0.07(0.66) 0.09(0.54) 0.096(0.528) -0.03(0.86) 
 
Note. *Pearson Correlation Coefficients: Prob > [r] under Ho: Rho=0; Hgb = 
hemoglobin; HDL = high density lipoprotein; LDL =l density lipoprotein; PFat = percent 





Table 4-14. Relationships Among Cardiac-Related Outcomes at 5-8 Years Post-
Kidney Transplantation and Body Composition Measures of Android Fat, Android 
Lean, Android Mass, and Android Percent Fat Obtained at Time of Transplant    
 
Variables Android Fat 
r (p value)* 
Android Lean 
r (p value)* 
Android Mass 
r (p value)* 
Android PFat 
r (p value)* 
Creatinine -0.01(0.97) 0.07(0.63) 0.04(0.78) -0.09(0.58) 
Glucose 0.24(0.12) 0.08(0.60) 0.18(0.25) 0.17(0.28) 
Hgb A1C 0.21 (0.16) 0.03(0.81) 0.14(0.38) 0.16(0.30) 
Triglyceride 0.17 (0.26) 0.30(0.05) 0.30(0.07) -0.10(0.51) 
HDL -0.46 (0.001) -0.45(0.002) -0.53(<0.001) -0.19(0.22) 
LDL -0.19(0.23) -0.023(0.88) -0.09(0.56) -0.16 (0.31) 
Coronary risk ratio 0.32(0.03) 0.32(0.008) 0.47(0.001) -0.03(0.83) 
Systolic BP 0.03(0.82) 0.07(0.64) 0.06(0.68) -0.04(0.78) 
Diastolic BP 0.01(0.97) 0.023(0.88) 0.02(0.91) -0.01(0.90) 
 
Note. *Pearson Correlation Coefficients: Prob > [r] under Ho: Rho=0; Hgb = 
hemoglobin; HDL = high density lipoprotein; LDL = low density lipoprotein; PFat = 






Table 4-15. Relationship Among Cardiac-Related Outcomes at 5-8 Years Post-
Kidney Transplantation and Body Composition Measures of Gynoid Fat, Gynoid 
Lean, Gynoid Mass, and Gynoid Percent Fat Obtained at Time of Transplant    
 
Variables Gynoid Fat 
r (p value)* 
Gynoid Lean 
r (p value)* 
Gynoid Mass 
r (p value)* 
Gynoid PFat 
r (p value)* 
Creatinine -0.04(0.79) 0.14(0.38) 0.07(0.64) -0.15(0.32) 
Glucose  0.15(0.32) 0.12(0.44) 0.17(0.28) 0.08(0.61) 
Hgb A1C 0.16(0.31) 0.094(0.54) 0.15(0.33) 0.08(0.61) 
Triglyceride -0.002(1.0) 0.093(0.55) 0.06(0.68) -0.04(0.81) 
HDL -0.21(0.18) -0.51<0.001) -0.46 (0.001) 0.14(0.36) 
LDL -0.19(0.23) -0.03(0.83) -0.13(0.41) -0.14(0.37) 
Coronary risk ratio 0.06(0.72) 0.36 (0.02) 0.28(0.07) -0.16(0.29) 
Systolic BP 0.05(0.74) 0.08(0.62) 0.08(0.60) -0.03(0.86) 
Diastolic BP 0.10(0.49) 0.14 (0.36) 0.15(0.32) -0.02 (0.90) 
 
Note. *Pearson Correlation Coefficients: Prob > [r] under Ho: Rho=0; Hgb = 
hemoglobin; HDL = high density lipoprotein; LDL = low density; BP = blood pressure; 





Table 4-16. Relationship Among Cardiac-Related Outcomes at 5-8 Years Post-
Kidney Transplantation and Body Composition Measures of Visceral Fat Body Fat, 
Visceral Fat Body Lean, Visceral Fat Body Mass, and Visceral Fat Body Percent Fat 
Obtained at Time of Transplant  
 
Variables VFat Body 
Fat 
r (p value) 
VFat Body 
Lean 
r (p value) 
VFat Body 
Mass 
r (p value) 
VFat Body 
PFat 
r (p value) 
Creatinine -0.003(0.98) 0.13(0.40) 0.07(0.64) -0.09(0.54) 
Glucose 0.19 (0.22) 0.08(0.61) 0.16(0.30) 0.16(0.31) 
Hgb A1C- 0.16(0.31) -0.01(1.00) 0.09(0.56) 0.15(0.32) 
Triglyceride 0.11(0.46) 0.32(0.04) 0.25(0.10) -0.01(0.96) 
HDL -0.37(0.01) -0.34(0.02) -0.43(0.003) -0.21(0.17) 
LDL -0.18(0.26) 0.055(0.73) -0.08(0.61) -0.16(0.32) 
Coronary risk ratio 0.26(0.09) 0.52(0.003) 0.45(0.002) -0.04(0.80) 
Systolic BP 0.04(0.79) 0.13(0.38) 0.10(0.50) -0.04(0.80) 
Diastolic BP 0.05(0.74) 0.13(0.40) 0.10(0.50) -0.01(0.90) 
 
Note. *Pearson Correlation Coefficients: Prob > [r] under Ho: Rho=0; Hgb = 
hemoglobin; HDL = high density lipoprotein; LDL = low density lipoprotein; BP = blood 
pressure; VFat = visceral fat; PFat = percent fat; r = correlation coefficient; p value ≤ 




Table 4-17. Relationship Among Cardiac-Related Outcomes at 5-8 Years Post-
Kidney Transplantation and Body Composition Measures of Android Gynoid Ratio, 
Android Percent Fat, Total Fat Mass, and Fat Mass Ratio Obtained at Time of 
Transplant  
   
Variables Android/ 
Gynoid Ratio 
r (p value)* 
Android 
Percent Fat 
r (p value)* 
Total Fat 
Mass 
r (p value)* 
Fat Mass 
Ratio 
r (p value)* 
Creatinine 0.01(0.97) -0.14(0.35) -0.05(0.74) -0.06 (0.68) 
Glucose 0.15(0.34) 0.18(0.23) 0.28(0.061) 0.20(0.20) 
Hgb A1C 0.16(0.30) 0.20(0.19) 0.26(0.09) 0.21(0.17) 
Triglyceride 0.02(0.89) -0.003(0.98) 0.13(0.41) 0.08(0.60) 
HDL -0.46(0.001) -0.15(0.33) -0.28(0.06) -0.39(0.007) 
LDL -0.09(0.57) -0.17(0.27) -0.21(0.17) -0.10(0.54) 
Coronary risk ratio 0.23(0.13) 0.01(0.94) 0.21(0.16) 0.20(0.19) 
Systolic BP -0.04(0.81) -0.04(0.79) 0.05(0.75) -0.03(0.85) 
Diastolic BP 0.09(0.56) 0.09(0.54) 0.15(0.33) 0.09(0.57) 
 
Note. *Pearson Correlation Coefficients: Prob > [r] under Ho: Rho=0  
Hgb = hemoglobin; HDL = high density lipoprotein; LDL = low density lipoprotein; BP 







Table 4-18. Relationship Among Cardiac-Related Outcomes at 5-8 Years Post-
Kidney Transplantation and Body Composition Measures of Whole Body Total Fat, 
Whole Body Total Lean, Whole Body Total Mass, and Whole Body Total Percent 
Fat Obtained at Time of Transplant   
 
Variable  WBTotal Fat 
r (p value)* 
WBTotal 
Lean- 
r (p value)* 
WBTotal 
Mass- 
r (p value)* 
WBTotal 
PFat- 
r (p value)* 
Creatinine -0.09 (0.53)  0.13 (0.39) 0.04(0.77) -0.20(0.20) 
Glucose 0.31(0.04)   0.12(0.44)     0.24(0.11)   0.20(0.20) 
HgbA1C 0.30 (0.05) 0.09 (.56) 0.21 (0.16)    0.20 (0.20) 
Triglyceride 0.12 (0.44) 0.13(0.39) 0.15 (0.31)    0.03(0.83) 
HDL   -0.27(0.07 )  -0.45(0.002) -0.45(0.002)   0.04(0.79) 
LDL -0.22 (0.15)    -0.06 (0.72)  -0.16( 0.32)  -0.15 (0.33) 
Coronary risk 
ratio 
0.20(0.20) 0.41(0.001) 0.39(0.001) -0.07(0.66) 
Systolic BP 0.05 (0.73) 0.12 (0.41)   0.11(0.45) -0.03 (0.85) 
Diastolic BP   0.15 (0.34) 0.19(0.22) 0.20(0.18)   0.02(0.91) 
 
Note. *Pearson Correlation Coefficients: Prob > [r] under Ho: Rho=0; WB= Whole-body; 
Hgb = hemoglobin; HDL = high density lipoprotein; LDL = low density lipoprotein; BP 




Table 4-15 shows an inverse relationship exists with HDL and gynoid lean (r = -
0.51; p = <0.001) and HDL and gynoid mass (r = -0.46; p = 0.001). The relationship with 
coronary risk ratio and gynoid lean (r = 0.36; p = 0.02) was significant. Relationships 
reaching levels of significance (p ≤ 0.20) that warrant continued consideration in fully 
powered studies include HDL and gynoid fat (r = -0.21; p = 0.18) and coronary risk ratio 
(r = 0.28; p = 0.07).  The correlations range from weak to moderate in strength and 
negative to positive in direction.  As gynoid lean increases, so does coronary risk ratio. 
HDL decreases as gynoid mass and gynoid lean increases.  For relationships reaching 
levels of significance (p ≤ 0.20), as coronary risk ratio increases so does gynoid mass, 
while HDL decreases as gynoid fat increases.    
 
A significant relationship also exists with triglyceride and visceral fat body lean  
(r = 0.32; p = 0.04) and coronary risk ratio and visceral fat body lean (r = 0.52; p = 
0.003). An inverse relationship exists with HDL and visceral fat body fat (r = -0.37; p = 
0.01), HDL and visceral fat body lean (r = -0.34; p = 0.02), HDL and visceral fat body 
mass (r = 0.07; p = 0.65). A positive relationship exists with coronary risk ratio and 
visceral fat body learn (r = 0.52; p = 0.003) and with visceral fat body mass (r = 0.45; p = 
0.002; Table 4-16). Relationships reaching levels of significance (p ≤ 0.20) that warrant 
continued consideration in fully powered studies include triglyceride and visceral fat 
body mass (r = 0.25; p = 0.10), HDL and visceral fat body percent fat (r = -0.21; p = 
0.17), and coronary risk ratio and visceral fat body fat (r = 0.26; p = 0.09). The 
correlations range from weak to strong in strength and some are negative and some are 
positive in direction. As visceral fat lean increases, so do triglyceride levels and coronary 
risk ratio. As HDL increases, visceral fat lean, visceral body fat, and visceral fat mass 
decrease. For relationships reaching levels of significance (p ≤ 0.20), triglyceride and 
coronary risk ratio goes up, as do visceral fat and visceral fat mass. When visceral body 
percentage fat goes up, HDL goes down. 
 
An inverse relationship exists with HDL and android gynoid ratio (r = -0.46; p = 
0.001) and with HDL and fat mass ratio (r = -0.39; p = 0.007), which are presented in 
Table 4-17. Relationships reaching levels of significance (p ≤ 0.20) that warrant 
continued consideration in fully powered studies include coronary risk ratio and android 
gynoid ratio (r = 0.23; p = 0.13), Hgb A1C and android percent fat (r = 0.20; p = 0.19), 
glucose and total fat mass (r = 028; p = 0.06), Hgb A1C and total fat mass (r = 0.26; p = 
0.09), HDL and total fat mass (r = -0.28; p = 0.06), LDL and total fat mass (r = -0.21; p = 
0.17), coronary risk ratio and total fat mass (r = 0.21; p = 0.16), Hgb A1C and fat mass 
ratio (r = 0.21; p = 0.17), and coronary risk ratio and fat mass ratio (r = 0.20; p = 0.19). 
The correlations range from weak to moderate in strength with some negative and some 
positive in direction.  As HDL increases, android gynoid ratio and fat mass ratio 
decrease.  For relationships reaching levels of significance (p ≤ 0.20), as coronary risk 
ratio, HgbA1C, and glucose increase, so do android gynoid ratio, android percentage of 
fat, total fat mass, and fat mass ratio. As HDL and LDL increase, total fat mass decreases.   
 
Table 4-18 shows a significant relationship was found with glucose and WB total 
fat (r = 0.31; p = 0.04), HgbA1C and WB total fat (r = 0.30 p = 0.05), coronary risk ratio 
and WB total lean (r = 0.41; p = 0.001), and coronary risk ratio and WB total mass (r = 
 
73 
0.39; p = 0.001). An inverse significant relationship was found with HDL and WB total 
lean (r = -0.45; p = 0.002) and HDL (r = -0.45; p = 0.002). As glucose and HgbA1C 
levels increase, so does WB total fat. AsWB total fat goes up, so do HgbA1C and 
coronary risk ratio levels. The correlations range from moderate to strong in strength and 
some are negative and some are positive in direction.   
 
Table 4-18 also shows relationships reaching levels of significance (p ≤ 0.20) that 
warrant continued consideration in fully powered studies include creatinine and WB total 
fat (r = -0.20; p = 0.20), HDL and WB total fat (r = -0.27; p = 0.07), LDL and WB total 
fat (r = -0.22; p = 0.15) demonstrate an inverse relationship. A positive relationship was 
found between coronary risk ratio and WB total fat (r = 0.20; p = 0.20), diastolic blood 
pressure and WB total mass (r = 0.20; p = 0.18), WB total PFat and glucose (r = 0.20; p = 
0.20), WB total PFat and HgbA1C (r = 0.20; p = 0.20), and WB total mass and glucose (r 
= 0.24; p = 0.11), and WB total mass and HgbA1C ( r = 0.21;p = 0.16). The correlations 
are weak in strength and some are negative and some are positive in direction. As 
creatinine level increases, WB total PFat decreases. As HDL and LDL levels increase, 
WB total fat decreases. As coronary risk ratio increases, so does WB total fat. As 
diastolic blood pressure increases, so does WB total mass. WB total PFat goes down as 
glucose and HgbA1C decrease.  
 
 
Research Question 4 
 
Research Question 4 asked, To what degree are anthropometric measures 
obtained at the time of transplant associated with serum levels of glucose, lipids, and 
creatinine and elevated blood pressure in kidney transplant recipients at 5-8 years 
postransplant? 
 
Table 4-19 reports the correlational analyses of anthropometric measures of 
weight and BMI at the time of transplant and cardiac-related outcomes 5-8 years post-
kidney transplantation. A significant relationship exists with Hgb A1C and weight (r = 
0.29; p = 0.06) and coronary risk ratio and weight (r = 0.33; p = 0.03). An inverse 
relationship exists with HDL and weight (r = -0.46; p = 0.001) and between HDL and 
BMI (r = -0.34; p = 0.02). An inverse relationship exists with LDL and BMI (r = -0.34; p 
= 0.04). Relationships reaching levels of significance (p ≤ 0.20) that warrant continued 
consideration in fully powered studies include glucose and weight (r = 0.27; p = 0.079), 
LDL and weight (r = -0.24; p = 0.13), diastolic BP and weight (r = 0.198; p = 0.190), 
glucose and BMI (r = 0.28; p = 0.06), and HgbA1C and BMI (r = 0.29; p = 0.06). The 
correlations range from weak to moderate in strength and some are negative and some are 
positive in direction.  As body weight increases so does coronary risk ratio while HDL 
decreases; as BMI increases LDL decreases. For relationships reaching levels of 
significance (p ≤ 0.20), as HgbA1C and glucose levels increase, so does BMI. As    




Table 4-19. Relationship Among Anthropometric Measures of Weight and BMI at 




r (p value)* 
BMI 
r (p value)* 
Creatinine 0.002(1.00) -0.04(0.78) 
Glucose 0.27(0.08) 0.28(0.06) 
Hgb A1C 0.30(0.06) 0.29(0.06) 
Triglyceride 0.12(0.45) 0.15(0.32) 
HDL -0.46(0.001) -0.34(0.02) 
LDL -0.24(0.13) -0.34(0.03) 
Coronary risk ratio 0.33(0.031) 0.19 (0.21) 
Systolic BP 0.11(0.49) 0.01 (0.93) 
Diastolic BP 0.20(0.19) 0.13(0.38) 
 
Note. *Pearson Correlation Coefficients: Prob > [r] under Ho: Rho=0; Hgb = 
hemoglobin; HDL = high density lipoprotein; LDL = low density lipoprotein; BP = blood 






Research Question 5 
 
Research Question 5 asked, To what degree are changes in anthropometric 
measures from baseline to 5-8 years posttransplant associated with serum glucose, lipids, 
and creatinine and elevated blood pressure at 5-8 years posttransplant? 
 
Table 4-20 shows the relationship among weight and BMI change with lab values 
and elevated blood pressure from baseline to 5-8 years posttransplant. A significant 
relationship exists with coronary risk ratio and BMI (r = 0.31; p = 0.04). Relationships 
reaching levels of significance (p ≤ 0.20) that warrant continued consideration in fully 
powered studies include creatinine and BMI (r = 0.25; p = 0.10). The correlations are 
moderate in strength in a positive in direction.  As BMI increases so does coronary risk 
ratio. For relationships reaching levels of significance (p ≤ 0.20), as creatinine increases 
so does BMI.    
 
 
Research Question 6  
 
Research Question 6 asked, To what degree are changes in body composition  
measures from baseline to 5-8 years posttransplant associated with serum glucose, lipids, 
and creatinine and elevated blood pressure at 5-8 years posttransplant? Tables 4-21 to  
4-26 show the changes in body composition measures from baseline to 5-8 years 
associated with serum glucose, lipids, and elevated blood pressure at a prolonged time 
posttransplant.  
 
An inverse relationship was found with creatinine and total fat (r = -0.35; p = 
0.02) and LDL and total lean (r = -0.37; p = 0.01). The relationship between current LDL 
and total percent fat (r = 0.32 p = 0.05) was statistically significant (Table 4-21). 
Relationships reaching levels of significance (p ≤ 0.20) that warrant continued 
consideration in fully powered studies include creatinine and total mass (r = -0.28; p = 
0.07), creatinine and total percent fat (r = -0.28; p = 0.07), triglyceride and total lean (r = 
-0.26; p = 0.09), coronary risk ratio and total lean (r = -0.20; p = 0.20), systolic BP and 
total fat (r = -0.21; p = 0.18), diastolic BP and total fat (r = 0.28; p = 0.07), diastolic BP 
and total mass (r = 0.28; p = 0.07), and diastolic BP and total percent fat (r = 0.27; p 
=0.07). The correlations are moderate in strength with some negative and some are 
positive in direction.  As LDL increases so does total percentage of fat. Creatinine and 
LDL increase while total lean and total fat decrease. For relationships reaching levels of 
significance (p ≤ 0.20), ascreatinine increases, total mass decrease. As creatinine 
decreases, so does total percet of fat.   As triglycerides and coronary risk ratio increase, 
total lean decreases.  As systolic blood pressure increase, total fat decreases, and total 
mass, total lean, and total percentage of fat decrease. As total percent fat, total fat, and 
total mass increase, so does diabstolic BP.  The correlations are moderate in strength with 





Table 4-20. Relationship Among Cardiac-Related Outcomes at 5-8 Years Post-
Kidney Transplantation and Change in Anthropometric Measures of Weight and 
BMI from Time of Transplant to 5-8 Years Post-Kidney Transplantation  
 
Variables Weight 
r (p value)* 
BMI 
r (p value)* 
Creatinine 0.02(0.87) 0.25(0.10) 
Glucose -0.17(0.27) -0.05(0.77) 
Hgb A1C -0.09 (0.56) -0.03(0.83) 
Triglyceride -0.06(0.69) 0.03(0.86) 
HDL 0.08(0.60) -0.15(0.32) 
LDL -0.01(0.93) 0.07(0.64) 
Coronary risk ratio 0.01(0.95) 0.31(0.04) 
Systolic BP -0.03(0.85) 0.05(0.73) 
Diastolic BP 0.15(0.34) 0.18(0.24) 
 
Note: *Pearson Correlation Coefficients: Prob > [r] under Ho: Rho=0; Hgb = 
hemoglobin; HDL = high density lipoprotein; LDL = low density lipoprotein; BP = blood 





Table 4-21. Relationship Among Cardiac-Related Outcomes at 5-8 years Post-
Kidney Transplantation and Change in Body Composition Measures of Total Fat, 
Total Lean, Total Mass, and Total PFat from Time of Transplant to 5-8 Years Post-
Kidney Transplantation  
 
Variables Total Fat 
r (p value)* 
Total Lean 
r (p value)* 
Total Mass 
r (p value)* 
Total PFat 
r (p value)* 
Creatinine -0.35(0.02) -0.07(0.64 -0.28(0.065) -0.28(0.07) 
Glucose -0.02 (0.91) -0.02(0.90) -0.021(0.90) 0.01(0.93) 
HgbA1C 0.06(0.68) 0.10(0.50) 0.095(0.54) 0.01(1.00) 
Triglyceride -0.04(0.81) -0.26(0.09) -0.153(0.32) 0.07(0.66) 
HDL -0.02(0.89) 0.00 (0.69) 0.02(0.89) -0.02(0.89) 
LDL 0.08(0.62) -0.37(0.01) -0.12(0.44) 0.32 (0.05) 
Coronary risk 
ratio 
0.08(0.62) -0.20(0.20) -0.04(0.79) 0.16(0.31) 
Systolic BP  -0.21(0.18) 0.03(0.85) -0.13(0.38) -0.17(0.25) 
Diastolic BP 0.28(0.07) 0.16(0.30) 0.28(0.07) 0.27(0.07) 
 
Note: *Pearson Correlation Coefficients: Prob > [r] under Ho: Rho=0; Hgb = 
hemoglobin; HDL = high density lipoprotein; LDL = low density lipoprotein; PFat = 




Table 4-22. Relationship Among Cardiac Related Outcomes at 5-8 Years Post-
Kidney Transplant and Changes in Body Composition Measures of Android Fat, 
Android Lean, Android Mass, and Android PF from Time of Transplant to 5-8 
Years Post-Kidney Transplantation 
 
Variables Android Fat 
r (p value) 
Android Lean 
r (p value)* 
Android 
Mass 
r (p value)* 
Android 
PFat 
r (p value)* 
Creatinine -0.34 (0.02) 0.08(0.60) -0.22(0.14) -0.37(0.01) 
Glucose 0.00(0.99) 0.04(0.80) 0.02(0.900) 0.01(0.96) 
Hgb A1C 0.08(0.60) 0.11(0.48) 0.11(0.47) 0.00(0.89) 
Triglyceride 0.11(0.46) -0.44(0.002) -0.13(0.41) 0.17(0.26) 
HDL -0.01(0.93) 0.06(0.69) 0.027(0.91) 0.02(0.89) 
LDL -0.00(0.90) -0.32(0.41) -0.16(0.31) 0.22(0.16) 
Coronary risk 
ratio 
0.08(0.63) -0.16(0.29) -0.02(0.92) 0.11(0.47) 
Systolic BP -0.24(0.11) -0.12(0.43) -0.13(0.40) -0.25(0.09) 
Diastolic BP 0.30(0.05) 0.23(0.13) 0.33(0.03) 0.26(0.08) 
 
Note: *Pearson Correlation Coefficients: Prob > [r] under Ho: Rho=0; Hgb = 
hemoglobin; HDL = high density lipoprotein; LDL = low density lipoprotein; BP = blood 





Table 4-23. Relationship Among Cardiac-Related Outcomes at 5-8 Years Post-
Kidney Transplantation and Changes in Body Composition Measures of Gynoid 
Fat, Gynoid Lean, Gynoid Mass, and Gynoid PFat from Time of Transplant to 5-8 
Years Post-Kidney Transplantation  
  
Variables Gynoid Fat 
r (p value)* 
Gynoid Lean 
r (p value)* 
Gynoid Mass 
r (p value)* 
Gynoid PFat 
r (p value)* 
Creatinine -0.33(0.03) -0.18(0.25) -0.31(0.04) -0.20(0.21) 
Glucose -0.03(0.83) -0.06(0.70) -0.05(0.73) 0.01 (0.93) 
Hgb A1C 0.04(0.78) 0.09 (0.54) 0.08(0.61) -0.01(0.97) 
Triglyceride -0.01(0.68) -0.26(0.08) -0.11(0.24) 0.06(0.70) 
HDL -0.03(0.86) 0.08(0.60) 0.02(0.87) -0.06(0.72) 
LDL 0.17(0.30) -0.38(0.01) -0.08(0.60) 0.37(0.01) 
Coronary risk ratio 0.07(0.64) -0.20 (0.18) -0.06(0.71) 0.18(0.25) 
Sytolic BP -0.16 (0.29) -0.04 (0.80) -0.13(0.40) -0.10(0.50) 
Diastolic BP 0.25(0.10) 0.10(0.51) 0.22(0.14) 0.26(0.10) 
 
Note: *Pearson Correlation Coefficients: Prob > [r] under Ho: Rho=0;  
Hgb = hemoglobin; HDL = high density lipoprotein; LDL = low density lipoprotein;  





Table 4-24. Relationship Among Cardiac-Related Outcomes at 5-8 Years Post-
Kidney Transplantation and Changes in Body Composition Measures of VFat Body 
Fat, VFat Body Lean, VFat Body Mass, and VFat Body PFat from Time of 
Transplant to 5-8 Years Post-Kidney Transplantation  
 
Variables VFat Body 
Fat 
r (p value)* 
VFat Body 
Lean 
r (p value)* 
VFat Body 
Mass 
r (p value)* 
VFat Body 
PFat 
r (p value)* 
Creatinine    -0.36(0.01) 0.14(0.38)   -0.27(0.08)    -0.36(0.02) 
Glucose 0.03(0.84) 0.14(0.36) 0.09(0.58) 0.01(0.93) 
Hgb A1C 0.08(0.57) 0.21(0.18) 0.16(0.29) 0.02(0.89) 
Triglyceride -0.01(1.00) -0.30(0.05) -0.13 (0.41) 0.06(0.71) 
HDL -0.02(0.89) -0.01(0.96) -0.02(0.88) 0.02(0.88) 
LDL 0.05(0.77)    -0.34(0.03) -0.09(0.56) 0.23(0.15) 
Coronary risk ratio 0.07(0.67) -0.26 (0.09) -0.05(0.77) 0.11(0.50) 
Systolic BP    -0.27(0.07) 0.07(0.62) -0.21(0.16)    -0.25(0.09) 
Diastolic BP 0.27 (0.07) 0.13(0.41) 0.29(0.05) 0.27(0.08) 
 
Note: *Pearson Correlation Coefficients: Prob > [r] under Ho: Rho=0; Hgb = 
hemoglobin; HDL = high density lipoprotein; LDL = low density lipoprotein; BP = blood 
pressure; VFat= visceral fat; PFat = percent fat; r = correlation coefficient;p value ≤ 0.05 






Table 4-25. Relationship Among Cardiac-Related Outcomes at 5-8 Years Post-
Kidney Transplantation and Changes in Body Composition Measures of Android 
Gynoid Ratio, Android Percent Fat, Total Fat Mass, and Fat Mass Ratio from Time 




r (p value)* 
Android 
Percent Fat 
r (p value)* 
Total Fat 
Mass 
r (p value)* 
Fat Mass 
Ratio 
r (p value)* 
Creatinine -0.41(0.01) -0.33(0.03) -0.33(0.03) -0.40(0.01) 
Glucose 0.03(0.83) -0.01(0.93) -0.00(1.00) 0.13(0.40) 
Hgb A1C 0.03(0.87) -0.02(0.89) 0.05(0.75) 0.14(0.36) 
Triglyceride 0.11(0.50) 0.07(0.65) 0.00(0.99) 0.11 (0.50) 
HDL 0.10(0.53) -0.01(0.97) -0.06(0.70) 0.08(0.61) 
LDL 0.01(0.94) 0.25(0.11) 0.08(0.62) -0.11(0.50) 
Coronary risk ratio 0.05(0.72) 0.13(0.37) 0.11(0.46) 0.04(0.80) 
Systolic BP   -0.40(0.01) -0.27(0.07) -0.26(0.08) -0.24(0.11) 
Diastolic BP 0.07 (0.63) 0.17(0.25) 0.18(0.22) 0.21 (0.17) 
 
Note: *Pearson Correlation Coefficients: Prob > [r] under Ho: Rho=0;  
Hgb = hemoglobin; HDL = high density lipoprotein; LDL = low density lipoprotein; BP 





Table 4-26. Relationship Among Cardiac-Related Outcomes at 5-8 Years Post-
Kidney Transplantation and Change in Body Composition Measures of WBTotal 
Fat, WBTotal Lean, WBTotal Mass, and WBTotal PFat from Time of Transplant to 
5-8 Years Post-Kidney Transplantation   
 
Variables WB Total 
Fat 
r (p value) 
WB Total 
Lean 
r (p value) 
WB Total 
Mass 
r (p value) 
WB Total 
PFat 
r (p value) 
Creatinine -0.14(0.35) -0.12(0.42) -0.15(0.33) -0.06 (0.70) 
Glucose -0.42(0.004) -0.16(0.30) -0.31(0.04) -0.37 (0.01) 
Hgb A1C -0.40 (0.01)   -0.15 (0.35)   -0.29 (0.05)   -0.34 (0.02) 
Triglyceride 0.02 (0.91)   0.02(0.92) 0.02 (0.90) -0.01(0.93) 
HDL 0.28 (0.06) 0.39(0.01)    0.38(0.01)    0.00(1.0) 
LDL 0.03(0.87)    -0.01(1.0) 0.01(0.95)   0.01(0.94) 
Coronary risk ratio -0.15(0.34)   -0.27(0.08) -0.24(0.12) -0.00(1.0) 
Systolic BP -0.25(0.09) -0.40(0.01) -0.37(0.01) -0.04(0.80) 
Diastolic BP -0.27(0.07) -0.27(  0.07) -0.30 (0.05) -0.14 (0.37) 
 
Note. *Pearson Correlation Coefficients: Prob > [r] under Ho: Rho=0  WB= whole-body; 
Hgb = hemoglobin; HDL = high density lipoprotein; LDL = low density lipoprotein; BP 






An inverse relationship was found between creatinine and android fat (r = -0.34; p 
= 0.02), creatinine and android percent fat (r = -0.366; p = 0.014), and triglyceride and 
android lean (r = -0.44; p = 0.002). Diastolic BP and android fat (r = 0.29; p = 0.05) and 
diastolic BP and android mass (r = 0.33; p = 0.03) are shown in Table 4-22. 
Relationships reaching levels of significance (p ≤ 0.20) that warrant continued 
consideration in fully powered studies include creatinine and android mass (r = -0.22; p = 
0.14), LDL and android percent fat (r = 0.22; p = 0.16), systolic and android fat (r = -
0.24; p = 0.11), systolic BP and android percent fat (r = -0.25; p = 0.09), diastolic BP and 
android lean (r = 0.23; p = 0.13), and diastolic BP and android percent fat (r = 0.26; p = 
0.08). As creatinine increases, android fat, android mass, and android percentage of fat 
decrease. While triglycerides increase, android lean decreases. As diastolic blood 
pressure increases so do android fat and android mass.   These correlations were weak to 
moderate in strength.  For relationships reaching levels of significance (p ≤ 0.20), systolic 
blood pressure increases as android fat and android percentage of fat decrease. As 
creatinine increases, android mass decreases; while LDL increases so does android 
percent of fat. These correlations are considered weak to strong in strength and are 
positive in direction (Sheskin, 2011).   
 
Table 4-23 indicates a significant relationship was found with LDL and gynoid 
percent fat (r = 0.37; p = 0.01). An inverse relationship was found with creatinine and 
gynoid fat (r = -0.33; p = 0.03), creatinine and gynoid mass (r = -0.31; p = 0.04), and 
LDL and gynoid lean (r = -0.38; p = 0.01). Relationships reaching levels of significance 
(p ≤ 0.20) that warrant continued consideration in fully powered studies include 
triglyceride and gynoid lean (r = -0.26; p = 0.08), coronary risk ratio (r = -0.20; p = 0.18), 
diastolic and gynoid fat (r = 0.249; p = 0.10), diastolic and gynoid mass (r = 0.22; p = 
0.14), and diastolic and gynoid percent fat (r = 0.26; p = 0.08). As LDL increases so does 
gynoid percentage of fat. While creatinine increases, gynoid fat and gynoid mass 
decrease; while LDL increases gynoid lean decreases. These correlations were moderate 
in strength.  For relationships reaching levels of significance (p ≤ 0.20), triglyceride 
increases while gynoid lean and coronary risk ratio decreases. As diastolic blood pressure 
increases so do gynoid fat, gynoid mass, and gynoid percentage of fat. These correlations 
are weak in strength, and some are negative and some positive (Sheskin, 2011).   
 
An inverse relationship with significance exists with creatinine and visceral fat 
body fat (r = -0.36; p = 0.01), creatinine and visceral fat body percent fat (r = -0.36; p = 
0.02), triglyceride and visceral fat body lean (r = -0.30; p = 0.05), and with LDL and 
visceral fat body lean (r = -0.34; p = 0.03). The diastolic BP and visceral fat body mass (r 
= 0.29; p = 0.05) are statistically significant (Table 4-24). Relationships reaching levels 
of significance (p ≤ 0.20) that warrant continued consideration in fully powered studies 
include creatinine and visceral fat body mass (r = -0.27; p = 0.08), Hgb A1C and visceral 
fat body lean (r = 0.21; p = 0.18), LDL and visceral fat body percent fat (r = 0.23; p = 
0.15), coronary risk ratio and visceral fat body lean (r = -0.26; p = 0.09), systolic and 
visceral fat body fat (r = -0.27; p = 0.07), systolic BP and visceral fat body mass (r = -
0.21; p = 0.16), systolic BP and visceral fat body percent fat (r = -0.25; p = 0.09), 
diastolic BP and visceral fat body fat (r = 0.27; p = 0.07), and diastolic BP and visceral 
fat body percent fat (r = 0.27; p = 0.08). As creatinine increases, visceral fat body and 
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visceral body percentage of fat decrease. Triglyceride and LDL increase while visceral 
fat body lean decreases. As diastolic BP increases so does visceral fat body mass. These 
correlations were weak to moderate in strength.  For relationships reaching levels of 
significance (p ≤ 0.20), as creatinine and systolic BP go up visceral fat body mass 
decreases. As HgbAIC goes up and coronary risk ratio goes down, visceral fat body lean 
increases. As LDL and diastolic BP increases, so does visceral fat body percentage. As 
systolic BP goes up , visceral fat body mass goes down. These correlations are considered 
weak in strength; some are negative and some positive (Sheskin, 2011).   
 
Table 4-25 indicates a relationship was found with creatinine and android gynoid 
ratio (r = -0.41; p = 0.01), creatinine and android percent fat (r = -0.33; p = 0.03), 
creatinine and total fat mass (r = -0.33; p = 0.03), and creatinine and fat mass ratio (r = -
0.40; p = 0.01) and were all inversely related. An inverse relationship was found with 
systolic BP and android gynoid ratio (r = -0.40; p = 0.01; Table 4-25). Relationships 
reaching levels of significance (p ≤ 0.20) that warrant continued consideration in fully 
powered studies include LDL and android percent fat (r = 0.25; p = 0.11),systolic BP and 
android/gynoid ratio ( r = -0.40; p = 0.001) systolic  BP and total fat mass (r = -0.26; p = 
0.08), systolic BP and fat mass ratio (r = -0.24; p = 0.11), and diastolic BP and fat mass 
ratio (r = 0.21; p = 0.17). As creatinine goes up, android gynoid ratio, android percent of 
fat, total fat mass, and fat mass ratio go down. As systolic BP increases, android gynoid 
ratio decreases. These correlations were moderate to strong in strength.  For relationships 
reaching levels of significance (p ≤ 0.20), as LDL increases so does android percent of 
fat. As diastolic BP increases, so does fat mass ratio. While systolic blood pressure goes 
up, android gynoid ratio, android percentage of fat, and total fat mass go down. These 
correlations are considered to range from weak to strong in strength with some negative 
and some positive (Sheskin, 2011).   
 
Table 4-26 indicates an inverse relationship with glucose and WB total fat  (r = -
0.42; p = 0.004), WB total mass (r =-0.31; p = 0.04) , and WB total PFat (r = -0.37; p = 
0.01) and with HgbA1C and WB total fat ( r  = -0.40; p = 0.01), WB total mass (r = -
0.29; p = 0.05), and WB total PFat ( r = -0.34; p = 0.02),  with systolic BP and WB total 
lean (r = -0.40; p = 0.01) and WB total mass (r = -0.37; p = 0.01), with diastolic BP and 
WB total mass (r = -0.30; p = 0.05). A significant relationship was found with HDL and 
WB total lean (r = 0.39; p = 0.01) and HDL and WB total mass (r = 0.38; p = 0.01). The 
correlations were weak to strong and some are negative and some positive in direction.  
As glucose goes up, so do WB total fat, WB total mass, and WB total PFat. As systolic 
BP goes down, WB total lean and WB total mass go up.  As diastolic BP goes down, WB 
total mass goes up. As HDL goes up, so do WB total lean and WB total mass.  As 
glucose and HgbA1C levels go up, WB total fat goes down. As WB total lean and WB 
total fat go up, HgbA1C and coronary risk ratio levels go down.  
 
Relationships reaching levels of significance (p ≤ 0.20) that warrant continued 
consideration in fully powered studies with an inverse relationship include HDL and WB 
total fat (r = 0.28; p = 0.06), coronary risk ratio and WB total lean (r =- 0.27; p = 0.08), 
coronary risk ratio and WB total mass (r =-0.24;p = 0.12), diastolic BP and WB total fat 
(r = -0.27; p = 0.07), diastolic BP and WB total lean (r =- 0.27; p = 0.07), and systolic BP 
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and WB total fat (r = -0.25; p = 0.09). The correlations were weak in relationship and 
some are negative and some positive in direction.  As coronary risk ratio increases, WB 
total lean and WB total mass decrease. As diastolic BP increases so do WB total fat and 












have reported significant weight gain (between 6 to 10 kg) in 
patients the first year post-kidney transplantation (Aksoy, 2016; Cashion et al., 2014).   
Weight gain following transplantation is known to increase obesity risk factors and 
contribute to comorbid disorders such as HTN Type II diabetes and CVD, which is the 
number one cause of mortality in this population (Beckmann, Ivanović, Drent, Ruppar, & 
Geest, 2015; Olarte & Hawasli, 2009). Despite the high percentage of individuals gaining 
a significant amount of weight following transplantation and the serious consequences 
associated with this weight gain, no studies have examined whether weight distribution 
throughout the body is associated with cardiac risk factors.  
 
Moreover, while concern exists for the increased cardiac risk that accompanies 
post-kidney transplant weight gain; in addition to the differential risks that may be 
associated with weight gain distribution, there is a lack of consensus regarding what 
measures of body weight provide the best information on these cardiac risk factors.  
Typical anthropometric measures of weight often include BMI and waist circumference.  
However, measures of body mass by DXA provide more precise data of lean and fat mass 
for various compartments of the body, and visceral fat in particular, which is believed to 
be associated with increased cardiac risk. Thus, the present study sought to address 
whether anthropometric or DXA measures of weight are most closed associated with 
cardiac risk factors. This chapter includes a discussion of the significant findings and 
compares the study results with existing research. Furthermore, it includes strengths and 
limitations of our study, practice implications, theoretical implications, as well as 





Unlike national data, the majority of our study sample (64.4%) was African 
American and reflective of the demographic characteristics of the community from which 
the sample was drawn. Moreover, our study cohort also captured a group at particularly 
high risk for cardiovascular disease in general and graft failure following kidney 
transplant in particular. Our findings, therefore, provide new information particularly 






Research Question 1 
 
The first research question sought to determine the association between 
anthropometric measures and serum glucose, lipid, and creatinine levels and blood 
pressure in kidney transplant recipients 5-8 years posttransplant. The study found that 
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high waist readings (WC and waist-to-hip ratio) were associated with an increased 
coronary risk ratio (r = 0.33; p = 0.05), and that higher diastolic BPs (above 90 mmhg) 
were associated with higher posttransplant weight. These findings are consistent with 
previous studies that reported posttransplant weight gain and found that it leads to a high 
diastolic BP, which in turn increases the renal recipient’s risk of developing CVD 
(Mohammadifard et al., 2013; Scherrer et al., 1991) and acute graft loss (Cosio et al., 
2001). Similarly, a high WC also increases the coronary risk ratio, which in turn 
increases the kidney recipient risk of developing CVD (Mohammadifard et al., 2013).  
 
 
Research Question 2 
 
Research Question 2 sought to address the association between body composi-
tion measures and serum glucose, lipid, and creatinine levels and blood pressure in 
kidney transplant recipients 5-8 years posttransplant. While Research Question 1 found 
increased WC and weight to be associated with increased CV risk and diastolic BP, 
respectively, several additional associations were found in Research Question 2 results 
between serum glucose, lipid, and creatinine levels and elevated blood pressure and 
measures of body composition. In addition to CV risk, measures of body composition 
were also associated with HDL, systolic BP, and creatinine. It was also found that 
android fat, visceral fat, and visceral fat body mass were all found to be associated with 
increased CV risk (Table 4-8 to 4-11).  
 
Furthermore, using measures of body composition, relationships with HDL were 
found with measures of total, total PFat, VFat, gynoid PFat, android PFat, and VFat body 
PFat and with percent gynoid and android fat (Table 4-7 to 4-11). Because approximately 
one third of recipients undergoing kidney transplant are significantly burdened with CAD 
and many experience subsequent CV events (Neale & Smith, 2015), measures of cardiac 
risk warrant careful monitoring.  
 
Instead of the relationships that Research Question 1 results found between 
weight and diastolic BP, using measures of body composition, relationships were found 
with the more meaningful measure of systolic BP in Research Question 2. Specifically, 
measures of visceral percent fat and android fat were found to be associated with systolic 
BP. However, surprisingly, these were inverse relationships, thus indicating that 
increased fat in these compartments was associated with decreased systolic BP. Last, 
using measures of body composition, additional relationships were found with creatinine 
levels. Total fat, android Pfat, gynoid Pfat, VFat, and VFat body PFat were all found to 
be inversely related to creatinine―that is, as these levels increased, creatinine levels 
decreased, which indicates improved function (Tables 4-7 to 4-12). This-result suggests 
that elevated levels of total fat, total percent fat, visceral fat, android fat, and gynoid fat 
are associated with low creatinine level, which reduces the risk of graft loss. However, a 
high level of creatinine, according to Younespour et al. (2016) and Maraghi et al. (2016), 
increases graft loss as well as the survivability of the kidney. An inverse relationship 
exists with creatinine and android percent fat (r = -0.45; p = 0.001), implying a high 





Research Question 3 
 
Research Question 3 sought to determine the degree to which body 
composition measures obtained from recipients at the time of transplant were associated 
with serum levels of glucose, lipids, and creatinine and elevated blood pressure obtained 
at 5-8 years following the transplant. Significant relationships were found among 11 
measures of body composition obtained at the time of transplantation and the HDL level 
at 5-8 years posttransplant (Tables 4-13 to 4-18). These measures included both android 
and gynoid lean and mass, as well as the android/gynoid ratio, percent body lean and total 
lean, percent body fat, fat mass ratio, and total fat and total mass. Because HDL levels at 
the time of transplant were not available, it was not possible to determine whether this 
association also existed at the time of transplantation. Regardless, it is noteworthy that all 
four measures of lean tissue as well as nearly half the remaining compartments measured 
at the time of transplant surgery were found to be related to HDL levels 5-8 years later. In 
terms of coronary risk ratio, three of the four measures of lean tissue (total, gynoid, and 
visceral fat body) were related, along with android fat and mass and total percent fat. 
However, total fat and visceral fat body lean were related in an unexpected direction— 
i.e., as lean values increased, so did coronary risk. Lastly, lean tissue android and visceral 
fat body were also related to triglyceride levels. The prevalence of lean tissue 
relationships to measure cardiac health raises a question regarding the perception that fat 
mass is of primary concern while increased levels of lean are considered healthier.  
 
In addition, HDL is used to assess patients’ risk for heart disease (Hewing, 
Moore, & Fisher, 2012). An inverse relationship was found with HDL and total fat (r = -
0.34; p = 0.02) and HDL and total lean (r = -0.50; p = < 0.001), which suggests a high 
total fat, total lean, and total mass lowers serum levels of HDL. Low serum levels of 
HDL from a high level of total fat, total lean, and total mass can increase the post-kidney 
transplant recipients’ risk for CAD, which is corroborated by the Framingham study 
(Castelli et al., 1986). The Framingham study showed the risk for CAD increases as 
triglyceride, total cholesterol, and LDL increase and those patients with CAD had low 
levels of HDL (Castelli et al., 1977; Castelli et al., 1986). In addition, Toth (2004) 
indicated that low serum levels of HDL are often seen with patients who have CAD. Low 
serum levels of HDL are also an independent risk factor for CAD (Puri et al., 2014; Toth, 
2004).   
 
An inverse relationship was found with HDL and visceral body fat (r = -0.46; p = 
0.001), HDL and visceral body lean (n = 45); (r = -0.341; p = 0.021), and HDL and 
visceral fat body mass (r = 0.07; p = 0.65). This indicates that a high visceral body fat 
mass and visceral body lean, lowers serum levels of HDL, which predisposes kidney 
recipients to obesity-related health complications. An elevated level of visceral fat in the 
abdominal area is linked to health complications such as Type 2 diabetes and CAD 




An inverse relationship exists with HDL and android fat (r = -0.46; p = 0.001), 
HDL and android lean (r = -0.45; p = 0.002), and HDL and android mass (r = -0.53; p  < 
0.001). Android lean is associated with lower serum levels of HDL, indicating the 
participants in this study were at risk for CVD. This finding is surprising because one 
would expect that participants with a high android lean would raise the serum levels of 
HDL, which would lower the participants’ risk for CVD rather than increase their risk. 
Our study found that a high android mass lowers the serum levels of HDL, which is 
consistent with Latt et al.'s (2018) finding, which showed that a high android mass 
worsens serum levels of HDL, leading to an increased risk for CVD in normal weight and 
overweight boys during puberty. It is the overall mass in the abdomen that is the issue 
whether lean or fat. 
 
High android fat is associated with lower serum levels of HDL, indicating the 
participants in the current study are at risk for CVD. Android fat distribution is associated 
with CVD (Kouda, Nakamura, Fujita, Ohara, & Iki, 2012). Min and Min (2014) studied 
5,696 adults from 2003 to 2006 to determine which fat percentages from android and/or 
gynoid fat predicted CVD. Their findings showed that regardless of gender, android and 
gynoid body fat percentages are positively linked to BMI and WC. Moreover, increases 
in android fat percentage were positively linked to total cholesterol, triglycerides, and 
HDL for males and total cholesterol, HDL, and LDL for females (Min & Min, 2014). On 
the other hand, gynoid fat percentage was positively linked to total cholesterol in males. 
For females, gynoid fat percentages were positively linked to triglycerides and HDL. Min 
and Min (2014) concluded that fat accumulation in the android region was a significant 
predictor of CVD compared to that in the gynoid region.  
 
A significant relationship was found with triglyceride and android lean; (r = 0.30; 
p = 0.05), which implies that low levels of android lean are associated with lower levels 
of triglycerides. Android lean represents the lower body fat. Jensen (2008) posited a 
decreased level of lower body fats in the android region decreases patients’ risk of CVD. 
An inverse relationship exists with HDL and gynoid lean (r = -0.51; p < 0.001). This 
suggests a high gynoid lean lowers the level of HDL, which is surprising because one 
would expect that lean body mass in the gynoid region would increase the levels of HDL 
rather than decrease them.  
 
A significant relationship exists with coronary risk ratio and total lean (r = 0.42; p 
= 0.004), implying that a high total lean leads to a high coronary risk ratio. Huang et al. 
(2015) found that high lean mass is an independent factor that increased the survival rates 
of Chinese patients with CAD because it protected them from mortality. These findings 
were similar to the findings of  Han et al. (2010) and Lavie et al. (2011) in showing that 
high lean mass is an independent risk factor that increases the survival rates of elderly 
patients and patients with CAD. The relationship between coronary risk ratio and total 
mass (r = 0.38; p = 0.01) were significant, suggesting a high total percent fat leads to a 
high coronary risk ratio.  
 
The relationship between coronary risk ratio and visceral fat body lean (r = 0.52; 
p = 0.003) was significant, meaning a lower visceral fat lowers the coronary risk ratio, 
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which supports previous findings. Ross and Janiszewski (2008) found weight loss, 
particularly in the abdominal area, reduces abdominal fat, which in return reduces the 
patients’ risk of CVD. The relationship between coronary risk ratio and android fat (r = 
0.32; p = 0.03) and coronary risk ratio and android mass (r = 0.47; p = 0.001) was 
significant. This indicates that a high android fat and a high android mass increase the 
coronary risk ratio. Despres (2012) found that regional body fat distribution, particularly 
android fat and android mass, increases the patients’ risk of having a CV event. A 
significant relationship exists with coronary risk ratio and gynoid lean (r = 0.36; p = 
0.02), implying that lean body mass lowers gynoid fat, which reduces the coronary risk 
ratio; this is consistent with previous findings showing how lowering gynoid fat by 
replacing it with lean body mass can improve a patient’s CV outcome. 
 
 
Research Question 4 
 
Research Question 4 sought to determine whether anthropometric measures 
obtained at the time of transplant were associated with serum levels of glucose, lipids, 
and creatinine and blood pressure in kidney transplant recipients at 5-8 years 
posttransplant. The findings from these analyses reflect those of the body composition 
measures (Table 4-19). Similarly, HDL was inversely related to weight, while coronary 
risk ratio was positively related to weight.  
  
A significant relationship was found with coronary risk ratio and weight (r = 0.33; 
p = 0.03). This implies that an increase in weight increases coronary risk ratio, which 
indicates that weight gain increases the coronary risk factors of developing CVD. This is 
consistent with previous findings showing how weight gain and CVD are linked (Akil & 
Ahmad, 2011; Baum, 2001b; Kannel, D'Agostino, & Cobb, 1996). Kannel et al. (1996) 
noted that being overweight worsens the CV risk profile. Baum (2001b) noted that 50% 
of the posttransplant population experienced weight gain. Weight gain is a major problem 
because of the interaction between obesity and immunosuppression medications, which 
increases the risk for CVD.  
 
An inverse relationship exists with HDL and weight (r = -0.46; p = 0.001). This 
means that when weight is lowered, HDL increases, which is consistent with prior 
findings which show that weight reduction increases HDLand lowers LDL. Dattilo and 
Kris-Etherton (1992) studied the effects of weight reduction on blood lipids and 
lipoproteins in a meta-analysis. They found, from the 70 studies, that weight reduction 
lowered LDL and increased HDL. The relationship between HDL and BMI (r = -0.34; p 
= 0.02) is inverse. This suggests that a lower BMI is associated with an increased HDL.   
 
 
Research Question 5 
 
Research Question 5 asked to what degree changes in anthropometric 
measures from baseline to 5-8 years posttransplant are associated with serum glucose, 
lipids, and creatinine and elevated blood pressure at 5-8 years posttransplant. The only 
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anthropometric measure found to be associated with the cardiac-related outcomes was 
BMI, which was associated with coronary risk ratio (r = 0.31; p = 0.04). This finding was 
expected, given that obesity has long been recognized as a common risk factor for CVD 
(Dimeny, 2002; Ghoorah, Campbell, Kent, Maznyczka, & Kunadian, 2016; Ladhani, 
Craig, Irving, Clayton, & Wong, 2017; Lentine et al., 2008; Orazio et al., 2007).  
Moreover, obesity-related CVD is more common in kidney transplant recipients than in 
the general population (Marcén, 2006).   
 
Although the change in BMI was only 3.11 from baseline (M = 29.03; SD = 4.76) 
to 5-8 years posttransplant (M = 32.14; SD = 9.61) in our cohort group, this represented 
an elevation to Class I obese (30-34.9). The degree of change, along with the probable 
trajectory of the gain, likely accounts for the significant finding. This finding is also 
consistent with previous findings (Beckmann, Ivanović, Drent, Ruppar, & Geest, 2015; 
Cashion et al., 2007; Cupples et al., 2012; Nuttall, 2015; Stanfill et al., 2015) which 




Research Question 6 
 
Research Question 6 sought to determine the degree to which changes in body 
composition measures from baseline to 5-8 years posttransplant were associated 
with serum glucose, lipids, creatinine, and elevated blood pressure. In contrast to 
anthropometric measures, which found only the change in BMI from time of transplant to 
5-8 years later to be associated with coronary risk ratio, multiple measures of body mass 
were associated with creatinine, LDL, diastolic BP, triglycerides, and systolic BP (Tables 
4-21 to 4-26).   
 
All the relationships with creatinine (Table 4-21) were inverse, which is 
consistent with studies which have found that high body fat and high body mass can 
reduce excretion of creatinine resulting from the loss of muscle mass associated with 
aging and chronic illness (Heymsfield et al., 2005). In addition, Oh, Choi, Lee, & Park 
(2017) have also reported that abdominal obesity reduces kidney function, which affects 
the kidney’s ability to excrete waste products effectively. As Gerchman et al. (2009) 
stated, visceral adipose tissue found in the abdomen reduces the glomerular filtration rate, 
which reduces the clearance of creatinine from the kidney.   
 
LDL was inversely related to three measures of lean tissue (total lean, gynoid 
lean, and visceral fat body lean) and positively related to total percent fat and gynoid 
percent fat. The relationships found with these compartments of lean tissue are consistent 
with previous findings that an increased lean body mass in the hips and thighs reduces 
LDL and increases the levels of HDL, thereby reducing the risk for CVD (Hioki et al., 
2015; Hoenig, Cowin, Buckley, McHenery, & Coulthard, 2011). Likewise our findings 
related to LDL, total percent fat, and gynoid percent fat are consistent with previous 
findings which reported that higher total percent is associated with LDL (Chiu, Williams 
& Krauss [2017]) and findings by Min and Min (2014) that gynoid percent fat was 
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positively correlated with LDL, indicating that an increase in gynoid percent fat 
accompanies an increase in LDL and, in return, an increased risk of CVD.    
 
Diastolic BP was found to be related to both android fat (r = 0.30; p = 0.05) and 
android mass (r = 0.33 p = 0.03) as well as visceral fat and mass (Tables 4-22 to  
4-26), indicating that increased weight in both android and visceral fat may contribute to 
increased diastolic BP. This finding is consistent with George et al. (2016), who studied 
the role of body fat and fat distribution in hypertension risk in urban Black South African 
women and found that trunk fat mass and arm fat mass accompanied increased diastolic 
BP levels. In the follow-up study to George et al. 5-8 years posttransplant, diastolic BP 
increased by 20.5%. Yano et al. (2016) also studied regional fat distribution and found 
that an increase in VAT leads to an increase in diastolic pressure 
 
An inverse relationship was found with systolic BP and android gynoid ratio (r = 
-0.40; p = 0.01), suggesting that a high A/G ratio is associated with systolic BP. This 
finding is surprising since one would expect that a high A/G ratio would increase systolic 
BP rather than lower systolic BP.  
 
  
Strengths and Limitations 
 
 This is the first longitudinal study of weight changes that occur in kidney 
transplant recipients to employ DXA scans to quantify measures of body composition. 
Although previous longitudinal studies have been conducted with similar samples, none 
have employed the same detailed measures of changes that occur in individual 
compartments of the body. In addition, this study expands upon the extant knowledge by 
examining the association and changes in body composition for their association with 
clinically important outcomes obtained 5 years plus posttransplant. The relationships 
found in this study provide important implications for practice and guidance for future 
research. Lastly, the BCAM model introduced to guide this study proved to be helpful in 
conceptualization, conduct, and analysis of the study findings. In addition to the BCAM 
model providing a valuable role in guiding future research, it may also aid HCPs in 
selecting the best methods to evaluate changes in BC and to more accurately tailor 
interventions considering individual biological and pathological conditions, thereby 
improving patient outcomes. 
 
Despite the strength of the current study, some limitations existed. First, the small 
sample size (N = 45) may affect generalizability to a larger kidney transplant population. 
Second, study participants were not randomly selected but were selected from a parent 
study in the same transplant center of a large midsouth university-affiliated transplant 
institute, further threatening the generalizability of study findings. However, as an early 
exploratory study that is the first to use this longitudinal approach with detailed DXA 
scanning of body compartments, replication of this research should be undertaken. Third, 
a small sample size may increase the possibility of a Type II error (Burns & Grove, 2009; 
Polit, 2010). A Type II error exists when the null hypothesis is false but is accepted as 
true from the statistical testing (Burn & Grove, 2009; Polit, 2010). However, this is 
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balanced to some degree by the large number of body composition measures, which 
could contribute to a Type I error. However, as an exploratory study, it is important to 
identify all potential contributing factors so they can be included in future, more fully 
powered and sophisticated explanatory modeling studies.   
 
 
Clinical and Practice Implications 
 
The results of the current study could serve as a work in process for future studies 
to target specific tissue measures for body fat and weight gain in the general and post-
kidney transplant population. Our work has found that commonly used indirect methods 
may be inappropriate for accurately accessing body fat and weight gain in the post-
kidney transplant population. In addition to the unique physiological conditions 
accompanying transplant that may affect distribution of weight, age, ethnicity/race, 
lifestyle, other clinical conditions influence the distribution of lean and fat mass across 
body compartments and thereby should also influence the choice of methods used to 
monitor body fat and weight. Clinical conditions may make certain indirect methods 
unsuitable for accurately assessing %BF in individuals. For example, BIA measures 
assume total body water measurement is the same for all individuals; therefore, in obese 
or dehydrated individuals %BF is overestimated (Dehghan & Merchant, 2008; Heyward 
& Wagner, 2004).  
 
 The BCAM is a science- and system-based model designed to guide practice 
decisions regarding selection of the best methods for measuring and monitoring weight.  
The BCAM illustrates a scientific-technological linkage between factors that influence 
weight gain and shows how the adverse changes in body composition affect the post-
kidney transplant population health outcomes. The conceptual framework of the BCAM 
can describe how body composition variation influences biological, lifestyle, health-
related, and biometric factors in the presence of weight gain. The physiological changes 
affect body composition variation in the presence of abnormal lab levels of serum 
glucose, lipid, coronary artery ratio, and creatinine and long-standing elevated blood 
pressure, which could lead to mortality and morbidity. The findings from the current 
study show an association between weight gain and obesity-related cardiovascular 
disease and abnormal cardiac variables of the blood values.   
 
 
Recommendations for Future Research 
  
As a prospective correlational study, our results provide direction for future 
research on how the BCAM could support healthcare professionals in finding an 
appropriate indirect method to measure body fat and weight gain in the post-kidney 
transplant population. Additional research with larger representative samples of the post-
kidney transplant population is needed in order to generalize the study findings and to 
conduct more sophisticated multivariate analysis or predictive modeling. These additional 
studies will help provide more statistical insights into the measurement of components of 
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body fat and weight gain and provide theoretical insight that will help to further develop 





 Postoperative weight gain is a common phenomenon in the kidney transplant 
population and is higher than in the general population. A weight gain of 10 kg in the first 
year and doubling to 32 kg in the second year is not unusual and often leads to obesity-
related complications. One of the obesity-related complications is the risk of developing 
cardiovascular disease that may lead to mortality in the kidney transplant population. 
Although various methods are used to measure and monitor weight gain over time, the 
literature lacks a consensus on which methods, specifically anthropometric or dual-
energy x-ray absorptiometry, are most accurate in the assessment of weight gain in the 
presence of diseases in the kidney transplant population. Furthermore, limited studies 
have addressed the association between changes in body composition as measured by 
dual-energy x-ray absorptiometry or anthropometric indices and serum glucose, lipids, 
and blood pressure as predictors of cardiovascular disease after kidney transplantation.  
 
 The results from this study show several significant emerging risk factors of 
developing post-kidney transplant cardiovascular disease from excessive weight gain and 
obesity-related complications. Excessive weight gain and obesity-related complications 
are concerns in the kidney transplant population due to increased morbidity and 
mortality. Furthermore, the significant relationships found among the dual-energy x-ray 
absorptiometry and cardiac-related outcomes suggest that dual-energy x-ray 
absorptiometry provides a better assessment of body fat, weight gain, and potential 
cardiac risk factors than do the currently used anthropometric measures of weight and 
waist circumference. Thus, future research scientists and clinical practitioners should 
continue to examine the use of dual-energy x-ray absorptiometry for understanding the 
emerging coronary risk that accompanies weight gain and as a basis upon which more 
precise targeted interventions could be designed that would improve the health and life 
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